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Introduction 
 
Today, genetics plays an important role in medicine.  While most of the world’s deadliest 
diseases do not have a purely genetic basis, researchers have discovered the genetic link behind 
diseases such cystic fibrosis, Tay-Sachs, Huntington’s, hemophilia, Down syndrome, and sickle 
cell disease.  Aside from these disorders (which have a clear genetic origin), researchers have 
made enormous progress in understanding the clinical significance of mutations that lead to other 
diseases, including many cancers. 
The most widely studied cancer, especially with regard to its genetic basis, is breast 
cancer.1  Among women, breast cancer is the second leading cause of cancer death (behind lung 
cancer) and the second most commonly diagnosed cancer (after nonmelanoma skin cancer).2  
Though about 12% of women are already expected to develop breast cancer at some point in 
their lives, certain genetic mutations in two genes called BRCA1 and BRCA2 significantly 
increase one’s risk.3  These mutations are rare (inherited by only 0.25% of the population), but 
can result in a 65% chance of developing the disease.4 
 After a genetic link between breast cancer risk and chromosome 17 was discovered in the 
1990s, researchers and companies raced to develop a test to check for a mutation in BRCA1 and 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 Note: For each of the past three years, the National Cancer Institute (NCI) has spent about twice as much money 
funding breast cancer research than lung and prostate cancer research, even though breast cancer has a lower 
incidence rate.  Source: "Cancer Research Funding," National Cancer Institute, National Institutes of Health. 
http://www.cancer.gov/cancertopics/factsheet/NCI/research-funding. Accessed March 28, 2014.  
2 "Genetics of Breast and Ovarian Cancer (PDQ®)," National Cancer Institute (NCI), National Institutes of Health 
(NIH). http://www.cancer.gov/cancertopics/pdq/genetics/breast-and-ovarian/HealthProfessional/. December 16, 
2013. Accessed February 2, 2014.  
3 "Breast Cancer Risk in American Women," National Cancer Institute, National Institutes of Health. 
http://www.cancer.gov/cancertopics/factsheet/detection/probability-breast-cancer. October 24, 2012. Accessed 
February 1, 2014.  
4 "BRCA1 and BRCA2: Cancer Risk and Genetic Testing," National Cancer Institute, National Institutes of Health. 
http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA. August 5, 2013. Accessed February 2, 2014.  
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BRCA2.5  Such a test would be used to shed light onto one’s predisposition for the disease and to 
help guide prevention and screening options.  In 1994, a research team from a company called 
Myriad Genetics won the race to isolate BRCA1, patented the genes, and commercialized the first 
BRCA1/2 genetic test.6  In the following years, controversy surrounding Myriad’s business 
practices emerged, resulting in a lawsuit challenging the validity of gene patents.  
 On June 13, 2013, the Supreme Court unanimously ruled that genes cannot be patented.   
This decision, widely supported by physicians, academic researchers, and patient advocacy 
groups, broke Myriad’s monopoly in the BRCA1/2 testing market.  Immediately following the 
ruling, new companies announced plans to commercialize similar tests, but at much lower costs.  
Now, less than a year later, over ten companies and academic centers have developed BRCA1/2 
tests.   
 Though these new testing companies offer BRCA1/2 testing at a lower cost, many 
payment and access issues still exist.  This research paper aims to survey these access issues and 
to investigate why payer policies are so varied.  Given little literature exists that discusses how 
payers are addressing BRCA1/2 testing, this paper also acts as a first step in the creation of a 
comprehensive report on new BRCA1/2 testing options (post-Supreme Court case) and insurance 
policies for the reimbursement of this test.   
 Results have shown that insurance policies for genetic tests, especially for BRCA1/2, vary 
widely.  Some of the nation’s largest private payers do not even have published policies.  Other 
large payers have local coverage policies, but no national determinations.  Additional companies 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
5 Note: From here on out, unless individually distinguished, BRCA1 and BRCA2 will be collectively referred to as 
BRCA1/2. 
6 Note: There are two separate ‘discovery’ stories for BRCA1 and BRCA2, the details of which are not discussed in 
this paper.  BRCA1 was patented in 1994 and BRCA2 was patented in 1996.  For more information regarding the 
discovery stories of each of these two genes, consider the following article:  Matthijs, G., Huys, I., Van Overwalle, 
G., & Stoppa-Lyonnet, D. (2013). The European BRCA patent oppositions and appeals: coloring inside the lines. 
Nature biotechnology 31, no. 8: 704-710. 	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only seem to be contracted with Myriad, meaning that (though cheaper test options exist with 
other companies), care providers are forced to order through Myriad for some patients.  
Coverage for genetic counseling and large rearrangement testing also varies. 
Though there are inconsistencies among private payers, public payer policies are even 
more vague.  Medicare will not cover testing unless an individual has had breast or ovarian 
cancer.  Given the main purpose of the test is to guide prevention and screening options, this 
policy makes little sense.  Similar to Medicare, Medicaid does not have a national coverage 
policy for BRCA1/2 (or for most genetic tests), and many state Medicaid policies do not cover 
testing.    
Aside from these reimbursement issues, there are also inconsistencies in the guidelines 
for whom should even get tested for a BRCA1/2 mutation.  There are two main recommendations 
for BRCA1/2 testing, those by the National Comprehensive Cancer Network (NCCN) and the 
United States Preventative Services Task Force (USPSTF).  These recommendations differ 
slightly and could benefit from many clarifications.   
Given the complex nature of the United States’ healthcare system, it is not surprising that 
so many discrepancies exist in coverage for BRCA1/2 testing.  After all, this is a relatively new 
technology, and because the market was recently opened for new companies to enter, one could 
view it as a new industry as well.  Nevertheless, despite the inherent complexities that arise with 
an emerging healthcare technology and its implementation and dissemination, it is important for 
policy makers and payers to develop clear, concise, and thoughtful payment and coverage 
guidelines. 
The importance of properly addressing BRCA1/2 testing and reimbursement is even more 
apparent given its potential to act as a model for the commercialization of future genetic tests.  In 
	   4	  
many ways, BRCA1/2 could be thought of as a ‘poster child’ for genetic testing.  After all, 
BRCA1 and BRCA2 are two of the most widely studied genes in human history and research on 
these two genes has been extremely well funded.7,8  Additionally, the genes’ important role in 
breast cancer susceptibility is extensively documented in the scientific and medical literature.  
The controversy surrounding Myriad Genetics and the publicity generated by Angelina Jolie’s 
double mastectomy have also increased awareness of the two genes.9  Lastly, breast cancer has 
very vocal advocates and is characterized by high political mobilization.  All of these factors 
have placed BRCA1/2 in a unique position to act as a model for how genetic testing should be 
addressed going forward.  Though challenging to create uniform testing guidelines and 
consistent reimbursement standards, researchers and policy makers should view the recent 
openness of the BRCA1/2 testing market as an opportunity to set an important precedent for 
situations that are sure to be even more complex.  
 
 
 
 
 
 
 
 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
7 Note: Myriad Genetics alone claims it has spent over $500 million on BRCA1/2 research.  Source: Ray, T., "Not 
Backing Down in BRCA Test Infringement Case, Ambry Slaps Myriad with Antitrust Countersuit," GenomeWeb. 
August 7, 2013. http://www.genomeweb.com/clinical-genomics/not-backing-down-brca-test-infringement-case-
ambry-slaps-myriad-antitrust-counte. Accessed April 24, 2014.  
8 Note: A search for "BRCA1" on PubMed retrieved over 10,000 scientific and medical abstracts/citations.  A 
similar search with the keyword "BRCA2" brought up over 6,000 results.  Source:  "NCBI Global Cross-database 
Search," NCBI. http://www.ncbi.nlm.nih.gov/gquery/?term=BRCA1. Accessed March 30, 2014.  
9 Note: On May 14, 2013, Angelina Jolie (famous Hollywood actress and director) wrote an opinion piece in The 
New York Times detailing her decision to get a double mastectomy.  With a mutation in BRCA1 and a strong family 
history, Jolie’s doctors estimated that she had an 87% chance of developing breast cancer.  By getting a double 
mastectomy, Jolie reduced her risk to under 5%.  In her article, Jolie wrote how she was motivated to undergo the 
surgery because she lost her mother to breast cancer and hopes to remain in her children’s lives for a long time.  This 
opinion piece received a significant amount of media attention and increased awareness of the BRCA1/2 genes.    
Source: Jolie, A., "My Medical Choice," The New York Times. Opinion Pages. 
http://www.nytimes.com/2013/05/14/opinion/my-medical-choice.html. Accessed April 8, 2014. 
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Historical & Scientific Background  
 
 
Overview 
A. Genetic Testing 
B. Breast Cancer  
C. BRCA1/2 
D. Testing for BRCA1/2 
E. Myriad Genetics 
F. Myriad’s Business Practices 
G. Gene Patents 
H. AMP v. Myriad Genetics (June 2013) 
I. Summary 
 
 
Genetic Testing 
 
 Genetic testing is now considered a routine and important component of medicine.  Well 
known since the 1970s for its use during pregnancy (to check for inherited conditions), DNA 
testing has various other applications as well.10  For instance, genetic information is used to 
personalize drug regimens and to lend insights into one’s predisposition for diseases, such as 
cancer.  Unfortunately, one of the difficulties associated with cancer research is that there are 
many different factors that come into play and genetics is only one piece of the puzzle.   
 Improvements in DNA sequencing over the past two decades have made it economically 
feasible to incorporate various genetic tests into standard medical practice.  Current market 
leaders, such as Illumina and Life Technologies can sequence a human genome, with high 
accuracy, for a few thousand dollars (see Figure 1).11  To compare, it took an international 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
10 Press, N., "Genetic Testing and Screening," from Birth to Death and Bench to Clinic: The Hastings Center 
Bioethics Briefing Book for Journalists, Policymakers, and Campaigns, ed. Mary Crowley. 2008. Garrison, NY: The 
Hastings Center: 73-78. 
11 Wetterstrand, K., “DNA Sequencing Costs: Data from the NHGRI Large-Scale Genome Sequencing Program,” 
National Human Genome Research Institute. www.genome.gov/sequencingcosts. October 29, 2013. Accessed 
February 1, 2014.   
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collaboration of researchers approximately 13 years and $3.8 billion to sequence the first human 
genome, completed in 2003.12,13,14  
Though we now have the ability to sequence full genomes, other genetic tests have also 
been developed that look for mutations in just one, or a handful, of genes.  In addition to being 
much cheaper, these tests are much more practical because they target specific areas of the 
genome where doctors suspect a mutation(s).  Tests that analyze a genome for mutations in a 
specific gene are usually referred to as single-gene tests, whereas multi-gene panels look for a 
greater number of mutations that influence one’s predisposition to a disease.15    
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
12 Note:  In 2003 a “high quality” “rough draft” of the human genome was completed.  It was not until 2006 that the 
final Human Genome Project (HGP) papers were published.  These final papers helped “to close gaps, reduce 
ambiguities, and allow for only a single error every 10,000 bases, the agreed-upon standard for the HGP.”  Source: 
“Human Genome Project Information,” Genomics.energy.gov. 
http://www.ornl.gov/sci/techresources/Human_Genome/home.shtml. July 25, 2011. Accessed February 2, 2014.   
13 Note:  The exact ‘cost’ of the Human Genome Project has been disputed, as the project was multi-faceted. 
According to the Battelle Institute report in 2011, the Federal Government “had direct expenditures totaling almost 
$3.8 billion” for the sequencing programs.  Another commonly referenced figure for the total cost of the project is 
$13 billion.  However, this larger figure refers to “a wide range of scientific activities related to genomics;” the 
“human genome sequencing represents only a small fraction of the overall 13-year budget.” 
14 “Economic Impact of the Human Genome Project,” Battelle Technology Partnership Practice.  
http://battelle.org/media/press-releases/$3.8b-investment-in-human-genome-project-drove-$796b-in-economic-
impact-creating-310-000-jobs-and-launching-the-genomic-revolution. May 2011. Accessed February 2, 2014. 
15 Note: It should be noted that even within one gene, there can be a wide range of possible mutations.  Thus, some 
genetic tests can test for a specific mutation in a gene (a ‘point mutation’), multiple mutations within one gene, or 
multiple mutations that span several genes.   
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Breast Cancer  
 
Breast cancer is one of the most widely studied diseases.  According to the National 
Cancer Institute (NCI), the most common type of breast cancer is ductal carcinoma, which 
“begins in the lining of the milk ducts;” however, breast cancer refers quite broadly to any cancer 
that forms in the breast tissue.  The cancer is far more common in women than in men.  In 2013, 
there were an estimated 232,430 new female cases and 2,240 new male cases.  In the same year, 
about 39,620 females died due to the disease, compared to 410 males.16   
The Surveillance, Epidemiology, and End Results (SEER) Program of the NCI estimates 
that 12.4% of women born in the United States today will develop breast cancer at some point in 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
16 “Breast Cancer,” NCI, NIH. http://www.cancer.gov/cancertopics/types/breast. Accessed February 1, 2014. 
Figure 1 ⏐  Cost per Genome.  This figure displays the rapid decrease in cost for 
sequencing an entire human genome. Source: Wetterstrand, K., “DNA Sequencing 
Costs: Data from the NHGRI Large-Scale Genome Sequencing Program,” National 
Human Genome Research Institute. www.genome.gov/sequencingcosts. October 29, 
2013. Accessed February 1, 2014.   
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their lives (“about a 1 in 8 chance of being diagnosed).”17  Though incidence rates are expected 
to fluctuate year-to-year, there has been a slight overall increase since the 1970s, when women 
had about a 10% chance of being diagnosed.18  These rates are averages, and more specific 
incidence rates (by race, age group, etc.) can be found from the SEER report.  For instance, the 
probability of developing breast cancer increases with age; most breast cancers are diagnosed 
after age 50 (Table I).19,20 
 
Table I | Age and Breast Cancer Risk. 
Current Age (yrs) Risk of Developing Breast Cancer in the Next 10 Years (%) 
 
20   0.06 
30   0.44 
40   1.47 
50   2.38 
60   3.56 
70   3.82 
80   3.04 
 
 
As Table I demonstrates, age is a very strong risk factor for developing breast cancer.  
Other risk factors include breast density, family history and personal history of breast cancer, 
high amounts of radiation therapy, high alcohol consumption, long-term use of hormone 
therapies, high body mass index, reduced physical activity, and race.21  Furthermore, though only 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
17 "Breast Cancer Risk in American Women," National Cancer Institute, National Institutes of Health. 
http://www.cancer.gov/cancertopics/factsheet/detection/probability-breast-cancer. October 24, 2012. Accessed 
February 1, 2014.  
18 Note: More information on breast cancer incidence can be found from the SEER (Surveillance, Epidemiology, 
and End Results Program) Cancer Statistics Review Report, last updated in August of 2012.  Visit:  
Howlader, N., et al. (eds)., SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD, 
http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER web 
site, April 2013.  
19 Data Selected from Table 4.18: Cancer of the Female Breast (Invasive)" of the SEER Cancer Statistics Review 
1975-2009. http://seer.cancer.gov/csr/1975_2009_pops09/results_single/sect_04_table.18.pdf.  
20 "Genetics of Breast and Ovarian Cancer (PDQ®)," NCI, NIH.  
21 Note: According to the American Cancer Society, "white women are slightly more likely to develop breast cancer 
than are African-American women, but African-American women are more likely to die of this cancer. However, in 
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a small proportion of breast cancer cases (5-10%) have a known genetic link, individuals with 
these known genetic mutations have a significantly higher risk of developing heritable breast 
cancer.22 
 
BRCA1/2 
 
The two genes that are most strongly associated with a significantly increased risk of 
developing heritable breast cancer are BRCA1 and BRCA2.  Genes are sections of DNA that code 
for certain proteins.23  A gene’s DNA sequence dictates the primary structure of a protein, so 
when a mutation occurs in DNA, proteins often become misfolded and damaged.  This change in 
structure then affects a protein’s function.  Random mutations in our DNA actually occur quite 
frequently; however, it is the presence of key machinery, such as repair proteins, that help to 
modulate these damages.  Both BRCA1 and BRCA2 are tumor suppressor genes.  Tumor 
suppressor genes code for proteins that are essential for DNA repair pathways.24  Thus, when a 
mutation in BRCA1/2 occurs, the proteins created by these genes (tumor suppressor proteins) 
become damaged and are unable to repair damaged DNA.   
 Specific mutations in BRCA1/2 greatly increase the risk of developing breast (and 
ovarian) cancer.  These mutations are inherited in an autosomal dominant pattern, which means 
that mutations can be passed down from one’s mother or father and that the harmful effects will 
be present even if only one parent passes on a mutated copy of the gene.  If one parent has a 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
women under 45 years of age, breast cancer is more common in African- American women. Asian, Hispanic, and 
Native-American women have a lower risk of developing and dying from breast cancer." Source:  "What are the risk 
factors for breast cancer?," American Cancer Society. January 31, 2014. 
http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-risk-factors. Accessed April 24, 2014.  
22 "Genetics of Breast and Ovarian Cancer (PDQ®)," NCI, NIH.  
23 Note:  Following the Central Dogma of Molecular Biology, DNA is converted to RNA through a process called 
transcription.  Then, RNA is converted to proteins through a process called translation.   
24 "BRCA1 and BRCA2: Cancer Risk and Genetic Testing," NCI, NIH.   
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BRCA1/2 mutation, there is a 50% chance that his or her child will inherit the deleterious 
mutation.25  
 If one inherits a harmful mutation, then there is a 45% chance (with a BRCA2 mutation) 
and a 55-65% chance (with a BRCA1 mutation) of developing breast cancer.  These individuals 
also have an 11-17% chance (with a BRCA2 mutation) and a 39% chance (with a BRCA1 
mutation) of developing ovarian cancer, compared to the average in the general population of 
1.4%.26,27  These risk percentages are averages, and vary based on other factors such as age and 
race.  For instance, individuals of Ashkenazi Jewish descent are much more likely to carry a 
BRCA1/2 mutation than other populations.  Whereas BRCA1/2 mutations occur in 0.25% (1/400) 
of the general population, harmful mutations occur in 2.3 to 2.7% of the Ashkenazi Jewish 
population.28,29,30 
 Though there is a significantly higher probability of developing breast cancer with a 
BRCA1/2 mutation, very few women actually carry such a mutation.  Thus, guidelines have 
emerged detailing which individuals would benefit from testing, and when they should consider 
it.  Various organizations and societies have their own guidelines.31  In the United States, the 
most widely followed recommendations are those laid out by the United States Preventative Task 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
25 "BRCA1 and BRCA2: Cancer Risk and Genetic Testing," NCI, NIH. 
26 "BRCA1 and BRCA2: Cancer Risk and Genetic Testing," NCI, NIH. 
27 Note:  According to the National Cancer Institute, ovarian cancer is the ninth most common cancer in the United 
States and the fifth most deadly.  In 2013, there was an estimated 22,240 newly diagnosed cases and 14,030 deaths.  
Source: "Genetics of Breast and Ovarian Cancer (PDQ®)," NCI, NIH.  
28 "Final Recommendation Statement - Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-
Related Cancer in Women," U.S. Preventive Services Task Force (USPSTF). 
http://www.uspreventiveservicestaskforce.org/uspstf12/brcatest/brcatestfinalrs.htm. December 2013. Accessed 
February 2, 2013. 
29 Roa, B. B., Boyd, A. A., Volcik, K., & Richards, C. S. (1996). Ashkenazi Jewish population frequencies for 
common mutations in BRCA1 and BRCA2. Nature Genetics 14, no. 2: 185-187. 
30 Struewing, J. P., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., McAdams, M., & Tucker, M. A. (1997). The 
risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. New England 
Journal of Medicine 336, no. 20: 1401-1408. 
31 "BRCA1 and BRCA2: Cancer Risk and Genetic Testing," NCI, NIH. 
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Force (USPSTF) and the National Comprehensive Cancer Network (NCCN).  These 
recommendations differ slightly (to be discussed in Chapter 3).   
Generally, individuals who are thought to have a family history of breast and ovarian 
cancer are encouraged to seek genetic counseling (Figure 2).  If a physician or genetic counselor 
recommends further exploration, then it is “most informative to first test a family member who 
has had breast or ovarian cancer.”32,33  If this affected family member tests positive for a harmful 
BRCA1/2 mutation, then other family members (who have not had breast/ovarian cancer) may 
want to consider testing.  Such testing for additional family members is cheaper than the initial 
test because researchers know precisely where the mutation is on the gene.  Thus, instead of 
sequencing the full gene to look for a mutation, researchers can pinpoint specific regions where 
this ‘known familial mutation’ would be.  If individuals are unaware of their family history, it is 
not recommended to get BRCA1/2 testing unless he/she has early-onset breast or ovarian cancer.  
Additionally, because “no risk-reduction strategies for children exist,” children should not 
undergo BRCA1/2 testing until they become adults.34   
 
 
 
 
 
 
 
 
 
 
 
 
 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
32 "BRCA1 and BRCA2: Cancer Risk and Genetic Testing," NCI, NIH. 
33 Note: The logic of testing an affected family member first (before the patient), is that this affected family member 
(considering he/she has already developed breast or ovarian cancer) is the most likely to carry a BRCA1/2 mutation.   
34 "BRCA1 and BRCA2: Cancer Risk and Genetic Testing," NCI, NIH. 
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Meet with Primary Care Physician 
Goal: Identify individuals who have an increased risk of carrying a harmful 
BRCA1/2 mutation 
Method: Gather a detailed family history; use various screening tools (See 
Appendix 4)  
Outcome: Recommend high-risk individuals for further counseling.  If individuals 
receive a “low risk” result from the screening tools, there is little recognized 
benefit of continuing through the genetic testing process.  
↓  
 
Meet with a Genetic Counselor 
Goal: Identify individuals who are at a high risk of carrying a BRCA1/2 
mutation and guide them through the testing process 
Method: Gather a detailed family history, complete additional risk assessments, 
genetic testing education (discuss possible test results and their respective 
implications), identify other high-risk family members, discuss risk-reduction 
strategies. 
Outcome: Patients may choose to proceed with genetic testing, or to pursue other 
options 
↓  
 
Genetic Testing 
Goal: Identify if, and where, a mutation in BRCA1/2 exists 
Method: DNA sequencing; the particular type of analysis varies (will be 
discussed later).  For instance, specific tests are recommended for Ashkenazi 
Jewish individuals and for individuals with a known familial mutation.   
Outcome: Possible test results include: (A) Positive for a deleterious mutation    
(B) Negative test result (C) Variant of Unknown Significance (VUS) 
↓  
 
Continued Genetic Counseling 
Goal: Interpret genetic test results and implications for patients 
Method: Discuss meaning of test results. Depending on the test result, 
additional education and continued counseling may be necessary.  
Outcome: Patients may decide to pursue various options such as enhanced 
screening or prophylactic surgeries.  Depending on the test result, relatives of 
patients may also be contacted and brought into the genetic testing and 
counseling process.  
 
 
Figure 2 | Common Steps in the Genetic Testing Process for BRCA1/2.  This 
figure was created by the author to illustrate the most common pathway to getting 
tested for a BRCA1/2 mutation.  These steps follow the USPSTF’s 
recommendations (see Chapter 3). 
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As Figure 2 illustrates, genetic counselors are central in the genetic testing process for 
BRCA1/2.  Genetic counselors are particularly important because test results are not always 
straightforward.  After getting tested, patients could receive one of a few different results.  
Individuals could test positive for a known, deleterious mutation.  In such instances, patients may 
choose to undergo prophylactic surgeries to reduce their risk of developing cancer, or may want 
to increase the frequency of their screenings.  Patients could also receive a negative test result, 
indicating that their BRCA1/2 sequence does not contain a mutation.  Lastly, patients can receive 
an uninformative test result, meaning that the patient has a variant of unknown significance 
(VUS).  This uninformative result occurs when a BRCA1/2 mutation is found, but researchers do 
not know whether the mutation is deleterious.  Usually researchers do not know the clinical 
significance of these mutations because they lack enough data to understand how harmful the 
mutation is (if at all).  
 
 
Testing for BRCA1/2  
 
When genetic testing is ordered for BRCA1/2, a patient’s DNA is collected, either from a 
buccal swab or a blood sample.  This sample is then sent to a company for analysis.  For the past 
15 years, the only company that performed this test in the United States was a genetic testing 
company called Myriad Genetics.  Researchers Mark Skolnick, Walter Gilbert, Peter Meldrum, 
and Kevin Kimberlin founded Myriad in 1991 to help Skolnick and his team at the University of 
Utah in the sequencing of, and subsequent development of a test for, BRCA1.  In August of 1994, 
Skolnick’s team won the race against many other research groups across the country to sequence 
BRCA1.  Researchers quickly filed a patent application on BRCA1, and, in 1996, filed a patent 
application on BRCA2, the other major breast cancer susceptibility gene.  Shortly afterwards, the 
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company released their first genetic test, called BRACAnalysis®, which tests for mutations in 
BRCA1/2.35  Though Myriad was initially founded with the goal of developing this genetic test, 
the company now offers other diagnostic tests as part of their broader goal of “elucidating the 
role genes play in human disease.”36  The different versions of the tests Myriad currently offers 
for BRCA1/2 can be seen in Table II.  
 
Table II | Myriad: BRCA1/2 Testing Options 
Test Cost Test Details 
Integrated/ 
Comprehensive 
BRACAnalysis® 
$4,040  Complete BRCA1/2 sequence;  5 common large rearrangements 
BRACAnalysis®   $3,340  Complete BRCA1/2 sequence 
Single Site 
BRACAnalysis® for 
BRCA1 
$475  Tests for known familial mutations 
Single Site 
BRACAnalysis® for 
BRCA2 
$475  Tests for known familial mutations 
Multisite 
BRACAnalysis® $575  3 Ashkenazi Jewish founder mutations 
BRACAnalysis Large 
Rearrangement Test 
(BART) 
$700  Just large rearrangement testing, not sequencing 
MyRisk® $4,000 - $4,500 
25 genes for 8 hereditary cancers (breast, 
ovarian, gastric, colorectal, pancreatic, 
melanoma, prostate, and endometrial). 
Expected to be released in September 2014. 
 
 
 
 
 
 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
35 “Brief History of Myriad,” Myriad Genetics. http://www.myriad.com/about-myriad/history/. Accessed February 
2, 2014. 
36 “Brief History of Myriad,” Myriad Genetics.  
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Myriad Genetics Controversy 
 
 Since developing a test for BRCA1/2, and filing patents on the two genes, Myriad 
Genetics has received a significant amount of negative publicity and attention.  This attention is 
in large part (if not entirely) due to the controversial nature of gene patents and the company’s 
business practices.  Researchers and physicians have claimed that Myriad’s patents on BRCA1/2 
have limited research and have prevented additional genetic testing companies from entering into 
the market.  With a monopoly in the market, Myriad has been able to charge an extremely high 
price (over $3,000) for its BRACAnalysis® test.37  
Motivated by the high testing cost (limiting access to the test) and the belief that human 
DNA should not be patent eligible, a group of researchers, physicians, patients, and advocacy 
groups came together in 2009 to file a lawsuit against Myriad (see Figure 3).  The plaintiffs 
argued that Myriad’s patents were invalid under Section 101 of the Patent Act, which states that, 
to obtain a patent, one must “invent or discover any new and useful … composition of matter.”38  
The Supreme Court has previously stated that this provision contains an important implicit 
exception: “laws of nature, natural phenomena, and abstract ideas are not patentable,” as they 
“are the basic tools of scientific and technological work.”39  Thus, plaintiffs argued that patents 
on the sequence of BRCA1/2 are invalid for precisely this reason – DNA, as a natural 
phenomenon, cannot be patent eligible.   
   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
37 Note: Given current sequencing costs, a price of over $3,000 is quite high.  However, the analysis and 
interpretation that comes with the test result is one of the main reasons for the high testing cost.  As the only testing 
company for the past 15 years, Myriad has built up an extremely valuable database of data.  This database contains 
information on the clinical significance of variants of unknown significance (VUS) and will give Myriad a 
competitive advantage over entering testing companies.  A movement has begun, often referred to as Free the Data, 
that is trying to release this genetic information. 
38 “35 USC §101 – Inventions patentable,” Legal Information Institute, Cornell University. 
http://www.law.cornell.edu/uscode/text/35/101. Accessed February 2, 2014. 
39  Mayo Collaborative Services, Mayo Medical Laboratories, et al. v. Prometheus Laboratories, Inc., 566 U.S. 1 
(2012). http://www.supremecourt.gov/opinions/11pdf/10-1150.pdf. 
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Figure 3 | Plaintiffs in AMP v. Myriad.  
*The ACLU and The Public Patent Foundation were not plaintiffs, but provided legal counsel    
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Gene Patents 
 
To understand the controversy surrounding gene patents and the importance of 
Association for Molecular Pathology (AMP) v. Myriad Genetics, it is helpful to review the 
historical context.  The right to patent and to hold intellectual property arises from Article 1, 
Section 8, Clause 8 of the United States Constitution, which states that Congress shall have the 
power “to promote the progress of science and useful arts, by securing for limited times to 
authors and inventors the exclusive right to their respective writings and discoveries.”40  The four 
main methods to protect one’s intellectual property (IP) are through owning patents, copyrights, 
trademarks, and trade secrets.41  Within the biotech field, patents are the most applicable because 
they protect ‘inventions.’  Essentially, a patent gives the ‘assignee’ the right to sue anyone who 
infringes upon his or her “exclusive right to make, use, and sell the patented innovation for a 
limited period of time.”42  Today, the U.S. Patent and Trademark Office (USPTO), a Federal 
agency, manages patent and trademark claims. 
Historically, the USPTO has granted patents on human genes.  A study published in 2005 
found that over 4,000 of the approximately 23,000 human genes have been noted or claimed as 
intellectual property.43  Another study found that the USPTO has “granted over 50,000 patents 
containing at least one DNA-related claim.”44  With about 20% of the human genome patented 
(although estimates vary significantly), one could rightly wonder why Myriad has acquired so 
much negative attention.  One potential reason is that the genes Myriad patented are not trivial; a 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
40 “Constitution of the United States,” U.S. Constitution, Article 1, Section 8, Clause 8. National 
Archives and Records Administration. http://www.archives.gov./exhibits/charters/constitution_transcript.html. 
Accessed February 2, 2014.  
41 “Office of Policy and International Affairs,” U.S. Patent and Trademark Office (USPTO), 
http://www.uspto.gov/ip/global/index.jsp. October 1, 2013.  Accessed February 2, 2014.  
42 "Patent,” Cornell University Law School: Legal Information Institute.  
http://www.law.cornell.edu/wex/patent. August 19, 2010.  Accessed February 2, 2014.  
43 Jensen & Murray (2005). Intellectual property landscape of the human genome. Science 310 (5746): 239-240. 
44 Liang, G. (2012). Molecules or Carriers of Biological Information: A Chemist’s Perspective on the Patentability 
of Isolated Genes. Albany Law Journal of Science and Technology 22: 133-645. 
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mutation in BRCA1/2 leads to a significantly increased risk of developing heritable breast 
cancer.45  With pink ribbons covering anything from yogurts to charity walk banners, it is hard to 
deny that breast cancer is one of America’s most visible diseases.  Furthermore, like many 
scientific breakthroughs, Myriad’s discovery relied heavily on the work of previous researchers.  
For example, Mary-Claire King, a geneticist at UC-Berkeley, was one of the first scientists to 
believe there was a heritable component to breast and ovarian cancer.  After years of searching, 
she discovered the genetic link between breast cancer risk and chromosome 17 in the early 
1990s.46  Her discovery subsequently ignited a race among researchers to identify, sequence, and 
clone the gene(s) that accounted for this heritability.  Lastly, perhaps the main reason Myriad has 
gathered so much negative attention is that, once the company won the race to sequence 
BRCA1/2, Myriad strictly enforced its patents in a manner that angered a wide range of 
individuals.47 
 
 
AMP v. Myriad Genetics (June 2013)  
 
After the initial lawsuit in 2009, the case was passed through the courts and did not reach 
the Supreme Court until the spring of 2013 (Table III).48  Though seven patents and intellectual 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
45  Note: As discussed above, a woman’s lifetime chance of developing breast cancer increases from 12% to 45% 
(with a BRCA1 mutation) or 55-65% (with a BRCA2 mutation).  Similarly, a woman’s lifetime chance of developing 
ovarian cancer is 1.4%, which increases to 11-17% (with a BRCA2 mutation) and 39% (with a BRCA1 mutation).  
Source: "BRCA1 and BRCA2: Cancer Risk and Genetic Testing," NCI, NIH. 
46 Note: To learn more about Dr. Mary Claire King’s perspective on ‘the race’ to map, sequence, and test for 
BRCA1/2, consider reading her recent article:  King, M.C. (2014). “The Race” to Clone BRCA1. Science 343, no. 
6178: 1462-1465.  
47 Note: Myriad gathered negative attention from a variety of interest groups.  These groups had similar goals, but 
differed slightly in their motivations.  For example, civil rights and advocacy groups argued that Myriad’s high 
testing cost limited access to the test.  Patients believed they deserved access to second opinions before undergoing 
life-altering medical procedures.  Researchers had received cease-and-desist letters and many fundamentally 
believed that genes should not be patentable material.  
48 Table Sources: (1) Association for Molecular Pathology (AMP) et al. v. Myriad Genetics, Inc., 569 U.S. 1 (2013). 
http://www.supremecourt.gov/opinions/12pdf/12-398_1b7d.pdf.  (2) “Association for Molecular Pathology v. 
Myriad Genetics – Timeline of Events,” American Civil Liberties Union. 
https://www.aclu.org/timelines/association-molecular-pathology-v-myriad-genetics-timeline-events.  
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property claims were in question, the critical point at stake was whether or not DNA (in its 
isolated form) can be patented.49   
 
Table III | AMP v. Myriad Timeline 
Date Event 
May 2009 American Civil Liberties Union (ACLU) and Public Patent Foundation (representing more than 20 plaintiffs) file suit against Myriad. 
March 2010 Judge Robert Sweet, of the Southern District of NY (Federal District Court), rules that DNA is not patent eligible. 
July 2011 Defendants appeal to the Court of Appeals for the Federal Circuit (CAFC).  CAFC rules that gene patents are valid. 
March 2012 Supreme Court sends the case back to the CAFC for further review.  
August 2012 CAFC again rules that patents on genes are valid. 
September 2012 Plaintiffs appeal to the Supreme Court.  
April 2013 Supreme Court hears oral arguments. 
June 13, 2013 Supreme Court invalidates gene patents (AMP v. Myriad Genetics) 
 
 
 
 
 
 
 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Accessed February 2, 2014.   (3) Cook-Deegan et al., “BRCA Briefing Page,” Duke University: Institute for 
Genome Sciences & Policy. http://www.genome.duke.edu/centers/cpg/Myriad/. Accessed February 2, 2014. 
49 (1) Skolnick et al., U.S. Patent No. 5,747,282  (2) Shattuck-Eidens et al., U.S. Patent No. 5,693,473 (3) Tavtigian 
et al., U.S. Patent No. 5,837,492).  
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On June 13, 2013, the Supreme Court ruled loosely in the plaintiff’s favor.50  As the 
Opinion of the Court reads, “Myriad’s principal contribution was uncovering the precise location 
and genetic sequence of the BRCA1 and BRCA2 genes within chromosomes 17 and 13.51  The 
Court found that while Myriad “found an important and useful gene, separating that gene from 
its surrounding genetic material is not an act of invention.”  If Myriad’s patents were methods 
patents, detailing an innovative new procedure for isolating BRCA1/2 or for manipulating the 
genes, then the patents might have been found valid.  However, given that “the claims focus on 
the genetic information encoded in the BRCA1 and BRCA2 genes,” and this information is 
determined by nature, the Supreme Court ruled that the claims were not valid.52  
 
 
Summary 
 
Genetics plays an important role in the development of many diseases.  One of these 
diseases is breast cancer.  Mutations in two genes, BRCA1 and BRCA2, increase one’s chances of 
developing heritable breast cancer.  Though mutations in BRCA1/2 are rare, the probability of 
developing breast cancer increases so significantly with a harmful mutation in these genes that 
they have become two of the most widely studied human genes.  In 1996, Myriad Genetics was 
the first company to develop a test (called BRACAnalysis®) for mutations in these genes.  Since 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
50 Note: The actual case was much more complicated.  While the Supreme Court did rule in the plaintiff’s favor by 
saying that isolated DNA is not patentable, the Court upheld Myriad’s cDNA patents.  cDNA stands for 
‘complementary DNA.’  The logic behind this ruling is that isolated DNA (or gDNA) is not patent eligible because 
it is a product of nature and not an act of invention (i.e., simply isolating a gene is not new and noteworthy).  
However, the Supreme Court did not consider cDNA to be a product of nature, as it involves significant 
manipulation by man.  This cDNA decision is also controversial.  Because all of Myriad’s cDNA patents were 
upheld, the company still believes they hold a strong enough patent portfolio to prevent other testing companies 
from entering the market.  However, as the next chapter shows, many companies did enter the market and claim that 
they are not infringing upon Myriad’s patents.  Myriad has sued many of these companies, but the cases are still 
ongoing and, in the meantime, these companies will continue to offer BRCA1/2 testing.  
51 Association for Molecular Pathology (AMP) et al. v. Myriad Genetics, Inc., 569 U.S. 1 (2013). 
http://www.supremecourt.gov/opinions/12pdf/12-398_1b7d.pdf. 
52 AMP et al. v. Myriad Genetics, Inc. 
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the release of this test, thousands of women have benefitted from the information, and 
subsequent analysis, that Myriad has provided.   
Though Myriad has helped thousands of women personalize their breast cancer 
prevention and treatment strategies, the company has gained a significant amount of negative 
attention due to their intellectual property (IP) and business practices.  The controversy 
surrounding Myriad’s patents and high testing costs provided the impetus for a lawsuit 
challenging the validity of gene patents.  Twenty plaintiffs (representing a variety of interest 
groups, from patients to physicians and research organizations) filed suit against Myriad in 2009, 
arguing that DNA, as a naturally occurring material, is not patent eligible.  On June 13, 2013, the 
Supreme Court sided with the plaintiffs by unanimously declaring gene patents invalid.53  The 
Court’s decision was widely considered to be one of the most important alterations to U.S. patent 
policy in recent history.  Immediately following the Court decision, many academic institutions 
and private companies announced their plans to develop genetic tests for BRCA1/2.  Though 
Myriad still has a significant competitive advantage over these companies, there is no doubt that 
the genetic testing landscape for BRCA1/2 will be dramatically different going forward.54  
 
 
 
 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
53 Note:  The Supreme Court ruled that Myriad’s patents on the isolated genes BRCA1 and BRCA2 were invalid; 
however, they upheld Myriad’s patents on cDNA.   
54 Note:  This court case is particularly important for Myriad because a majority of the company’s earnings are from 
its BRACAnalysis® test.  According to Myriad's 2013 Annual Report, the BRACAnalysis® test "accounted for 
75.1% of total revenue."  Myriad’s BART test (large rearrangement analysis) accounted for another 9.6%.  Source: 
"Annual Report," Myriad Genetics. August 14, 2014. http://investor.myriad.com/secfiling.cfm?filingID=1193125-
13-334245. Accessed April 17, 2014.	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A Changing Genetic Landscape 
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Aftermath of the Supreme Court Case  
 
The effects of the Supreme Court’s ruling in June of 2013 could be seen immediately.  
On June 13, 2013, the same day that the decision was released, the Deputy Commissioner for 
Patent Examination Policy, A.H. Hirshfeld, released a memorandum to all Patent Examining 
Corps explaining the new policy change.  As Hirshfeld writes, AMP v. Myriad “significantly 
changes the Office’s examination policy regarding nucleic acid-related technology.”55  The letter 
calls on examiners to “reject product claims drawn solely to naturally occurring nucleic acids or 
fragments thereof, whether isolated or not, as being ineligible subject matter under 35 U.S.C. 
§101.”56  
Within a week of the ruling many biotech companies and medical centers announced 
plans to develop BRCA1/2 tests, claiming that they would offer them at significantly lower prices 
than Myriad.  Though each of the new testing companies will be summarized in the table below, 
readers should consult Appendix 2 for more details regarding the pricing and technical details of 
each of these tests.   
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
55 Hirshfeld, A. H., “Memorandum: Supreme Court Decision in Association for Molecular 
Pathology v. Myriad Genetics, Inc.,” United States Patent and Trademark Office (USPTO). June 13, 2013. 
http://www.uspto.gov/patents/law/exam/myriad_20130613.pdf. Accessed February 6, 2014. 
56 Hirshfeld, United States Patent and Trademark Office. 
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New Competitors 
 
Research Methods 
 
 The following table on current BRCA1/2 testing companies and costs was primarily 
drawn from company websites.  This information was gathered to investigate how much (or how 
little) BRCA1/2 testing costs have changed over the past 15 years and to aid in the analysis of 
payer policies.  Company names were found from reading news articles following the June 2013 
Supreme Court case.  Since these companies and laboratories are interested in publicizing their 
new BRCA1/2 tests, it was not difficult to compile a list of them.  Company websites differed in 
the amount of information publically available.  In most instances, especially when company 
websites provided unclear, contradictory, or insufficient information, company representatives 
were contacted by phone and email.  Please note that this information is time sensitive.  New 
companies may be entering the market and test prices may have changed since the latest 
revision.57   
 
 
 
 
 
 
 
 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
57 Note:  In addition to the companies listed in Appendix 2, there are a couple academic centers that offer BRCA1/2 
testing, but just for their own patients.  For instance, the University of North Carolina's Molecular Genetics Lab 
offers testing only for individuals referred from its Cancer Genetics Clinic.  The Institute of Genomic Medicine 
(New Jersey's Medical School) also offers BRCA1/2 testing, but not commercially.  Furthermore, due to "insurance 
restrictions," the lab "does not provide testing for most patients through the NJMS lab anyways."  Baylor Medical 
Genetics Laboratories does not yet have an in-house sequencing test for BRCA1/2 and sends all samples to Counsyl 
for analysis.  Though there has been speculation that the University of Pennsylvania and Washington University in 
St. Louis would offer tests, as of April 20, 2014, these institutions have not released a test.  Private companies, such 
as DNA Direct, Inc. and Pathway Genomics, have also expressed interest in entering the testing market but have not 
developed tests yet.  
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Overview 
 
 The following table lists the current BRCA1/2 testing options in the United States.  
Companies and academic institutions are presented in chronological order, with the first 
company to offer testing presented first (Myriad Genetics).  The date each company entered the 
BRCA1/2 testing market is listed underneath each company name, along with company’s VUS 
rate.  Then, test titles, costs, descriptions, and turn around times (TATS) are provided.   Full-gene 
sequencing is abbreviated as "seq" and duplication/deletion analysis is abbreviated as "dup/del." 
CPT codes for each of the tests are listed in Appendix 6.  
Readers should consult Appendix 2 for further details on each of these new testing 
companies.  Appendix 2 provides a brief description of the company, states the sequencing 
technology used, and, if the company offers multi-gene panels, then these genes are listed as 
well.  
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Table IV |  Summary of New BRCA1/2 Testing Options 
Company 
(Date of 
Entrance) 
(VUS rate) 
Test Title Cost Test Description TATs 
Integrated/ 
Comprehensive 
BRACAnalysis® 
$4,040 Complete BRCA1/2 sequence; 5 common large rearrangements 14 days 
BRACAnalysis® (not 
comprehensive) $3,340 
Comprehensive 
BRACAnalysis® now 
recommended for most patients  
14 days 
BRCA1 or BRCA2 
Single Site 
BRACAnalysis®   
$475 Known familial mutations in BRCA1 or BRCA2 14 days 
Multisite 
BRACAnalysis® $575 
3 Ashkenazi Jewish founder 
mutations 14 days 
BRACAnalysis Large 
Rearrangement Test 
(BART) 
$700 Offered as an add-on to BRACAnalysis®  14 days 
Myriad 
Genetics 
 
1996 
 
 
BRCA1 VUS: 
0.6%. 
 
BRCA2 VUS: 
1.6% 
MyRisk® B/w $4,000 and $4,500 
25 genes for 8 hereditary 
cancers (breast, ovarian, gastric, 
colorectal, pancreatic, 
melanoma, prostate, and 
endometrial). Expected to be 
released in September. 
TBD 
UCLA 
Diagnostic 
Molecular 
Pathology 
Lab 
 
May 2012 
 
VUS: n/a 
BRCA1 & 2 Ashkenazi 
Jewish Mutations approx. $500 
3 Ashkenazi Jewish founder 
mutations 3-28 days 
BRCA1 or BRCA2 site 
specific analysis $400 
Detection of a known familial 
mutation in BRCA1 or BRCA2 7-14 days 
BRCA Ashkenazi 
Jewish panel $500 3 founder mutations 7-10 days 
Ambry 
Genetics 
 
June 13, 2013 
 
 
VUS: 4.4% 
BRCA1/2 Deletion/ 
Duplication Only $500 Del/dup analysis  14 days 
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BRCA1/2 Sequence + 
Deletion/Duplication  $2,200 
Full gene sequencing and 
del/dup analysis  14-21 days 
BRCA Ashkenazi 
Jewish 3-site mutation 
panel w/ reflex to 
BRCA1/2 analysis 
$2,250 
3 founder mutations.  If test 
comes back negative, it reflexes 
to full sequencing of BRCA1/2. 
14-21 days 
BRCA1/2 analysis w/ 
reflex to BRCAplus® if 
negative 
$3,350 
Full gene sequencing of 
BRCA1/2.  If test comes back 
negative, it reflexes to del/dup 
analysis and analysis of 4 other 
high-risk genes.  
14-21 days 
BRCAplus® $3,300 
Sequence and del/dup analysis 
of 6 clinically actionable genes 
for breast cancer  
21 days 
BreastNext® $3,900 Del/dup analysis of 18 genes for breast cancer 6-10 weeks 
OvaNext® $3,900 
Full gene sequencing and 
del/dup analysis of 23 genes for 
breast, ovarian and/or uterine 
cancers. 
8-12 weeks 
 
CancerNext® $4,250 
Full gene sequencing and 
del/dup analysis of 28 genes for 
cancer susceptibility. 
8-12 weeks 
Single Gene Analysis $1,350 Sequencing for any gene, such as BRCA1 or BRCA2 12 weeks 
Known Familial 
Mutation $450 Point mutation analysis  12 weeks 
BRCA1/2 Ashkenazi 
Jewish 3-site n/a 
Test not performed by 
Washington; Samples sent to 
Mayo for testing and analysis 
12 weeks 
BRCA1/2 Complete 
Analysis $2,200 Sequencing and dup/del 12 weeks 
University 
of 
Washington 
 
June 14, 2014 
 
VUS: 15% 
BROCA - Cancer Risk 
Panel $3,350 
Complete seq. of genes and 
detection of large del/dup and 
mosaicism. Genes for breast or 
ovarian cancer, colorectal, 
endometrial, pancreatic, 
endocrine, or melanoma. 
12 weeks 
Hereditary Breast and 
Ovarian Cancer Testing $1,250 
Sequence and rearrangement 
analysis of BRCA1/2.  20-30 days 
Ethigen 
 
June 19, 2013 
 
VUS: 5-7% 
Rapid Hereditary 
Breast and Ovarian 
Cancer Testing 
$1,950 Sequence and rearrangement analysis of BRCA1/2.  < 15 days 
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Expanded Cancer Panel $2,250 
Multigene panel (sequencing 
and del/dup analysis) for 
BRCA1/2 and 17 other genes  
20-30 days 
Breast Ovarian Cancer 
NGS Panel 
$1450 
(institutional)  
$1950         
(3rd party) 
Sequencing of 30 genes 
involved in hereditary breast and 
ovarian cancer predisposition. 
4-6 weeks 
BRCA1 and BRCA2 
deletion/duplication 
analysis  
$500 
(institutional 
only) 
 2 weeks 
BRCA1 and BRCA2 
gene sequence analysis 
$500 
(institutional 
only) 
  2 weeks 
Fulgent 
Therapeutics, 
LLC 
 
mid-June 2013 
 
 
VUS: 6% 
Hereditary Cancer 
Panel (HCP) 
$1450 
(institutional)  
$1950         
(3rd party) 
Sequencing (no del/dup) of 49 
genes involved in susceptibility 
for many cancers  
4-6 weeks 
BRCA1/2 Sequencing $1,850   2 weeks 
BRCA1/2 Del/Dup $1,000   7-10 days 
BRCA1/2 Familial 
Variant  
For 1: $350     
For 2: $500  2-3 weeks 
BRCA1/2 Sequencing 
and Del/Dup Analysis $2,200   2 weeks 
BRCA1/2 Ashkenazi 
Founder Mutation 
Panel 
$450   7-10 days 
OncoGeneDx 
Comprehensive Cancer 
Panel 
$4,530 
Sequence and Del/Dup Analysis 
for 35 genes for cancer 
susceptibility  
10 weeks 
Breast Cancer High 
Risk Panel $3,700 
Sequence and Del/Dup Analysis 
for 6 genes for breast cancer 10 weeks 
Gene DX 
 
 
 
August 28, 
2013 
 
VUS: 5%        
(will have an 
updated VUS 
rate within the 
next month) 
Breast/Ovarian Cancer 
Panel $3,850 
Sequence and Del/Dup Analysis 
for 26 genes for breast and 
ovarian cancer 
10 weeks 
Quest 
Diagnostics 
BRCAvantage® 
Comprehensive 
Evaluation  
$2,495 Sequencing and del/dup analysis in BRCA1/2 14 days 
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BRCAvantage® 
Ashkenazi Jewish 
Evaluation  
$500 3 founder mutations 7 days 
BRCAvantage® Single 
Site $500 
Detection of a known familial 
mutation in BRCA1/2. 14 days 
 
mid-October 
2013 
 
 
VUS: 1.9%   
(VUS rate based 
off only 500 
samples.  Will 
update in May 
2014 w/ 2000 
more samples; 
expected to 
increase) 
BRCAvantage® 
Rearrangement 
Evaluation  
$500 Detection of dup/del in BRCA1/2. 14 days 
BRCA1 and BRCA2 
familial testing $415 
Testing for known familial 
BRCA1/2 mutations just by 
sequence analysis.   
2-4 weeks 
Custom del/dup testing  $650 
Custom deletion/duplication 
testing by quantitative PCR. 
Test costs $450 for additional 
family members. 
4-6 weeks 
(2nd family 
member: 3-
4 weeks) 
The 
University 
of Chicago 
Genetic 
Services 
 
November 20, 
2013 
 
VUS: n/a 
BRCA1 and BRCA2 
founder mutations $475   2-4 weeks 
BRCA1 or BRCA2 
Targeted Analysis $500 
Just sequencing of BRCA1 or 
BRCA2. 14 days 
BRCA1/2 
Comprehensive 
Analysis 
(BRCAssure®) 
$2,895 Sequencing and del/dup analysis of BRCA1/2. 21 days 
BRCA1/2 Del/Dup 
Analysis  $700 
Just del/dup analysis of 
BRCA1/2. 14 days 
LabCorp 
 
 
December 2, 
2013 
 
 
VUS: 4.6% 
BRCA1/2 Ashkenazi 
Jewish Profile $600 Just sequencing of BRCA1/2. 10-12 days 
Hereditary breast and 
ovarian cancer  $1,500 
Full-gene seq. and del/dup 
analysis for breast and ovarian 
cancer 
2 weeks 
High-Risk Hereditary 
Breast Cancers  $1,500 
Full-gene seq. and del/dup 
analysis of 6 genes for cancer 
susceptibility & other 
syndromes  
2 weeks 
 
InVitae 
 
 
December 
2013 
 
 
VUS: 6% 
Women's Hereditary 
Cancers $1,500 
Full-gene seq. and del/dup 
analysis of 17 genes for cancer 
susceptibility  
2 weeks 
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Hereditary Cancer 
Syndromes $1,500 
Full-gene seq. and del/dup 
analysis of 29 genes for 16 
different cancers and disorders  
2 weeks 
 
Family Testing 
Services $200 Targeted mutation analysis 2 weeks 
Center for 
Human 
Genetics 
January 2014 
VUS: n/a 
3 founder mutations $450  --- 
Counsyl 
Spring 2014 
VUS: 5.3% 
Counsyl Inherited 
Cancer (BRCA) Screen $999 Sequence and dup/del analysis  2 weeks 
BRCA Mutation Panel  Won’t disclose 
Full gene sequencing and 
del/dup analysis; 28 days 
BRCA Ashkenazi 
Jewish Founder 
Mutations  
Won’t 
disclose    
BRCA1/2 Targeted 
Sequencing, Familial  
Won’t 
disclose   28 days 
BRCA1/2 Gene 
Sequencing  
Won’t 
disclose    
University 
of Michigan 
State 
Testing Lab 
 
Spring 2014 
 
VUS: TBA 
BRCA1/2 del/dup 
analysis  
Won’t 
disclose   21-28 days 
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As Table IV demonstrates, many new testing companies have entered the BRCA1/2 
testing market since June 2013.   The following graphs help to illustrate these market changes. 
Figure 4 demonstrates that many new testing companies have entered the market with cheaper 
tests.  This graph compares comprehensive BRCA1/2 analysis test costs (so full gene sequencing 
and large rearrangement testing).  Not all companies offer this particular version of BRCA1/2 
testing, so only those companies with comparable tests were included.  Figure 5 shows how 
BRCA1/2 testing companies (except for the University of Washington) have extremely similar 
turn-around-times (TATs); most companies return a patients’ test results in under 20 days.  
Lastly, Figure 6 illustrates how Myriad has the lowest VUS rate of all BRCA1/2 testing 
companies.  Ambry, with a rate of 4.4%, and LabCorp, with a rate of 4.6%, are the next lowest 
companies.58  The University of Washington has the highest VUS rate at 15%.  Though these 
graphs display general market trends since June 2013, they should be viewed holistically and in 
conjunction with Table IV and Appendix 2.  These BRCA1/2 testing companies all offer slightly 
different tests, and each test is then associated with its unique VUS rate and turn-around-time, so 
it is difficult to directly compare each of the companies.  
 
 
 
 
 
 
 
 
 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
58 Note:  Technically, Quest Diagnostics has reported a VUS rate of 1.9%.  However, this is only based off 500 
samples.  Company representatives expect this rate to increase soon as they are about to recalculate the VUS rate 
with 2,000 more samples.  
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Figure 4 ⏐  Cost Comparison.  This figure displays the drop in test cost following the June 
2013 Supreme Court case.  This particular figure displays the costs for comprehensive 
BRCA1/2 analysis (so both full gene sequencing and rearrangement analysis).  Only those 
companies that offered this particular test were included in this figure.  Readers should consult 
Table IV and Appendix for other companies that offer BRCA1/2 testing. 
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Figure 5 ⏐  Turn Around Time Comparison.  This figure displays the 
turn around times (TATs) of the existing BRCA1/2 testing companies for 
their sequencing and large rearrangement test.  All companies have 
extremely similar TATs, except for the University of Washington with a 
TAT of 12 weeks.  
 
 
 
 
Figure 6 ⏐  VUS Rate Comparison.  This figure displays the VUS rates of each 
existing BRCA1/2 testing company.  Myriad has the lowest rate (at 1.6%) and the 
University of Washington has the highest (at 15%).  Most companies have rates 
in the 4-6% range.    
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Cost on Decision Making 
 
After presenting new BRCA1/2 test options (made possible by the 2013 Supreme Court 
decision), it is helpful to examine the literature on how important cost is for patients’ considering 
BRCA1/2 testing.  Several studies have aimed to determine the significance of reimbursement for 
patients, and, more broadly, to examine the various motivations behind genetic testing decision-
making.  
For instance, in 2000 and 2001, Velicer and Taplin explored awareness of BRCA1/2 
testing and breast cancer survivors’ intention of getting tested.  To this end, researchers 
conducted a “population-based survey of 276 female survivors between the ages of 40 and 49 
and living 5 to 10 years post-diagnosis.”59  They found that only 26% of these women would be 
willing to get tested if they had to pay for it.  Of these women, only 7% would be willing to pay 
more than $200 for the test.  However, if insurance did cover testing, then 67% of women would 
be willing.  Researchers also found that the most commonly cited benefit for getting tested 
(according to the patients) was learning more about their children’s or relative’s risk.  However, 
the most commonly cited disadvantage was a concern about losing insurance.  Overall, Velicer 
and Taplin concluded that most women seem to have a positive attitude towards BRCA1/2 
testing, but that their study demonstrates “how strongly [breast cancer survivors’] intent to obtain 
genetic testing is tied to insurance coverage.”60   
 A similar study by Peterson et al. aimed to determine the impact of concerns such as cost, 
confidentiality, and insurance discrimination on BRCA1/2 testing decisions.61  Peterson worked 
with a group of 384 patients who were part of a Breast and Ovarian Cancer Risk Evaluation 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
59 Velicer, C.M. and Taplin, S. (2001). Genetic testing for breast cancer: Where are health care providers in the 
decision process?. Genetics in Medicine 3: 112-119.    
60 Velicer and Taplin, Genetics in Medicine. 
61 Peterson, E.A., Milliron, K.J., Lewis, K.E., Goold, S.D., et al. (2002). Health insurance and discrimination 
concerns and BRCA1/2 testing in a clinic population. Cancer Epidemiol Biomarkers Prev 11: 79–87. 
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Program in Ann Arbor and Grand Rapids, Michigan.  Within this group, 184 individuals met the 
qualifications for BRCA1/2 testing and 58% of them chose to proceed with testing.  The 
remaining 42% of individuals declined testing, and over half of them “cited concerns about cost 
and insurance discrimination as their reason.”62  Peterson et al. estimated that “approximately 
half of the patients [who] declined testing because of insurance coverage concerns would be 
positive for a BRCA1/2 mutation,” indicating that (at least in this study) cost was prohibiting 
many women from finding out valuable health information.  Concerns over cost were intensified 
in individuals with lower incomes.  Though there was not a “significant difference between the 
higher and lower income groups for the importance attached to test result confidentiality,” there 
was a “significant difference [P-value of 0.003] based on income in the importance attached to 
insurance coverage for testing between the two income groups.”63  While this conclusion is to be 
expected, it nevertheless reinforces the importance of cost for low-income individuals 
considering testing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
62 Peterson et al., Cancer Epidemiol Biomarkers Prev. 
63 Peterson et al., Cancer Epidemiol Biomarkers Prev. 
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Summary 
 
Since the 2013 Myriad Supreme Court case, many new companies have entered the 
BRCA1/2 testing market.  While some of these companies are long-established diagnostic testing 
companies (Quest and LabCorp), most are smaller labs that specialize in testing for a few 
hereditary disorders.  These new companies offer a variety of test options.  Small tests, such as 
for a known familial mutation, can cost as low as $200 (Invitae), and large multi-gene panels 
cost anywhere from $1,000 to $4,000.   
Given less than a year has passed since the court case (in June of 2013), it is likely that 
the market has not reached equilibrium and test prices will continue to fluctuate.  Test options 
may also change.  For example, as will be discussed in the next section, insurance companies do 
not currently cover multi-gene panels.  Yet, most of the new BRCA1/2 testing companies have 
many multi-gene test offerings.  If insurance companies continue to not cover multi-gene tests, 
then lower costs could help to incentivize out-of-pocket purchase.  If demand gets even lower, 
such tests may need to be removed from a company’s test portfolio entirely.  Further research is 
needed on when (if ever) physicians prefer to order multi-gene panels rather than single gene 
sequencing.  Additionally, because the literature overviewed here focused on patient opinions 
from the early 2000s, future research should investigate the effect of cost on decision-making 
today. 
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Rules for Coverage and Reimbursement 
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BRCA1/2 Testing Recommendations  
 
In order to consider insurance coverage of BRCA1/2 tests, it is important to first 
understand the medical guidelines for when an individual should get tested.  In the United States, 
there are two main BRCA1/2 testing recommendations – those by the United States Preventative 
Services Task Force (USPSTF) and by the National Comprehensive Cancer Network (NCCN) 
(see Tables V, VI).  The major difference between the two sets of recommendations is that the 
NCCN lays out specific criteria for who should seek BRCA1/2 testing, whereas the USPSTF lays 
out a general process.   
The National Comprehensive Cancer Network (NCCN) is a "not-for-profit alliance of 25 
of the world's leading cancer centers."  Clinical professionals from these top cancer centers 
regularly create "clinical practice guidelines appropriate for use by patients, clinicians, and other 
health care decision-makers."64  For BRCA1/2, the NCCN first provides a list of  ‘Criteria for 
Further Genetic Risk Evaluation.’  If an individual meets one or more of the criteria in that 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
64 "About NCCN," National Comprehensive Cancer Network. http://www.nccn.org/about/default.aspx. Accessed 
March 29, 2014.  
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category, then the NCCN recommends referral to a cancer genetics professional (see Table 
V).65,66  This professional will offer the proper genetic counseling, and review over the 
‘Hereditary Breast and/or Ovarian Cancer Syndrome Testing Criteria.’  Meeting “one or more of 
these testing criteria warrants further personalized risk assessment, genetic counseling, and often 
genetic testing and management.”67 
The NCCN now also recognizes how “certain large genomic rearrangements are not 
detectable by primary sequencing assays, thereby necessitating supplementary testing, in some 
cases.”  Thus, the NCCN recommends “comprehensive testing, which encompasses full 
BRCA1/2 sequencing and detection of large gene rearrangements” for individuals who “meet the 
testing criteria for BRCA1/2 and have no known familial BRCA1/2 mutations.”68  Most of the 
BRCA1/2 testing companies outlined in the previous chapter offer this test (usually referred to as 
dup/del analysis).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
65 Bevers, T. B., Anderson, B. O., Bonaccio, E., Buys, S., Daly, M. B., Dempsey, P. J., ... & Yankeelov, T. (2009). 
Breast cancer screening and diagnosis. Journal of the National Comprehensive Cancer Network 7, no. 10: 1060-
1096. 
66 "Genetic/Familial High-Risk Assessment: Breast and Ovarian," NCCN Clinical Practice Guidelines in Oncology, 
National Comprehensive Cancer Network, Inc. 2014. 
http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. Accessed March 21, 2014.  
67 "Genetic/Familial High-Risk Assessment: Breast and Ovarian," NCCN Clinical Practice Guidelines. 
68 “Medical Policy: Genetic Testing for HBOC,” United HealthCare Services.   
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Table V | National Comprehensive Cancer Network BRCA1/2 Testing Guidelines 
 
Criteria for Further Genetic Risk Evaluation 
A. An affected individual with one or more of the following: 
• A known mutation in a breast cancer susceptibility gene within the family 
• Early-age-onset breast cancer 
• Triple negative (ER-, PR-, HER2-) breast cancer 
• Two breast cancer primaries in a single individual 
• Breast cancer at any age, and  
o ≥ 1 close blood relative with breast cancer ≤ 50 years, or 
o ≥ 1 close blood relative with epithelial ovarian cancer at any age, or 
o ≥ 2 close blood relatives with breast cancer and/or pancreatic cancer at any age 
o From a population at increased risk 
• ≥ 1 family member on the same side of the family with a combination of breast cancer and ≥ of the 
following (especially if early onset): pancreatic cancer, prostate cancer (Gleason score ≥ 7), 
sarcoma, adrenocortical carcinoma, brain tumors, endometrial cancer, leukemia/lymphoma; thyroid 
cancer, dermatologic manifestations, and/or macrocephaly, hamartomatous polyps of GI tract; 
diffuse gastric cancer 
• Ovarian cancer 
• Male breast cancer 
 
B. An unaffected individual with a family history of one of more of the following: 
• A known mutation in a breast cancer susceptibility gene within the family 
• ≥ 2 breast primaries in single individual 
• ≥ 2 individuals with breast primaries on the same side of the family 
• ≥ 1 ovarian cancer primary from the same side of the family 
• First- or second-degree relative with breast cancer ≤ 45 years 
• ≥ 1 family member on same side of family with a combination of breast cancer and ≥ 1 of the 
following (especially if early onset): pancreatic cancer, prostate cancer (Gleason score ≥ 7), 
sarcoma, adrenocortical carcinoma, brain tumors, endometrial cancer, leukemia/lymphoma; thyroid 
cancer, dermatologic manifestations, and/or macrocephaly, hamartomatous polyps of GI tract; 
diffuse gastric cancer 
• Male breast cancer 
 
Hereditary Breast and/or Ovarian Cancer Syndrome Testing Criteria.   
• Individual from a family with a known deleterious BRCA1/BRCA2 mutation 
• Personal history of breast cancer and one of more of the following: 
o Diagnosed ≤ 45 years 
o Diagnosed ≤ 50 years with: 
 An additional primary 
 ≥ 1 close blood relative with breast cancer at any age 
 An unknown or limited family history 
o Diagnosed ≤ 60 years with: 
 Triple negative breast cancer  
o Diagnosed at any age with: 
 ≥ 1 close blood relative with breast cancer diagnosed ≤ 50  
 ≥ 2 close blood relatives with breast cancer at any age 
 ≥ 1 close blood relative with epithelial ovarian cancer 
 ≥ 2 close blood relatives with pancreatic cancer and/or prostate cancer 
(Gleason score ≥7) at any age 
 A close male blood relative with breast cancer 
 For an individual of ethnicity associated with higher mutation frequency (eg, 
Ashkenazi Jewish) no additional family history may be required 
• Personal history of epithelial ovarian cancer 
• Personal history of male breast cancer 
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• Personal history of pancreatic cancer or prostate cancer (Gleason score ≥7) at any age with ≥ 2 close 
blood relatives with breast and/or ovarian and/or pancreatic or prostate cancer (Gleason score ≥7) at 
any age 
• Family history only (Significant limitations of interpreting test results for an unaffected individual 
should be discussed) 
o First- or second-degree blood relatives meeting any of the above criteria 
o Third degree blood relative with breast cancer and/or ovarian cancer with ≥ 2 close 
blood relatives with breast cancer (at least one with breast cancer ≤ 50y) and/or ovarian 
cancer 
o Clinical judgment should be used to determine if the patient has reasonable likelihood 
of a mutation, considering the unaffected patient’s current age and the age of female 
unaffected relatives who link the patient with the affected relatives. 
o Testing of unaffected individuals should only be considered when an appropriate 
affected family member is unavailable for testing.   
 
 
 
 
 
The U.S. Preventive Services Task Force (USPSTF) is an "independent panel of non-
Federal experts in prevention and evidence-based medicine," composed mostly of primary care 
providers.  The panel conducts "scientific evidence reviews of a broad range of clinical 
preventive health care services (such as screening, counseling, and preventive medications) and 
develops recommendations for primary care clinicians and health systems."  For BRCA1/2 
testing, the USPTSF recommends individuals with a family history of breast or ovarian cancer to 
first speak with their primary care provider (PCP) (see Table VI).69,70,71   PCPs are encouraged to 
screen women with one of several recommended screening tools (see Appendix 4).  Then, if a 
woman tests positive with one of these screening tools, she should “receive genetic counseling 
and, if indicated after counseling, BRCA testing."72  
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
69 "Preventive Services Panel Advises Against Broad BRCA Testing: 'Family History' Should Guide Testing," 
GenomeWeb. December 27, 2013. http://www.genomeweb.com/clinical-genomics/preventive-services-panel-
advises-against-broad-brca-testing-family-history-shou. Accessed March 21, 2014.  
70 Moyer, V.A. (2014) Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in 
Women: U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine 160, no. 4: 
271-281. 
71 Nelson, H.D., Pappas, M., Zakher, B., Mitchell, J.P., Okinaka-Hu, L., Fu, R. (2013). Risk assessment, genetic 
counseling, and genetic testing for BRCA-related cancer in women: A systematic review to update the U.S. 
Preventive Services Task Force recommendation.  Published online on December 24, 2013.  
72 Moyer, Annals of Internal Medicine. 
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Table VI | United States Preventative Task Force (USPSTF) BRCA1/2 Testing Guidelines73 
 
 
 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
73 Note: The USPSTF assigns to their recommendations various letter “grades” (A, B, C, D, or I).  These grades 
correspond to the following descriptions:  A. The USPSTF recommends the service. There is high certainty that the 
net benefit is substantial.  B. The USPSTF recommends the service. There is high certainty that the net benefit is 
moderate or there is moderate certainty that the net benefit is moderate to substantial.  C. The USPSTF recommends 
selectively offering or providing this service to individual patients based on professional judgment and patient 
preferences. There is at least moderate certainty that the net benefit is small.  D. The USPSTF recommends against 
the service. There is moderate or high certainty that the service has no net benefit or that the harms outweigh the 
benefits.  I. The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and 
harms of the service. Evidence is lacking, of poor quality, or conflicting, and the balance of benefits and harms 
cannot be determined. Source: "Grade Definitions," U.S. Preventive Services Task Force (USPSTF). July 2012. 
http://www.uspreventiveservicestaskforce.org/uspstf/grades.htm. Accessed April 7, 2014. 
	   42	  
Readers should note that the USPSTF's recommendations apply only to women, and 
specifically only those who have not been diagnosed with breast cancer.  The USPSTF 
encourages women who have been diagnosed with breast cancer and who have a family history 
of breast or ovarian cancer to "discuss further evaluation with their clinician."  However, no 
specific recommendations are made because "that assessment is part of disease management," 
which is "beyond the scope” of the USPSTF.”74   
 
 
New Competitors (Insurance Information) 
 
 
Research Methods 
 
 The following information on current coverage policies for BRCA1/2 testing was 
primarily drawn from company websites.  The websites of the companies discussed in the 
previous chapter were explored for any and all insurance and payment information.  Company 
websites differed in the amount of information publically available.   
  
Overview 
 
Most genetic testing companies offer free insurance pre-verification before proceeding 
with testing.  Given the diversity and complicated nature of insurance plans, this step is 
extremely important for patients so that they can learn their specific BRCA1/2 testing cost.  Some 
companies have established out-of-pocket cost thresholds.  For example, after a test is ordered, 
Myriad Genetics will check the patient’s insurance coverage.  If patients are expected to pay 
more than $375 out-of-pocket for the test, then Myriad will re-contact the patient before 
proceeding (Table VII).  However, if their expected contribution is less than this limit, testing 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
74 Moyer, Annals of Internal Medicine. 
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will continue without notification.  Other companies re-contact the patient after insurance 
verification, despite the patient’s expected cost.   
Table VII offers a summary of Appendix 3A.  Testing companies were evaluated to see if 
they offered pre-verification services.  If applicable, the cost thresholds at which companies will 
re-contact patients to ask if patients want to proceed with testing is also included.  Lastly, it is 
noted if a company bills with Medicare, Medicaid, and commercial insurers and whether 
financial assistance programs exist.  Cells with “---“ implies that there was no mention of that 
service.   
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Table VII | Insurance Information Offered by Testing Companies 
 
Pre-verification 
and 
Cost thresholds 
Medicare Medicaid Private Financial Aid Programs 
Myriad Yes. >$375 
Yes, if 
conditions 
are met. 
--- Yes Yes 
UCLA --- --- --- --- --- 
Ambry 
Yes.  
 
>$100 
Yes, if 
conditions 
are met. 
Some states’ 
Medicaid 
plans 
“Majority of 
commercial 
insurers” 
Yes.  Medicare/ 
Medicaid individuals 
not eligible. 
University 
of 
Washington 
Yes. 
Re-contact 
always. 
Yes, if 
conditions 
are met. 
Some states’ 
Medicaid 
plans 
--- Yes. Patients “may be eligible for a discount” 
Ethigen --- --- --- --- --- 
Fulgent --- --- --- --- --- 
GeneDX Yes.  >$100 
Yes, if 
conditions 
are met. 
No 
All 
commercial 
insurances. 
Yes. For those without 
commercial insurance. 
Quest 
Yes. 
Re-contact 
always. 
Yes, if 
conditions 
are met. 
Yes Yes --- 
University 
of Chicago 
No mention of 
pre-verification 
services.  
Yes, if 
conditions 
are met. 
Some states’ 
Medicaid 
plans 
Most 
insurance 
plans. 
No 
LabCorp 
Yes. 
Re-contact 
always 
Yes, if 
conditions 
are met. 
Yes Yes Yes 
Invitae Yes No No Yes Yes. For those without insurance. 
Center for 
Human 
Genetics 
--- --- --- --- --- 
Counsyl Yes.  >$299 No No 
Most 
insurance 
plans. 
Yes 
University 
of Michigan 
No mention of 
pre-verification 
services.  
Yes, if 
conditions 
are met. 
Some states’ 
Medicaid 
plans 
Most 
insurance 
plans. Not 3rd 
party billing 
for outside 
facility's 
samples. 
Yes, but many criteria 
must be met.  
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Insurance Policies 
 
 
Research Methods 
 
 The following table on BRCA1/2 reimbursement policies offers a summary of Appendix 
3 (parts B & C).  The information contained in Appendix 3 was found by searching individual 
insurance company websites for genetic testing policies and for policies related to the prevention 
and screening of breast cancer.   
The insurance policies overviewed here should not be considered exhaustive of all 
BRCA1/2 coverage policies.  Rather, these companies represent some of the larger and better-
known insurance companies in the country.  A 2007 report by the Harvard School of 
Government cites that Aetna, Blue Cross Blue Shield, Cigna, Humana, Kaiser, UnitedHealth, 
and Wellpoint are the nation’s largest insurers.  According to these estimates, BCBS insures 
about 33% of the US population, followed by Medicare and Medicaid at 15%, Wellpoint at 12%, 
United Health at 6%, and Aetna at 5%.   Humana, Cigna, and Kaiser each cover 3% of the 
population.75  Due to their large size, all of these payers were analyzed to see if they had specific 
BRCA1/2 coverage policies. 
In addition to these large insurers, the reader consulted a 2012 report by the Kaiser 
Family Foundation, which listed the largest three private insurers (in terms of enrollment) for 
each state.76,77  The author supplemented the starting list (of BCBS, Medicare, Medicaid, 
Wellpoint, United Health, Aetna, Humana, Cigna, and Kaiser) with insurance companies on this 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
75 "Health Care Delivery Covered Lives – Summary of Findings," John F. Kennedy School of Government, Harvard 
University. 2007. http://www.hks.harvard.edu/m-rcbg/hcdp/numbers/Covered%20Lives%20Summary.pdf. 
Accessed April 20, 2014. 
76 "Market Share and Enrollment of Largest Three Insurers- Large Group Market" 
http://kff.org/other/state-indicator/market-share-and-enrollment-of-largest-three-insurers-large-group-market/. 
Accessed April 20, 2014.  
77 Note: Data was originally drawn from the Center for Consumer Information & Insurance Oversight (CCIIO).  
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list that had memberships of over 100,000 people.  The resulting list of 24 insurance companies 
are shown in Table VIII.78  In many instances, specific policies could not be found.  It is 
important to note that the lack of an available coverage policy does not necessarily imply a non-
covered service, as payers may not publish all of their coverage determinations.   
In future research it will be necessary to undertake a more systematic assessment of payer 
policies for BRCA1/2 testing.  Given there is little research in this field, there is not a widely 
adopted methodology for which payers to include in such an analysis.  In 2013, Graf et al. wrote 
one of the “first known surveys of all major US private health insurers with publicly available 
genetic testing policies.”79  These authors similarly relied on simple Internet searches to find 
insurance policies.  However, they first acquired a list of insurers from Atlantic Information 
Services, Inc. and selected the insurance companies with 50,000 or more members.80  Future 
research could expand upon the number of insurance companies analyzed.  
 
Overview 
 
For more details regarding each of the following policies, see Appendix 3C (where these 
policies are actually provided).  Cells with “---“ implies that there was no mention of that 
service.   
 
 
 
 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
78 Note:  This list would have been much larger, but the author removed all subsidiaries of the BlueCross BlueShield 
(BCBS) Association.  Instead of looking for a specific policy for each of these subsidiaries, the author analyzed one 
of the largest components of BCBS (Anthem).  In future research, the other subsidiaries of BCBS should also be 
reviewed.  
79 Graf, M.D., Needham, D.F., Teed, N., & Brown, T. (2013). Genetic testing insurance coverage trends: a review of 
publicly available policies from the largest US payers. Personalized Medicine 10, no. 3: 235-243. 
80 Graf et al., Personalized Medicine. 
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Table VIII  |  BRCA1/2 Reimbursement Policies 
Insurance 
Company 
BRCA1/2 testing 
covered?   
Dup/Del 
Analysis 
covered? 
Multi-
gene 
Panels 
covered? 
Genetic 
Counseling 
covered? 
Only 
contracted 
with 
Myriad? 
Aetna Inc 
Yes, if NCCN criteria 
are met or >10% 
probability from 
accredited risk 
assessment tools. Claims 
to follow the USPSTF, 
ACOG, ACMG 
guidelines, but lists the 
NCCN criteria.  
No.  ---  Yes. 
Indirectly 
requires 
Myriad for 
testing.    
BlueCross 
BlueShield 
(Anthem)  
No national coverage 
policy found. Anthem 
follows NCCN criteria. 
Yes, if 
criteria are 
met.  
No. 
Yes. Required 
both pre-and 
post-test. 
No.  No 
mention of a 
specific testing 
company. 
Centene 
No national coverage 
policy found. 
Preauthorization 
required for genetic tests.   
---  ---  ---  ---  
Cigna 
Yes, if common criteria 
are met or >10% 
probability from 
accredited risk 
assessment tools.   
Yes, if 
criteria are 
met.  
No.  Yes. Required.  
No.  No 
mention of a 
specific testing 
company. 
Coventry 
Corp.  
Group 
Yes. Follow USPSTF 
recommendations that 
have an A or B rating 
---  ---  Yes. ---  
Dean 
Health 
Group 
Yes, listed, but no 
specific policy found. 
Covered w/ no member 
cost sharing 
---  ---  Yes. ---  
Emblem 
Health 
Yes, if listed criteria are 
met. 
Yes, if 
criteria are 
met. 
--- 
Covered pre-
and post-
testing, but 
not required 
Indirectly 
requires 
Myriad for 
testing.   
Geisinger 
Health Plan 
Yes, if NCCN criteria 
are met. 
Yes, if 
criteria are 
met. 
--- Yes.  
No.  No 
mention of a 
specific testing 
company. 
Group 
Health 
Cooperative  
Yes, but testing criteria 
not publicly available. 
Yes, but 
criteria not 
available. 
No --- --- 
Harvard 
Pilgrim 
Health Care 
Group  
Yes, listed, but no 
specific policy found. 
Covered w/ no member 
cost sharing. 
--- --- Yes --- 
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Health 
Alliance 
Midwest  
No policy found.  --- --- --- --- 
Health Net Yes, if NCCN criteria are met. 
Yes, if 
criteria are 
met. 
--- 
Responsibility 
of care 
provider. 
Indirectly 
requires 
Myriad for 
BART testing.    
Health New 
England 
Yes, if NCCN criteria 
are met. --- --- 
Only pre-test 
counseling 
required. 
Unclear. 
Health 
Partners 
Group 
Yes, if NCCN criteria 
are met. 
Yes, if 
criteria are 
met. 
--- Yes. Required pre-testing 
Indirectly 
requires 
Myriad for 
testing.    
Humana 
Yes, if NCCN criteria 
are met. Preauthorization 
required.  
Yes, if 
criteria are 
met.  
No. 
Yes. Part of 
their Genetic 
Guidance 
Program.  
No.  No 
mention of a 
specific testing 
company. 
Kaiser 
Foundation 
Group 
No national policy 
found. --- --- 
Yes. Required 
both pre-and 
post-test. 
No.  No 
mention of a 
specific testing 
company. 
Medica 
Group 
Yes, if NCCN criteria 
are met. Preauthorization 
required.  
Yes, if 
criteria are 
met.  
--- Yes. Required pre-testing 
Indirectly 
requires 
Myriad for 
BART testing.    
Medicaid No national policy found. --- --- --- --- 
Medical 
Mutual of 
Ohio 
Yes, listed, but no 
specific policy found. --- --- Yes. --- 
Medicare 
No national coverage 
policy. LCDs follow 
NCCN criteria, but only 
for people w/ a personal 
history of breast and 
ovarian cancer 
Yes, if 
criteria are 
met. 
--- 
Yes. Required 
both pre-and 
post-test. 
No.  No 
mention of a 
specific testing 
company. 
Select 
Health  
Yes, listed, but no 
specific policy found. --- --- Yes --- 
Spectrum 
Health No policy found. --- --- --- --- 
Tufts 
Health Plan 
Yes, if listed criteria are 
met. Covered w/ no 
member cost sharing. 
Yes, if 
criteria are 
met. 
---  Yes. 
Indirectly 
requires 
Myriad for 
BART testing.    
United 
Health Care 
Yes, if NCCN criteria 
are met. 
Yes, if 
criteria are 
met. 
---  Strongly recommended. 
No.  No 
mention of a 
specific testing 
company. 
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Privacy Regulations and Insurance  
 
 As the literature review on the importance of cost on decision making illustrated (see 
previous chapter), patients also have a significant fear of losing their health insurance as a result 
of genetic testing.  In the United States, there are two main regulations in place to protect the 
privacy of patients and their health care information.81,82 
First, the Federal Policy for the Protection of Human Subjects (known colloquially as 
‘The Common Rule’) was established in June of 1991.83  The Common Rule draws heavily from 
ethical considerations set forth by the Belmont Report in 1976.84  Enforced by the Office for 
Human Research Protections (OHRP), the Common Rule defines human subjects, details what 
types of research are exempt or nonexempt, and sets forth guidelines for informed consent and 
Institutional Review Boards. 
The Privacy Rule of the Health Information Portability and Accountability Act 
(HIPAA) establishes “a set of national standards for the protection of certain health 
information.”85  (Thus, HIPAA pertains more to privacy in health care, whereas the Common 
Rule helps guide research that involves human subjects).  The Department of Health and Human 
Services states that “a major goal of the Privacy Rule is to assure that individuals’ health 
information is properly protected while allowing the flow of health information needed to 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
81 Lowrance, W.W., “Privacy, Confidentiality, and Identifiably in Genomic Research,” National Human Genome 
Research Institute (NHGRI), October 3, 2006.  
82 Note: For a comparison of the Common Rule and HIPAA, see:  Williams, E.D. "Federal Protection for Human 
Research Subjects: An Analysis of the Common Rule and Its Interactions with FDA Regulations and the HIPAA 
Privacy Rule," The Library of Congress: Congressional Research Service. 
http://www.fas.org/sgp/crs/misc/RL32909.pdf. June 2, 2005.  Accessed March 19, 2014.  
83 "Federal Policy for the Protection of Human Subjects ('Common Rule')," U.S. Department of Health & Human 
Services. http://www.hhs.gov/ohrp/humansubjects/commonrule/. Accessed March 19, 2014.  
84 "The Belmont Report," U.S. Department of Health & Human Services. 
http://www.hhs.gov/ohrp/humansubjects/guidance/belmont.html. Accessed March 19, 2014.  
85 "Health Information Privacy," U.S. Department of Health & Human Services. http://www.hhs.gov/ocr/privacy/. 
Accessed March 19, 2014.  
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provide and promote high quality health care and to protect the public's health and well being.”  
The rule (enforced by the Office for Civil Rights) protects ‘individually identifiable health 
information,’ which includes demographic data as well as past, present, and future health 
conditions (and the payment associated with these conditions).   
 The Genetic Information Nondiscrimination Act (GINA) was passed in 2008 to 
further the protections guaranteed through the Common Rule and HIPAA.  GINA prohibits 
genetic discrimination in employment and prevents group health plans and insurers from altering 
premiums based on genetic information.  GINA also expands upon HIPAA's regulations by 
providing "additional underwriting protections, prohibit[ing] requesting or requiring genetic 
testing, and restrict[ing] the collection of genetic information."86 
Though GINA has alleviated many concerns related to employment and health insurance 
discrimination, it does have its limitations.  Most notably, GINA's protections "do not extend to 
life insurance, disability insurance, and long-term care insurance."87  However, researchers at the 
University of Pennsylvania claim that "the few cases of people being charged more or denied 
access to life insurance appear to be based on family history information and not based on results 
from genetic testing."88  Another limitation is that GINA's provisions regarding employment 
discrimination do not apply to employers with fewer than 15 people.  Lastly, though health 
insurance cannot be denied due to a genetic test result, eligibility and insurance premiums can be 
altered based on "manifestation of a disease or disorder."89  Thus, someone could not be denied 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
86 "FAQs on the Genetic Information Nondiscrimination Act," United States Department of Labor. 
http://www.dol.gov/ebsa/faqs/faq-GINA.html. Accessed March 19, 2014.  
87 "GINA: The Genetic Information Nondiscrimination Act of 2008 - Information for Researchers and Health Care 
Professionals," Department of Health and Human Services (HHS). April 6, 2009. 
https://www.genome.gov/Pages/PolicyEthics/GeneticDiscrimination/GINAInfoDoc.pdf. Accessed March 19, 2014.  
88 "Insurance FAQ," Basser Research Center for BRCA, University of Pennsylvania. 
http://www.penncancer.org/basser/education-and-support/insurance-faq/. Accessed April 7, 2014.  
89 "GINA: The Genetic Information Nondiscrimination Act of 2008," HHS.  
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health insurance due to a genetic susceptibility to breast cancer, but if he or she actually presents 
with the cancer, then insurance can be affected.90  
 
 
Other Coverage Issues  
 
In 2006, the Secretary’s Advisory Committee on Genetics, Health, and Society 
(SACGHS) wrote a report addressing problems in the coverage and reimbursement of genetic 
tests.  The SACGHS was created in 2002 to help serve as a “public forum for deliberations on 
the broad range of human health and societal issues raised by the development and use of genetic 
tests and, as warranted, to provide advice on these issues.”91  After a year of research and 
consultations, authors created “nine steps to alleviate the barriers and improve current 
mechanisms for coverage and reimbursement of genetic tests and services.”  Details of the nine 
steps are provided in the report, but Table IX overviews these nine steps.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
90 "Insurance FAQ," Basser Research Center for BRCA, University of Pennsylvania. 
91 "Coverage and Reimbursement of Genetic Tests and Services," Secretary’s Advisory Committee on Genetics, 
Health, and Society. February 2006. http://depts.washington.edu/genpol/docs/SACGHS-ReportDraftApril2005.pdf. 
Accessed March 20, 2014.  
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Table IX | Overview of Nine Steps to Improve Coverage of Genetic Tests (SACGHS) 
(1) Evidence-Based Coverage Decision Making.  
• Encourage “payers to reassess how they make decisions about which tests and 
services to cover and under what conditions they will reimburse them” 
(2) Insurance Market. 
• Many private insurance companies look to Medicare for guidance because it is the 
largest provider of health insurance in the US.  However, Medicare’s target 
population is much older than that of private companies and genetic tests are usually 
“used for preventive, reproductive, or life planning purposes.”  Thus, “it may not be 
appropriate for private health insurance plans to follow Medicare’s lead in making 
coverage decisions for predictive and predispositional genetic tests and services.” 
(3) Medicare Coverage Decision Making Process. 
• Reduce inconsistencies between Medicare coverage decisions at the national and 
local level 
(4) Medicare Screening Exclusion.  
• There is a need to reassess Medicare’s screening exclusion, which limits coverage for 
genetic tests and genetic counseling.  
(5) Medicaid Coverage of Genetic Tests and Services.  
• Genetic tests and genetic counseling are “optional” services under Medicaid, which 
makes them susceptible to state budget cuts.  Furthermore, “variation in Medicaid 
coverage across States can result in disparate access to genetic tests and services.”  
(6) Medicare Clinical Laboratory Fee Schedule. 
• Some health care providers have argued that “Medicare laboratory fees often do not 
reflect a genetic test’s true cost.”  
(7) Billing and Reimbursement for Genetic Counseling Services. 
• Genetic counseling is extremely important, but often not reimbursed.  CPT billing 
codes also need updating.   
(8) Provider Education and Training. 
• Health providers should have a working knowledge of genetics and should be 
adequately trained to use and interpret genetic tests.  
(9) Public Awareness. 
• Increased public awareness has the potential to facilitate coverage, but could also 
result in the “misinformation and inappropriate demand for genetic tests and services” 
 
 
Given this report was written in 2006, some of these recommendations are not applicable 
today.  For instance, Current Procedural Terminology (CPT) codes have been updated (see 
Appendix 6).  Code stacking has been eliminated and, now, instead of focusing on the laboratory 
test method used, CPT codes reflect the purpose of the test (in this case, the gene being 
analyzed).  Physicians and insurers have generally responded favorably to the new coding 
system.  However, it would be helpful to conduct a review, similar to that by Harrison et al., to 
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study the impact of, and issues in implementation, of the current coding system.92  The SACGHS 
report also calls for increased reimbursement of genetic counseling.  Fortunately, as the previous 
chapter demonstrates, coverage for genetic counseling has also improved - most insurance 
companies now recognize the importance of counseling both pre- and post-testing. 
Despite the decrease in relevance of some of these recommendations, the SACGHS 
report does highlight one of the major remaining issues regarding testing to this day – there are 
still many inconsistencies in testing and coverage policies.  Though research is limited, many 
other studies have reached this conclusion.  For instance, Wang et al. found large differences in 
payer policies between public versus private payers.93  On average, private payers “had more 
detailed coverage policies for genetic services” than public payers.  Whereas Medicare does not 
cover testing for individuals who have not had cancer, most private payers studied by Wang et 
al. covered BRCA1/2 testing for all women (with or without cancer), assuming they met the 
testing criteria.94   
Graf et al. also concluded that there is significant “variation between payers on the 
number and scope of policies” and that many “challenges remain in ensuring consistency.”  
However, authors did acknowledge that reimbursement of genetic tests could be expected to vary 
given “payers have varying coverage philosophies and decision-making strategies.” 
Nevertheless, additional research should focus on how payers are “approaching genetic testing: 
what general limits they place on the scope of genetic services, what genetic tests they address 
and when they reimburse for those tests.”95 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
92 Harrison T.A., Doyle D.L., McGowan C., et al. (2010). Billing for medical genetics and genetic counseling 
services: a national survey. Journal of Genetic Counseling 19, no. 1: 38–43. 
93 Wang, G., Beattie, M.S., Ponce, N.A., Phillips, K.A. (2011). Eligibility criteria in private and public coverage 
policies for BRCA genetic testing and genetic counseling. Genetics in Medicine 13, no. 12: 1045–1050. 
94 Note:  Different private payers have different testing criteria.  Most roughly follow the NCCN guidelines.  
95 Graf et al., Personalized Medicine. 
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By conducting a national survey of private health insurers, Schoonmaker et al. aimed to 
examine the factors influencing insurance coverage of BRCA1/2 testing and of other new genetic 
technologies.96  Schoonmaker concluded that the primary factors influencing coverage of new 
genetic tests were the "validity of the test" and its "safety and effectiveness."  Secondary factors 
included the cost of the test and "approval of professional groups."97  Given Schoonmaker's 
analysis was completed in 2000, it would be worthwhile to repeat a similar study now.    
The SACGHS report also highlighted the need for greater physician education.  Many 
studies have detailed the confusion among physicians regarding who is at risk for a BRCA1/2 
mutation and when testing should occur.  For instance, in 2011 Bellcross et al. investigated 
awareness of BRCA1/2 testing among primary care physicians (PCPs).  While the majority 
(87%) of PCPs were aware of testing, only 19% of PCPs “consistently recognized the family 
history patterns identified by the USPSTF as appropriate indications for BRCA evaluation.”98  
Such results led Bellcross et al. to conclude that knowledge of genetic tests and existing 
recommendations must be improved among care providers, “particularly in this era of increased 
BRCA direct-to-consumer marketing.”99 
 Though their research was conducted much earlier (and thus may be less representative 
of the current state of physician education), Sandhaus et al. and Doksum et al. reached similar 
conclusions.  Sandhaus et al. found that “32% of PCPs did not demonstrate sufficient knowledge 
of Mendelian inheritance,” indicating that physicians could easily misinterpret a patient’s risk of 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
96 Schoonmaker, M.M., Bernhardt, B.A., Holtzman, N.A. (2000). Factors influencing health 
insurers’ decisions to cover new genetic technologies. International Journal of Technology Assessment in Health 
Care 16, no. 1: 178–189. 
97 Schoonmaker et al., International Journal of Technology Assessment in Health Care  
98 Bellcross C.A, Kolor K., Goddard K.A.B., Coates R.J., Reyes M., Khoury M.J. (2011). Awareness and Utilization 
of BRCA1/2 Testing Among U.S. Primary Care Physicians. American J. of Preventive Medicine 40, no. 1: 61-66. 
99 Bellcross et al., American Journal of Preventive Medicine.  
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breast cancer.100  Consequences of risk misinterpretation also spill over to relatives of patients.  
Overestimates of risk can lead to increased anxiety, inappropriate surveillance, and extreme 
medical decisions, whereas underestimates of risk are associated with missed opportunities for 
intervention in high-risk women.101  Doksum et al. studied how physicians’ knowledge of, and 
experience ordering, BRCA1/2 tests varied by discipline.  His research team found that 
oncologists answered the most knowledge questions correctly, followed by OB-GYNS, followed 
by internists.102  Doksum et al. did not find an association between knowledge of the test, and 
ordering of the test, suggesting that though knowledge of the test is low, physicians are still 
discussing it with, and ordering it for, patients.103  Both groups of researchers concluded that 
there is a need for continued medical education (CME) programs for physicians to increase 
knowledge of genetics, epidemiology, and cumulative risk interpretation.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
100 Sandhaus, L.M., Singer M.E., Dawson N.V., Wiesner G.L. (2001). Reporting BRCA test results to primary care 
physicians. Genetics in Medicine 3: 327-334.  
101 Sandhaus et al., Genetics in Medicine. 
102 Doksum T., Bernhardt B.A., Holtzman N.A. (2003). Does knowledge about the genetics of breast cancer differ 
between nongeneticist physicians who do or do not discuss or order BRCA testing? Genetics in Medicine 5: 99-105. 
103 Doksum et al., Genetics in Medicine. 
	   56	  
Summary 
 
Though other organizations have slightly different recommendations, most physicians 
and insurers follow either the U.S. Preventative Services Task Force's (USPSTF) or the National 
Comprehensive Cancer Network’s (NCCN) guidelines when determining who should get tested 
for a mutation in BRCA1/2.  Once a genetic test is ordered, testing companies usually pre-verify 
with a patient's insurance to determine coverage.  Some genetic testing companies, such as 
Myriad, Ambry, Quest, and LabCorp claim to be contracted with the majority of private 
(commercial) insurers, Medicare, and some states' Medicaid plans.  Others, such as Invitae, only 
bill some (usually just private) insurers.  
 Individual insurance companies were chosen for analysis based on the number of covered 
lives (also referred to as enrollment or membership).  Of these 24 insurers, which together 
represent the largest insurance companies in the country, four insurers did not mention any 
coverage for BRCA1/2 testing.  Of payers that did cite BRCA1/2 test coverage, most referenced 
the USPSTF or the NCCN in their coverage determinations.  While there is general consensus on 
the medical necessity of large rearrangement testing, payer policies still vary in their recognition 
of genetic counseling.   
 In addition to these insurance discrepancies for BRCA1/2 testing, other coverage issues 
exist.  Studies have shown that many patients have a fear of losing health insurance after genetic 
testing.  Additional research should investigate if patients' still have this fear considering the 
Genetic Information Nondisclosure Act (GINA) was passed in 2008 with the goal of alleviating 
insurance discrimination concerns.  Knowledge among physicians of genetic testing criteria and 
genetic risk should improve and Medicare and Medicaid's coverage should be clarified and re-
assessed.  
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Test Costs and Data Sharing Efforts 
 
The cost of testing for BRCA1/2 has dropped significantly since the June 2013 Supreme 
Court case.  Myriad’s Comprehensive BRACAnalysis® test costs $4,040 and includes analysis 
of five large rearrangements in BRCA1/2.   Counsyl offers a similar test for a quarter of the cost 
($999).  Ambry, Quest, LabCorp, Fulgent, Invitae, Ethigen, and GeneDX also all have 
comprehensive BRCA1/2 tests for under $3,000.  In addition to having lower testing prices, these 
newer companies offer a variety of multi-gene panels.  Invitae gives care providers and 
researchers the opportunity to include as many genes as they want on a panel, all for the low 
price of $1,500. 
These decreases in test costs are significant, especially considering that cost has been 
shown to be an extremely important factor in genetic test decision making (and even more so for 
low-income patients).  However, there are other aspects of a BRCA1/2 test that entering 
companies must adequately address.  For instance, entering companies will need to focus on 
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achieving low rates of variants of unknown significance (VUS).104  Though difficult to 
substantiate given they stopped publically reporting their data, Myriad claims to have a VUS rate 
of 0.6% for BRCA1 and 1.6% for BRCA2.105  Most of the new testing companies have VUS rates 
in the 4 to 6% range (Appendix 2).  
Though these VUS rates are all roughly similar, there is extraordinary value in achieving 
very low rates.  Most patients who receive BRCA1/2 testing receive the straightforward results 
that either they have no variation from the wild type (WT) sequence or that a deleterious 
mutation is present.  However, in a “significant minority of results,” variants of unknown 
significance exist.106  These mutations are the result of genetic variations (mutations) in, or close 
by, the BRCA1/2 genes that are difficult to interpret.  It is challenging for researchers to learn the 
clinical significance of these mutations because not many people have been identified with these 
rare variations.  As more patients are tested, and more health information is gathered about these 
individuals and their families, the number of VUSs will decrease.   
Researchers, physicians, patients, and policy makers should be especially eager to share 
VUS data (such as Myriad’s) given how significantly patients have been shown to respond to 
such test results.  It is already a difficult decision to undergo BRCA1/2 testing.  However, once 
having decided to undergo testing, receiving news of a VUS seems to provide more 
psychological distress for patients than either a ‘positive’ or ‘negative’ test result.107   
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
104 Note:  As was discussed earlier, VUSs are mutations in BRCA1/2 that researchers do not know the clinical 
significance of.  VUS analysis relies on large data sets, giving Myriad an advantage over entering companies 
because they have built up a database over the past 15 years of thousands of patients’ DNA.   
105 Note: Myriad’s last “major deposit of data” in the public domain (to the Breast Cancer Information Core, 
maintained by the National Human Genome Research Institute) was in November of 2004.  Ever since, the company 
has “adopted a deliberate policy of retaining data as a trade secret.”  Source: Cook-Deegan et al., EJHG.    
106 Cook-Deegan, R., Conley, J.M., Evans, J.P., Vorhaus, D. (2013). The next controversy in genetic testing: clinical 
data as trade secrets?” European Journal of Human Genetics 21: 585-588. 
107 Brédart, A., Kop, J.L., DePauw, A., Caron, O., et al., (2013). Short-term psychological impact of the BRCA1/2 
test result in women with breast cancer according to their perceived probability of genetic predisposition to cancer. 
British Journal of Cancer 108: 1012-1020.  
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 In a recent study, Brédart et al. investigated patients’ perceived control over cancer risk 
after a BRCA1/2 gene test.  Researchers hoped to learn about how patients respond to VUSs, as 
they argued that research has disproportionately focused on the psychological impact of 
‘positive’ or ‘negative’ BRCA1/2 test results, rather than on unclassified variants.  In Brédart’s 
study, 15% of the women tested received VUS results and, after receiving these results, many of 
these women felt high levels of anxiety, depression, and intrusion.  Authors hypothesized that the 
effect of receiving a VUS result, over a positive result, on depression “may be related to the lack 
of clearly defined risk management recommendations, leaving women uncertain about the 
actions to be taken to cope with increased cancer-related anxiety.”  Additionally, because some 
of these women were “not informed of the possibility of receiving a [VUS] result, they only 
expected to receive either a positive or a negative result,” leading them to view their VUS results 
as “puzzling.”108   
Many additional researchers have found that receiving ambiguous test results can trigger 
a false sense of alarm in women (referred to as the ‘genetic-uncertainty-causes-distress-
hypothesis’ by researcher Joël Vos).  However, other research has noted that women are making 
appropriate risk management techniques.  Vos’ work supports the notion that the “disclosure of a 
UV-test [VUS] result is associated neither with the feeling of certainty nor with the feeling of 
uncertainty about the heredity of the cancer.”  Interestingly, he finds that, though patients 
correctly recalled a VUS test result as “non-informative,” they interpreted this result as 
“pathogenic at the same time.”  This perception made patients more likely to undergo 
prophylactic interventions.  Vos hypothesized that choosing to undergo such surgeries could help 
fulfill patients’ “strong wish for certainty and control.”109  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
108 Brédart et al., British Journal of Cancer. 
109 Vos, J., Otten, W., van Asperen, C., Jansen, A., Menko, F., Tibben, A. (2008). The counsellees’ view of an 
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Though varied in their conclusions, studies on the psychological distress patients endure 
after a VUS test result demonstrate the significance of decreasing the frequency of receiving 
such an ambiguous result.  There are many possible policy solutions that would help lower VUS 
rates.  Most of these proposals rely on the idea that data sharing is necessary for progressing 
research and for improving healthcare outcomes.  Of course, when data sharing initiatives arise, 
there are many ethical and legal factors to consider.  Complete anonymity is impossible to 
guarantee when DNA sequence data is involved.  Thus, policy makers and researchers must 
first determine what level of risk is acceptable.  Such a determination would be helpful in 
guiding de-identification efforts and privacy regulations.  Further engagement with the 
community and additional research on how to fine-tune the informed consent process would also 
be beneficial.  Lastly, insurance companies, individual payers, genetic testing registries, 
national health systems, and granting agencies could all help influence research groups and 
private companies to upload data into a shared space.  For instance, payers could recommend 
the use of companies that engage in data sharing efforts over testing companies that do not. 
 
 
Ambiguity & Inconsistencies among Public Payers 
 
Aside from the drop in BRCA1/2 test costs, this analysis has revealed a large amount of 
inconsistency and ambiguity in payer policies for BRCA1/2 testing.  Yet, there is little 
explanation for why this variation occurs.  One of the major questions that should be addressed 
going forward is why Medicare’s coverage policies exclude individuals who have not had breast 
or ovarian cancer.  One could argue that the sole purpose of the test is to help women, who are at 
a very high risk of developing breast and ovarian cancer, manage their screening, prevention, and 
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treatment options so that they will not develop the disease.  Thus, refusing to reimburse for the 
test unless the individual has breast and ovarian cancer, makes little sense.  In some cases, a 
patient’s family member has been identified as having a BRCA1/2 mutation.  If this patient has 
Medicare, even though there is a known mutation in the family, her genetic test will not be 
covered.  Given Medicare officials have not come forward with any kind of explanation for 
this policy, the Centers for Medicare & Medicaid Services (CMS) should consider removing 
this screening exclusion as soon as possible.   
 Policy makers should also encourage CMS to establish clear, national coverage 
determinations for BRCA1/2 testing.  Unfortunately, their lack of a specific policy for BRCA1/2 
testing is not a unique problem, but instead spreads to many diagnostic, screening and preventive 
services.  In fact, only two National Coverage Determinations (NCDs) exist for any type of 
genetic test, and there is little explanation for the wide variety in state reimbursement levels (see 
Appendix 3).  Data collected in 2012 by the Kaiser Family Foundation indicate that Medicaid 
offices from 6 of the 50 states do not cover any "Diagnostic, Screening and Preventive 
Services."110,111,112  Furthermore, 23 of the 50 states that do cite coverage of these services "do 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
110 Note: Diagnostic, Screening, and Preventive Services are defined, by the Kaiser Foundation (reflecting Federal 
regulations) as followed:  Diagnostic Services are medical procedures or supplies recommended by a physician or 
other licensed practitioner of the healing arts, within the scope of his or her practice under state law, to identify the 
existence, nature, or extent of illness, injury, or other health deviation in an individual. Examples include 
radiological or laboratory tests indicated by the presence of specific signs or symptoms.  Screening Services are 
defined as the use of standardized tests given under medical direction in the mass examination of a designated 
population to detect the existence of one or more particular diseases or health deviations or to identify for more 
definitive studies individuals suspected of having certain diseases.  Preventive Services are defined as services 
provided by a physician or other licensed practitioner of the healing arts within the scope of his or her practice under 
state law to prevent disease, disability, and other health conditions or their progression; to prolong life; and to 
promote physical and mental health and efficiency.   
111 "Medicaid Benefits: Diagnostic, Screening and Preventive Services," Kaiser Commission on Medicaid and the 
Uninsured (KCMU) Medicaid Benefits Database. 2012. http://kff.org/medicaid/state-indicator/diagnostic-screening-
and-preventive-services/. Accessed April 20, 2014.  
112 Note: The states that do not offer any diagnostic, screening or preventive services are: Alabama, Arkansas, 
Kansas, New Mexico, Wisconsin, Wyoming	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so in various ways."  For example, some states only cover certain immunizations or have 
specified age criteria for preventive services.113  
If CMS is unwilling to establish a NCD for BRCA1/2 testing, then state policies should at 
least be made readily accessible to the public.  According to section 1903(i)(7) of the Social 
Security Act, “State Medicaid programs are prohibited from paying for lab tests that exceed the 
Medicare payment amount."114  Medicaid’s dependence on Medicare’s pricing levels should be 
clarified and, if such dependence exists, then it is even more important for Medicare officials 
to make clearer and readily accessibly coverage policies.   
 A recent report by CMS titled “Payments for Laboratory Test: Comparing Medicare, 
State Medicaid, and Federal Employees Health Benefits Programs" also testifies to the little 
information available regarding what genetic tests Medicaid covers.  CMS undertook this study, 
in which surveys were sent to State Medicaid and Federal Employee Health Benefit programs, to 
learn more about genetic laboratory test coverage and to receive feedback on establishing 
payment rates.115  In regards to State Medicaid coverage, CMS found that “officials from all but 
one State [New Mexico] described some level of coverage for genetic tests.”  However, 
“officials from 17 States stated that their States have no specific policy addressing them.”  The 
remaining states used a variety of factors to influence coverage decisions.   For instance, 
Arizona's Medicaid contractor does not cover genetic testing if it is used “to determine whether a 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
113 Note: The states that cite various exclusions to their coverage for diagnostic, screening or preventive services are: 
Alaska, Arizona, Colorado, DC, Florida, Hawaii, Idaho, Illinois, Iowa, Kentucky, Louisiana, Maine, Michigan, 
Nebraska, Nevada, New Jersey, Ohio, Oklahoma, Pennsylvania, South Carolina, Texas, Utah, Virginia, Washington  
114 "Memorandum Report: Coverage and Payment for Genetic Laboratory Tests, OEI-07-11-000 11," Department of 
Health and Human Services. June 12, 2013. https://oig.hhs.gov/oei/reports/oei-07-11-00011.pdf. Accessed March 
22, 2014.  
115 "Memorandum Report: Coverage and Payment for Genetic Laboratory Tests, OEI-07-11-000 11," DHHS 
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member carries a hereditary predisposition to cancer or other diseases."116  When officials from 
State Medicaid programs were asked to provide payment rates for genetic tests (including 
BRCA1/2 analysis), only 8 state Medicaid programs were able to provide specific payment rates.  
These payment rates varied widely, “$1,000 in Pennsylvania to nearly $4,500 in Iowa.”  See 
Appendix 3B for the prices of the remaining states.117  Ideally, CMS should establish a national 
coverage determination for BRCA1/2 testing.  However, if they are unable to, then policy 
makers should at least try to harmonize state coverage policies so that there are not such great 
disparities in test cost.   According to Kaiser estimates, in the years 2010 and 2012 (respectively) 
there were over 66 million total Medicaid enrollees and 49 million Medicare enrollees.  
Considering the immense number of people affected, revisions to Medicaid and Medicare 
BRCA1/2 testing policies should be given high priority.118,119   
 
 
Variation in Private Insurance  
 
Another downside of Medicare’s policy is that it sets a poor example for private 
insurance companies.  As the 2006 SACGHS report highlights, Medicare has a unique place in 
the insurance market because other, smaller, private insurance companies look to it as a 
model.120  Yet, Medicare’s target population is much older than that of the general population.  
Thus, genetic testing, which is predominately used in a younger population, is not an area in 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
116 "Chapter 300: Medical Policy for AHCCCS Covered Services," AHCCCS Medical Policy Manual (AMPM), 
Arizona's Medicaid Agency. March 1, 2011. 
http://www.azahcccs.gov/shared/Downloads/MedicalPolicyManual/Chap300.pdf. Accessed April 7, 2014.  
117 "Memorandum Report," Department of Health and Human Services. June  
118 "Total Medicaid Enrollment, FY2010," Kaiser Commission on Medicaid and the Uninsured and Urban Institute. 
2010. http://kff.org/medicaid/state-indicator/total-medicaid-enrollment/. Accessed April 20, 2014.  
119 "Total Number of Medicare Beneficiaries," Kaiser Family Foundation. 2012. http://kff.org/medicare/state-
indicator/total-medicare-beneficiaries/. Accessed April 20, 2014.  
120 "Coverage and Reimbursement of Genetic Tests and Services," Secretary’s Advisory Committee on Genetics, 
Health, and Society. February 2006. http://depts.washington.edu/genpol/docs/SACGHS-ReportDraftApril2005.pdf. 
Accessed March 20, 2014.  
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which Medicare would be expected to have an exemplary plan.  Therefore, SACGHS authors 
argue that private companies should not necessarily look to Medicare for guidance on how to 
form their own private policies.   
 Fortunately, the private payers analyzed here have not adopted Medicare’s coverage 
exclusion.  Nevertheless, there is still some variation among private payer policies.   First, there 
are still disparities in recognition and coverage of the test.  For instance, Centene, a large insurer 
with over 2.7 million members, does not have a national BRCA1/2 coverage policy available 
online and the insurer hardly mentions covering any genetic tests.121  There should not be such 
differential recognition of BRCA1/2 testing among insurers, especially among some of the 
nation’s largest payers. 
As was recommended for public payers, large insurance companies should also be 
encouraged to develop comprehensive national policies for BRCA1/2 testing.  BlueCross 
BlueShield is a national association with 37 different state and regional companies within the 
national group.  To determine coverage policies, patients and care providers must contact their 
local offices.  If patients are trying to determine their particular coverage policy for genetic 
testing, then they have already been identified as being at high-risk for a mutation.  This is a 
stressful point in these patients’ lives and it should not be this difficult to track down a coverage 
policy.  Establishing national coverage policies would, hopefully, reduce the confusion among 
payers and patients and aid in harmonization.   
Variation was also found in coverage for genetic counseling. Whereas for most 
companies genetic counseling is a required (and covered) service both pre-and post-testing, for a 
few it is only recommended.  Cigna has been especially vocal about the importance of genetic 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
121 "2013 Annual Review: Reaching for the Summit," Centene Corporation.  
Centene: http://www.centene.com/wp-content/uploads/2014/03/AnnualReport-2013.pdf. Accessed March 22, 2014.  
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counseling - the insurer even stipulates that patients’ genetic counselors have certain credentials, 
illustrating the company’s commitment to ensuring that patients receive proper guidance and 
education throughout the testing process.  Alternatively, HealthNew England only requires 
genetic counseling pre-testing, HealthNet considers counseling to be the responsibility of the 
care provider, and United Healthcare only strongly recommends counseling.  Given the well-
established merits of genetic counseling, payers should (uniformly) require it both pre-and 
post-testing.  
Private payers also differ in the specificity of their coverage policies for BRCA1/2.  For 
instance, some policies imply that testing must be completed with Myriad, while others do not 
specify which laboratory must be used.  It is not clear how deliberate these requirements are.  For 
instance, Aetna necessitates the use of Myriad within the "BRCA Test Authorization Workflow" 
section of their medical coverage policy.  Within this policy, Myriad is listed as the only testing 
site.  The policy states that a "'Prior Authorization' request for BRCA Molecular Testing is to be 
sent along with the TRF form from Myriad Genetics."  Thus, given these particular authorization 
requirements, only requests that are reported through Myriad will be deemed eligible.  
HealthNet, and other payers analyzed, also specify that Myriad’s BRACAnalysis Large 
Rearrangement Test (BART)® be used for dup/del analysis.    
It is possible that these two insurance companies view there to be too much risk in 
partnering with newer companies.  After all, though many disapprove of Myriad’s business 
practices, most researchers and physicians agree that Myriad runs a well-respected and high 
quality laboratory.  However, the most likely reason that some payers have specified the use of 
Myriad for testing is that these payers have simply not responded to the market change yet.  For 
the past 15 years, Myriad has been the only company to offer BRCA1/2 testing.  Thus, when 
	   66	  
insurance policies dictate the use of Myriad for testing, these policies could require Myriad 
simply because there have been no other options for so long.  Some of the insurance policies 
analyzed were internally reviewed more recently than others, which would make them more 
likely to reflect the current consensus on what tests should and should not be reimbursed.  
Perhaps, in a year or two, especially after these new testing companies are more established, 
coverage policies will be made broader.  
 There is general consensus among private payers regarding reimbursement for 
rearrangement (del/dup) analysis and the small variation in coverage that does exist is most 
likely attributable to timing.122  Myriad argues that because the NCCN only recently added large 
rearrangement testing to be included with general BRCA1/2 sequencing, “many insurance 
companies have not yet adopted it as a covered test.”123  While some payers do not mention large 
rearrangement in their coverage policies, only one payer (Aetna) explicitly declared 
rearrangement analysis as not medically necessary.  Aetna’s policy was scheduled to be reviewed 
in February of 2014, so it is possible a new policy will be released soon that covers 
rearrangement analysis.124  
Another one of the few areas of harmonization among private payer policies is that no 
insurance policy was found that covers multi-gene panels.  However, there is also a noticeable 
trend among testing companies to include these larger panels in their test offerings.  Almost all 
of the new testing companies described in this analysis have developed multi-gene panels that 
look for mutations in BRCA1/2, as well as for mutations in many more genes.  As Ethigen’s 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
122 Note: To clarify, there are several types of BRCA1/2 testing.  There are point mutation tests, full gene sequencing 
tests, and also large rearrangement (duplication and deletion) analysis tests.  Rearrangement analysis is now 
recommended by the NCCN and most private insurers also cover this additional method of testing.  Aetna is the 
only policy that was analyzed here that did not consider dup/del testing to be medically necessary. 
123 "Understanding BART," Myriad Genetics. June 2012. http://d1izdzz43r5o67.cloudfront.net/brac/BART-PT-
Aid.pdf. Accessed March 22, 2014. 
124 Note: As of March 20, 2014, no revised policy was found.  
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website states, improved sequencing technologies have allowed for a “breadth of testing not 
previously possible, at little to no additional cost … providing us with a much more detailed 
analysis of cancer risk than has historically been available.”125  Though testing companies appear 
to be quite optimistic about these larger panels, no payer policies were found that acknowledge 
the medical utility of such tests.   
 
 
Clarifications in Testing Guidelines 
 
In addition to the variety of insurance policies for BRCA1/2 testing, there are also many 
guidelines for who should get tested in the first place.  As discussed in Chapter 3, the NCCN and 
USPSTF’s guidelines are the most commonly referenced.  The NCCN lays out specific 
guidelines, and the USPSTF recommends that patients first use a screening tool, and then (if 
positive), patients should seek genetic counseling to determine if they should proceed with 
testing.  Many screening tools exist (see Appendix 6), and the USPSTF does not recommend one 
over the others.   
The USPSTF recommendations do not include individuals who have already had cancer.  
This discrepancy is explained by the USPSTF’s role as a preventative services task force; the 
agency states that screening for cancer patients is not within its scope.  Given the organization’s 
focus, such an exclusion makes sense.  However, unfortunately, this exclusion complicates the 
recommendation and reimbursement process because many insurance companies follow 
USPSTF guidelines.  Additionally, there is a glaring contradiction between the USPSTF’s and 
Medicare’s guidelines.  Medicare will not cover testing unless the individual has had breast 
cancer.  So, by the USPSTF recommendations, individuals should seek genetic testing and 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
125 “Expanded Cancer Panel,” Ethigen. http://ethigen.net/index.php/services/expanded-cancer-panel. Accessed 
March 20, 2014.  
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counseling before developing breast cancer, but it is only after they have manifested with the 
disease that will Medicare pay for the test.    
Going forward, it would be helpful to receive clarity on why so many different 
recommendations exist.  In addition to the NCCN and the USPSTF, many other organizations 
and societies have developed their own recommendations governing who should get testing for a 
BRCA1/2 mutation.  These include: The American Congress of Obstetricians and 
Gynecologists,126 The American Society of Clinical Oncology,127 The National Society of 
Genetic Counselors,128 and The Society of Gynecologic Oncologists.129  The presence of so 
many different guidelines leads one to wonder how there could be such a diverse set of opinions 
on an issue that should be evidence-based.   
Further clarification is also needed regarding how physicians or insurers choose 
which guidelines to follow, those by the USPSTF or the NCCN.  Many of the private payers 
included in this paper cite that they follow USPSTF criteria for BRCA1/2 testing.  However, 
when the specific policies are analyzed, the guidelines resemble NCCN criteria rather than 
USPSTF guidelines.  This technicality may not be extremely significant because one would 
assume that patients and physicians reading the policies would just follow the actual guidelines.  
However, it is important to be accurate and consistent.  All payers should clearly state which 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
126 American College of Obstetricians and Gynecologists. (2009). ACOG Practice Bulletin No. 103: hereditary 
breast and ovarian cancer syndrome. Obstetrics and Gynecology 113, no. 4, 957. 
127 Robson, M. E., Storm, C. D., Weitzel, J., Wollins, D. S., & Offit, K. (2010). American Society of Clinical 
Oncology policy statement update: genetic and genomic testing for cancer susceptibility. Journal of Clinical 
Oncology 28, no. 5, 893-901. 
128 Berliner, J. L., Fay, A. M., Cummings, S. A., Burnett, B., & Tillmanns, T. (2013). NSGC practice guideline: risk 
assessment and genetic counseling for hereditary breast and ovarian cancer. Journal of Genetic Counseling 22, no. 
2, 155-163. 
129 Lancaster, J. M., Powell, C. B., Kauff, N. D., Cass, I., Chen, L. M., Lu, K. H., ... & Herzog, T. J. (2007). Society 
of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer 
predispositions. Gynecologic Oncology 107, no. 2, 159-162. 
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recommendations they follow when determining BRCA1/2 coverage, and the 
recommendations they cite should be consistent with the ones they list later on in the policy.  
 
 
 
Broader Implications: Technology Access and Research Disparities  
 
 When analyzing new technology and diagnostic tools, especially tools with a significant 
impact on human health, it is necessary to consider the social implications of such research.  
Access to, and equitable distribution of, technology is one of the largest areas of concern in 
science, technology, and society research.  Generally speaking, the Supreme Court case has been 
acclaimed as a ‘win’ for patients because it opened up the market for new testing companies to 
enter.  Breaking Myriad’s monopoly then drove down the test price, theoretically increasing 
access.  Though increased access to new technology should not automatically be viewed as a 
positive change, in this instance, greater access to BRCA1/2 testing is a positive social goal as 
long as the testing is properly administered.  (Meaning that the test should only be given to those 
who could stand to benefit from its results, which is a very small percentage of the general 
population). 
Despite the decrease in test cost, there are still many access issues related to BRCA1/2 
testing.  For example, the significant variation in insurance coverage for the test has been 
discussed in this paper.  Hall and Olopade have written an extensive review of other disparities 
in genetic testing, highlighting the inequality of BRCA1/2 testing in their analysis.130  
Specifically, Hall and Olopade discuss how the majority of research on BRCA1/2 has been 
conducted on Western, European populations.  Low testing volumes and small data sets 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
130 Hall, M.J. & Olopade, O.I. (2006). Disparities in Genetic Testing: Thinking Outside the BRCA Box. Journal of 
Clinical Oncology 24, no. 14: 2197-2203. 
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compromise the interpretation of genetic variants in minority populations – explaining why there 
are disproportionately high variants of unknown significance (VUS) rates among African 
Americans.  Unfortunately, despite having a lower incidence of breast cancer, African American 
women in the United States actually “have a higher mortality rate from breast cancer than white 
counterparts.”131,132  Hall and Olopade argue that “differential access to and utilization of genetic 
counseling and cancer predisposition testing among underserved racial and ethnic minorities 
compared with the white population has led to growing health care disparities in clinical cancer 
genetics.”133  Similarly, Armstong et al. found that, “even after adjusting for cancer risk, women 
who sought BRCA1/2 testing were significantly less likely to be African-American.”134  Though 
Hall and Olopade acknowledge that the NIH has many initiatives to “increase minority 
recruitment into clinical research,” they maintain that “as long as testing remains limited to 
Western, predominantly white populations, the preventive potential of genetic testing to reduce 
cancer incidence worldwide will not be realized."135 
In addition to efforts to achieve more equal access to improvements in genetic testing, 
broader research on the ethical consequences of genetic testing and research should be 
encouraged.   Fortunately, this research has been very well supported by the Federal 
government.  When the Human Genome Project began in the 1990s, the National Human 
Genome Research Institute (NHGRI) established an Ethical, Legal and Social Implications 
(ELSI) Research Program to “foster basic and applied research on the ethical, legal and social 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
131 Hall & Olopade, Journal of Clinical Oncology. 
132 Chu, K.C., Lamar, C.A., Freeman, H.P. (2003) Racial disparities in breast carcinoma survival rates: seperating 
factors that affect diagnosis from factors that affect treatment. Cancer 97, no. 11: 2853-60. 
133 Hall & Olopade, Journal of Clinical Oncology. 
134 Armstrong, K., Weber, B., Stopfer, J., Calzone, K., Putt, M., Coyne, J., Schwartz, J.S. (2003) Early use of 
clinical BRCA1/2 testing: associations with race and breast cancer risk. American Journal of Medical Genetics 
117A, no. 2: 154-60. 
135 Hall & Olopade, Journal of Clinical Oncology. 
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implications of genetic and genomic research for individuals, families and communities.”136  
This research program “funds and manages studies, and supports workshops, research consortia 
and policy conferences related to these topics.”137  Another idea, advocated by Professor 
Langdon Winner, is to incorporate public deliberations into the research process early on.138  
Winner argues that such public participation is a great way to integrate research on social and 
ethical concerns with research and development (R&D) efforts.139   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
136 "The Ethical, Legal and Social Implications (ELSI) Research Program," The National Human Genome Research 
Institute (NHGRI). February 14, 2014. http://www.genome.gov/elsi/. Accessed March 20, 2014.  
137 "The Ethical, Legal and Social Implications (ELSI) Research Program," NHGRI.  
138 Note:  In his testimony to the House’s Committee on Science, Professor Langdon Winner was specifically 
discussing nanotechnology.  However, many parallels can be drawn to molecular diagnostic tools.  
139 "Langdon Winner's testimony to the Committee on Science of the U.S. House of Representatives on The Societal 
Implications of Nanotechnology," The Loka Institute. April 9, 2003. 
http://www.loka.org/Documents/Winner_nano_testimony.pdf. Accessed March 20, 2014.  
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Limitations & Future Research 
 
 One of the main improvements to this research would be to expand its scope.  Only 24 
insurance company policies were reviewed in this analysis.  These insurance companies are 
among the largest payers in the country.140  Nevertheless, conclusions could be strengthened by a 
broader analysis.  
 In future research, it would be interesting to look at any effects the Affordable Care Act 
(ACA) may have on genetic test reimbursement.  Given the timing of the ACA’s 
implementation, it is too early to see its effects on genetic test reimbursement.  Future research 
should also examine the consequences of this variability in payer policies for patients, providers, 
and society at large.  For instance, though there appears to be a significant amount of ambiguity 
in coverage policies, it is possible these discrepancies have little effect on clinical practice.  Once 
a more thorough understanding of coverage policies for BRCA1/2 is reached, it would also be 
helpful to expand such an analysis to genetic testing coverage in general.  There is little research 
on payer policies for genetic tests and a comprehensive analysis on the current state of affairs 
may be helpful for policy makers and care providers.  This work should aim to learn how these 
payer policies are influencing access to BRCA1/2 testing and what kinds of policy tools would 
aid in equitable use of these diagnostic tools.   
 
 
 
 
 
 
 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
140 Note: Wang et al. estimated that his analysis (of only a few insurance plans) included over “50 million privately 
insured lives, 1.5 million lives under a local Medicare carrier, and 18.7 million lives under four state Medicaid 
programs.”  This report analyzed many more private insurance companies, so 50 million would be an extremely 
conservative estimate.  
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Conclusions 
 
This paper has provided an overview of the genetic testing landscape for BRCA1/2 
following the June 2013 Myriad Supreme Court case.  Since the case, many new genetic testing 
companies have entered the market and the cost of BRCA1/2 testing has decreased significantly.  
However, many access issues remain.  To survey these access issues, this paper examined 
current payment methods, analyzed variation among testing guidelines and payers, and suggested 
ways in which access to BRCA1/2 testing could improve.  To this end, the author has provided 
the following policy recommendations: 
 
• Maximize the leverage of national health agencies and payers to encourage the safe 
and secure sharing of VUS data.    
• Uniformly require all payers to cover genetic counseling, both pre-and post-testing. 
• Revisit the major genetic testing recommendations (NCCN, USPSTF) and consider 
creating one uniform 'testing criteria.'   
• Increase transparency from insurers, especially public payers 
⇒ Encourage the Centers of Medicaid and Medicare (CMS) to create a 
National Coverage Determination (NCD) for BRCA1/2 testing. 
 If unable to develop a NCD, then local offices must develop clear 
coverage policies and make such policies apparent on state 
websites.   
⇒ Remove Medicare's screening exclusion.  Provided that women meet the 
‘testing criteria,’ they should receive coverage for BRCA1/2 testing even if 
they have not been diagnosed with breast cancer.  
 
 
This paper has demonstrated that guidelines for, and insurance coverage of, BRCA1/2 
vary widely.  Given genetic testing for BRCA1/2 is a relatively new market, some discrepancies 
are expected to exist.  However, policy makers and payers must still develop clear, concise, and 
thoughtful testing guidelines and reimbursement policies.  The need to properly address these 
polices is heightened by the test’s position to serve as a model for the commercialization of 
genetic tests going forward.  
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Appendix 1 
Abbreviations 
 
ABMD  American Board of Medical Genetics  
ABN  Advance Beneficiary Notice of Noncoverage  
ACA  Affordable Care Act 
ACGC  American Board of Genetic Counseling  
ACLU  American Civil Liberties Union 
ACMG   American College of Medical Genetics 
ACOG  American College of Obstetricians and Gynecologists 
AMP  Association for Molecular Pathology  
BRCA1/2 Breast Cancer Genes 1 and 2 
CMS  Centers for Medicare and Medicaid Services 
CPT  Current Procedural Terminology 
Del/Dup  Deletion and Duplication Analysis 
HBOC  Hereditary Breast and Ovarian Cancer syndrome 
HMO  Health Maintenance Organizations 
IP  Intellectual Property 
LCD    Local Coverage Determination  
LOA  Letter of Agreement 
LOMN  Letter of Medical Necessity 
NCD    National Coverage Determination  
NCI  National Cancer Institute  
NCCN   National Comprehensive Cancer Network  
NGS  Next Generation Sequencing (or Next-Gen) 
NIH  National Institutes of Health 
NHGRI  National Human Genome Research Institute 
NLA  National Limit Amounts 
PCP  Primary Care Physician 
USPTF   United States Preventative Task Force 
USPTO  United States Patent and Trademark Office  
SEER  Surveillance, Epidemiology, and End Results  
TRF  Test Requisition Form 
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Appendix 2 
BRCA1/2 Testing Companies 
 
 
Note to Reader: This Appendix provides a description of each of the companies that now offer 
BRCA1/2 testing.  Short descriptions of these tests, their costs, and turn around times are 
provided in Chapter 3: A Changing Genetic Landscape.  Thus, the purpose of this Appendix is to 
elaborate upon the information presented in Chapter 3.  For example, each company’s 
sequencing technology is listed, as well as all of the genes in their multigene panels (if they offer 
multigene panels).    
 
 
Myriad Genetics          
See discussion of Myriad as a company in Chapter 2: Historical & Scientific Background.141,142  
 
Genes on the upcoming MyRisk® test: BRCA1, BRCA2, MLH1, MLH2, PMS2, EPCAM, APC, 
MUTYH, CDKN2A, PALB2, STX11, PTEN, TP53, CDH1, BMPR1A, SMAD4, ATM, BARD1, BRIP1, 
CDK4, CHEK2, NBN, RAD51C, RAD51D 
 
 
UCLA Diagnostic Molecular Pathology Laboratory  
UCLA has offered BRCA1/2 sequencing for the three Ashkenazi Jewish founder mutations since 
May 2012.143  A few academic labs were given rights by Myriad to test for these three mutations, 
which explains why UCLA has been able to offer this test since 2012.  According to their 
website, all other samples (for full gene sequencing) are sent to Myriad for analysis.  UCLA’s 
Ashkenazi panel relies on Sanger sequencing.  
 
 
Ambry Genetics                   
The same day that the Supreme Court released its decision (June 13, 2013), Ambry Genetics, a 
clinical genetic testing company based out of Aliso Viejo, California, announced their entrance 
into the BRCA1/2 testing market.  Ambry was founded in 2001 and now has a test menu of over 
300 different genes.  Many of these genes (75 of ~300 genes) are involved in the development of 
hereditary cancer, which establishes Ambry as one of the largest cancer testing companies in 
North America.”144  Ambry was also one of the first labs to introduce next generation sequencing 
(NGS) technology into the clinical setting and to offer multi-gene hereditary cancer panels. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
141 Note: Myriad uses multiplexed quantitative PCR and microarray-CGH analysis for seq. and dup/del analysis.  
142 Note:  For more information regarding Myriad’s VUS rate and classification programs, visit: "MyVision: Myriad 
Variant Classification Program," Myriad Genetics. 2013. https://s3.amazonaws.com/myriad-
library/brochures/Myriad+VCP+Brochure.pdf. Accessed April 21, 2014.  
143 Note:  UCLA may have started to offer this testing earlier than May 2012; however, this is the date they appeared 
on the National Genetic Testing Registry (GTR).  No information was available online regarding their start date.	  	  
144 "BRCA1/BRCA2 Test Logistics," Ambry Genetics. 
http://www.ambrygen.com/sites/default/files/pdfs/forms/most_updated/cancer/BRCA_Test_Information_sheet_1.14
.pdf. Accessed February 7, 2013.  
	   94	  
 
Ambry offers many hereditary cancer panels, which vary in their level of analysis.145  For 
instance, Ambry’s BreastNext® analyzes 18 genes, while the larger CancerNext® panel analyzes 
28 genes.  Though Ambry offered a breast and ovarian cancer panel before June 2013 (without 
BRCA1/2 included), the Supreme Court case allowed the company to add BRCA1/2 (the most 
important genes for hereditary breast and ovarian cancer) into the panel.  Ambry uses NGS or 
Sanger sequencing for their multi-gene panels and multiplex ligation-dependent probe 
amplification (MLPA) for dup/del analysis.  All mutations and VUS's are confirmed through 
Sanger sequencing. 
 
Genes on the BRCAplus® test:  BRCA1, BRCA2, CDH1, PTEN, STK11 and TP53 
Genes on the BreastNext® test: ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, MRE11A, 
MUTYH, NBN, NF1, PALB2, PTEN, RAD50, RAD51C, RAD51D, STK11 and TP5 
Genes on the OvaNext® test: ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, 
MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, NF1, PALB2, PMS2, PTEN, RAD50, RAD51C, 
RAD51D, STK11, and TP53. 
Genes on the CancerNext® test: APC, ATM, BARD1, BRCA1, BRCA2, BRIP1, BMPR1A, CDH1, 
CDK4, CDKN2A, CHEK2, EPCAM, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, NF1, PALB2, 
PMS2, PTEN, RAD50, RAD51C, RAD51D, SMAD4, STK11, and TP53 
 
 
The University of Washington                 
The University of Washington announced on June 14, 2013 that they would add the BRCA1/2 
genes to their BROCA testing panels.146  The Department of Laboratory Medicine at the 
University of Washington now offers five different BRCA1/2 tests: the BROCA cancer risk 
panel, sequencing and rearrangement analysis, an Ashkenazi Jewish panel, single gene testing, 
and known familial mutation testing.  These tests are performed on an Illumina HiSeq2000.  
 
Note: The clinical lab and the King lab are separate entities.  The King Lab offers free BROCA 
testing for families who meet its testing criteria, so this free test is only for subjects in King's 
genetic research studies.  The clinical lab at UW provides commercial BROCA panel testing for 
patients who are referred by their providers - "specimens come from all over the country and 
from some international clients."  
 
 
Genes on the BROCA Cancer Risk Panel: AKT1, APC, ATM, ATR, BAP1, BARD1, BMPR1A, 
BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK1, CHEK2, CTNNA1, FAM175A (Abraxas), 
GALNT12, GEN1, GREM1, HOXB13, MEN1, MLH1, MRE11A, MSH2 (+EPCAM), MSH6, MUTYH, 
NBN, PALB2, PIK3CA, PPM1D, PMS2, POLD1, POLE, PRSS1, PTEN, RAD50, RAD51, RAD51C, 
RAD51D, RET, SDHB, SDHC, SDHD, SMAD4, STK11, TP53, TP53BP1, VHL, and XRCC2 
 
 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
145 "2014 CPT Codes and Client Pricing," Ambry Genetics.  January 17, 2014. 
http://www.ambrygen.com/sites/default/files/Master_Pricelist_testCode_1_17_2014_0.pdf. Accessed February 6, 
2014.  
146 "Genetics and Solid Tumor Diagnostic Testing: BRCA1 and BRCA2 added to BROCA Cancer Risk Panel," 
Department of Laboratory Medicine, University of Washington Medical Center. 
http://depts.washington.edu/labweb/Divisions/MolDiag/MolDiagGen/index.htm. Accessed April 18, 2013.	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Ethigen           
Ethigen is a genetic testing company based out of Salt Lake City, Utah that emphasizes the 
importance of having a certified genetic counselor involved in the genetic testing process.  The 
company began with a focus on genetic testing for hereditary breast and ovarian cancer, Lynch 
syndrome, and polyposis syndromes, but hopes to expand their scope into other hereditary 
conditions.147  On June 19, 2013, Ethigen announced the addition of BRCA1/2 sequencing and 
rearrangement analysis to their list of services.  BRCA1/2 sequencing is offered as an individual 
test, or as part of a larger hereditary cancer panel.148  Illumina NGS platforms are used.    
 
Genes on the Expanded Cancer Panel: BRCA1/2, MLH1, MSH2, MSH6, APC, MUTYH (MYH), 
PTEN, TP53, CDK4, STK11, SMAD4, BMPR1A, CDH1, MET, FH, FLCN, PDGFRA, and KIT. 
Rearrangements are also included for BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, EpCAM, APC, and 
MYH. 
 
 
Fulgent Therapeutics, LLC                   
Fulgent Therapeutics, LLC is pharmaceutical company based in Temple City, CA that 
specializes in "developing and commercializing innovative cancer therapeutics and companion 
diagnostics."149  Founded in 2011, Fulgent currently offers single gene and multi-gene panels for 
breast, lung, ovarian, colon, and pancreatic cancer.  In June of 2013, Fulgent added BRCA1/2 to 
its hereditary cancer panels and established a tiered pricing structure for institutional versus third 
party billing.150  Fulgent uses an Illumina MiSeq® for its multi-gene panels and now for 
BRCA1/2 analysis as well.  Mutations are confirmed with Sanger sequencing, or sometimes with 
an Ion Proton® Life Technologies machine.  MLPA is used for dup/del analysis.  If a VUS result 
is given, Fulgent offers free of charge sequencing for any additional family members.  
 
Genes on the Breast Ovarian Cancer NGS Panel: ATM, ATR, BAP1, BARD1, BLM, BMPR1A, 
BRCA1, BRCA2, BRIP1, CDH1, CDKN2A, CHEK2, CTNNB1, EPCAM, MLH1, MRE11A, MSH2, 
MSH6, MUTYH, NBN, PALB2, PMS2, PTEN, RAD50, RAD51, RAD51C, RAD51D, STK11, TP53, 
XRCC3 
Genes on the Hereditary Cancer Panel (HCP): APC, ATM, ATR, AXIN2, BAP1, BARD1, BMPR1A, 
BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, EXO1, FANCA, FANCC, 
FANCD2, FANCE, FANCF, FANCG, GALNT12, MEN1, MLH1, MRE11A, MSH2, MSH3, MSH6, 
MUTYH, NBN, PALB2, PDGFRA, PMS1, PMS2, PRSS1, PTCH1, PTEN, RAD50, RAD51, RAD51C, 
RAD51D, RBBP8, RET, SMAD4, STK11, TP53, VHL, XRCC3 
 
 
 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
147 "About Us," Ethigen. 2014. http://ethigen.net/. Accessed February 19, 2014.  
148 "Ethigen Launches Next Generation (NGS) BRCA Testing With Expanded Hereditary Cancer Panel," PR Web. 
June 19, 2013. http://www.prweb.com/releases/Ethigen/BRCA/prweb10843704.htm. Accessed February 19, 2014.	  	  
149 "About Fulgent Therapeutics," Fulgent Therapeutics. 2012. http://fulgent-therapeutics.com/our-company/about-
us/. Accessed February 19, 2014.  
150 "Fulgent Therapeutics Announces Their Comprehensive Hereditary Cancer Test Including BRCA1 and BRCA2 
Analysis," PR Web. June 14, 2014. http://www.prweb.com/releases/2013/6/prweb10833921.htm. Accessed 
February 19, 2014.  
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GeneDX            
GeneDX is a genetic testing company, based out of Gaithersburg, MD, that specializes in testing 
for rare hereditary disorders.  The company was founded in 2000 and is a subsidiary of Bio-
Reference Laboratories, Inc., which is the fourth largest publicly traded clinical laboratory in the 
U.S.151  As part of GeneDX’s mission to “make clinical testing available to people with rare 
genetic conditions and their families,” the company offers a variety of BRCA1/2 test options.152   
GeneDX also offers many multi-gene panels, such as a breast and ovarian cancer panel that 
evaluates 26 genes and a larger OncoGene panel that analyzes 35 genes.   GeneDX’s cancer 
panels use an Illumina MiSeq®.  If a VUS result is given, GeneDX will test additional family 
members for free.153 
 
Genes on the OncoGeneDx Comprehensive Cancer Panel: APC, ATM, AXIN2, BARD1, BLM, 
BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, FAM175A, FANCC, 
HOXB13, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PALLD, PMS2, PTEN, RAD50, 
RAD51C, RAD51D, SMAD4, STK11, TP53, VHL, XRCC2 
Genes on the Breast Cancer High Risk Panel: BRCA1, BRCA2, CHH1, PTEN, STK11, TP53 
Genes on the Breast/Ovarian Cancer Panel: ATM, BARD1, BLM, BRCA1, BRCA2, BRIP1, CDH1, 
CHEK2, EPCAM, FAM175, FANCC, HOXB13, MLH1, MRE11A, MSH2, MSH6, NBN, PALB2, PMS2, 
PTEN, RAD50, RAD51C, RAD51D, STK11, TP53, XRCC2 
 
 
 
Quest Diagnostics            
Quest Diagnostics was another one of the most vocal companies to declare entrance into the 
BRCA1/2 testing market.  In contrast to companies such as Ambry, Fulgent, and Ethigen, Quest 
is one of the largest diagnostic and laboratory information companies in the US.  With a 
workforce of approximately 41,000 employees, Quest’s diagnostic tests serve 50% of U.S. 
physicians and 30% of American adults.154  When Quest released its test in October of 2013, 
they became the “largest clinical laboratory company to introduce a BRCA test since the U.S. 
Supreme Court's human gene patent ruling in June.”155  The company’s test, called 
BRCAvantage®, uses next-generation sequencing methods and multiplex ligand-dependent 
probe amplification (MLPA) to detect deletions, duplications, and rearrangements.  Patients and 
care providers can order four different versions of the test, each of which vary in level of analysis 
and cost. 
 
 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
151 "GeneDx to Launch Comprehensive Breast Cancer Genetic Test," GeneDX. June 13, 2013. 
http://www.genedx.com/genedx-to-launch-comprehensive-breast-cancer-genetic-test/. Accessed February 9, 2014.  
152 "About," GeneDX. http://www.genedx.com/about-genedx/. Accessed February 9, 2014.  
153 Note: GeneDX’s VUS rate is expected to change by May 2014.  Readers can call GeneDX’s main number and 
ask to speak with a customer service genetic counselor for an updated number. 	  
154 "Fact Sheet," Quest Diagnostics. http://www.questdiagnostics.com/home/about/facts. Accessed February 6, 2014.  
155 "Quest Diagnostics Introduces BRCAvantage™, Broadly Expanding Patient Access to BRCA Genetic Testing 
for Inherited Breast and Ovarian Cancers," Quest Diagnostics. October 15, 2013. 
http://newsroom.questdiagnostics.com/2013-10-15-Quest-Diagnostics-Introduces-BRCAvantage-Broadly-
Expanding-Patient-Access-to-BRCA-Genetic-Testing-for-Inherited-Breast-and-Ovarian-Cancers. Accessed 
February 6, 2014.  
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University of Chicago          
The University of Chicago Genetic Services Lab began to offer BRCA1/2 testing in November of 
2013.  The lab focuses on "testing of rare orphan genetic diseases for which testing is not readily 
available elsewhere."156  Chicago offers two different BRCA1/2 tests - familial mutation 
sequence analysis testing or founder mutation testing.  These tests are $415 and $475, 
respectively.  Though the lab does not specifically market a large rearrangement test for 
BRCA1/2, if individuals want dup/del analysis, they can order custom analysis for $650.  The lab 
works "works closely with research groups to develop new tests for genetic disorders as their 
genetic bases become identified," and all tests are available commercially.157   Sequencing is 
done with Sanger sequencing.  
 
 
LabCorp®             
On December 2, 2013, Laboratory Corporation of America® Holdings (LabCorp®) announced 
they would offer BRCA1/2 testing.158  Based out of Burlington, NC, LabCorp® is an extremely 
large laboratory network that offers “more than 4,000 tests ranging from routine blood analyses 
to reproductive genetics to companion diagnostics.”159  LabCorp uses Sanger sequencing for 
sequencing and a multiplex ligation-dependent probe amplification (MLPA) platform for dup/del 
analysis.    
 
 
Invitae           
Invitae is a genetic testing company, specializing in diagnostics for hereditary disorders, based in 
San Francisco, CA.  The company has the mission of “reinvent[ing] genetic testing by making it 
more affordable and accessible than ever before.”  The company announced in early December 
that they would offer BRCA1/2 testing and multi-gene panels including BRCA1/2 for a flat price 
of $1,500.160  Invitae offers full gene sequencing (using NGS methods) for 218 genes and their 
associated disorders.  However, the most unique aspect of Invitae is that the company allows for 
personalized panels.  Patients can work with their physician to compose a gene panel that 
includes the one to 218 genes that Invitae offers.  All numbers and combinations of genes, 
disorders, and panels are offered for the price of $1,500.161 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
156 "About Us," University of Chicago Genetic Services Laboratory. http://dnatesting.uchicago.edu/about-
us/overview. Accessed April 20, 2014.  
157 "About Us," University of Chicago Genetic Services Laboratory.	  	  
158 "LabCorp to Offer BRCAssure Breast Cancer Mutation Tests," Laboratory Corporation of America® Holdings. 
December 2, 2013. 
https://www.labcorp.com/wps/wcm/connect/IntGeneticsLib/integratedgenetics/resources/pdfs/other/brcassure+press
+release. Accessed February 11, 2014.  
159 "About LabCorp," Laboratory Corporation of America® Holdings. 
https://www.labcorp.com/wps/portal/!ut/p/c0/04_SB8K8xLLM9MSSzPy8xBz9CP0os_hACzO_QCM_IwMLo1AL
AyNj1yBnQxNfAwMDY_2CbEdFANq6iRA!/. Accessed February 11, 2014.  
160 "Invitae Offers BRCA1/BRCA2 Testing, Providing Clinicians with a Reliable, Fast, Affordable Option for 
Patients," Invitae. December 11, 2013. https://www.invitae.com/en/news/2013/12/11/invitae-offers-brca1brca2-
testing-providing-clinicians-reliable-fast-affordable-option-patients/. Accessed February 11, 2014.  
161 "Support," Invitae. https://www.invitae.com/en/faq/. Accessed February 11, 2014.	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Genes on the High-Risk Hereditary Breast Cancers Panel: BRCA1, BRCA2, , PTEN, TP53, STK11, 
CDH1 
Genes on the Women's Hereditary Cancers Panel: BRCA1, BRCA2, PTEN, TP53, MLH1, MSH2, 
MSH6, EPCAM, PMS2, STK11, CDH1, CHEK2, RAD51C, BRIP1, PALB2, NBN, ATM 
Genes on the Hereditary Cancer Syndromes Panel: BRCA1, BRCA2, PTEN, TP53, MLH1, MSH2, 
MSH6, EPCAM, PMS2, APC, BMPR1A, SMAD4, STK11, MUTYH, CDH1, CDK4, CDKN2A, PALLD, 
MET, MEN1, RET, PTCH1, VHL, CHEK2, BRIP1, PALB2, RAD51C, NBN, ATM 
 
 
 
Center for Human Genetics       
The Center for Human Genetics is a small non-profit based in Cambridge, MA that offers 
BRCA1/2 testing for the three Ashkenazi Jewish founder mutations.  Though the lab uses 
targeted variant analysis (PCR with RFLP) for their current mutation analysis, they hope to offer 
full-gene sequencing and dup/del analysis in the future.  The Center first began to publicize their 
test in January of 2014; most of the center’s patients are referred by physicians in New England. 
 
 
Counsyl   
In the spring of 2014, Counsyl released the cheapest BRCA1/2 sequencing test available today.  
This test offers sequencing and dup/del analysis using a NGS Illumina-based assay, but Counsyl 
has also developed their own hardware and software.   Patients who use Counsyl for testing are 
eligible for a complimentary phone consultation with a genetic counselor.  
 
 
Michigan           
The University of Michigan also released a BRCA1/2 sequencing test in the Spring of 2014, but 
has not released their prices.  According to the lab’s website, bi-directional Sanger Sequence 
Analysis is used with an Applied Biosystems 3730 capillary sequencing instrument.  The lab just 
started testing, so they do not have an established VUS rate and are also not sure what the 
breakdown of their client base will be (i.e., samples sent in from throughout the country or just 
from physicians at the University’s clinics).  
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Appendix 3A 
Coverage Policies 
Testing Company Overviews 
 
Myriad 
Though patients can choose to cover the test price on their own, Myriad claims that most 
insurance plans cover BRACAnalysis®, allowing most patients to pay “less than 10% of the test 
price.”162  If a patient chooses to bill with insurance, Myriad first verifies coverage.  Then, if the 
projected cost is greater than $375, Myriad will re-contact the patient before proceeding with the 
sequencing analysis.  Medicare will cover BRACAnalysis® if the specific medical criteria are 
met, but otherwise, “test cost is the patient’s responsibility.”    
 
 
UCLA 
The UCLA Clinical Laboratory does not have any information available online about their 
insurance coverage for BRCA1/2 testing.163   
 
 
Ambry Genetics  
Ambry performs free pre-verification for patients and interested clients as part of their 
commitment to “improving patient access to medically necessary genetic testing.”  The company 
is contracted with the “majority of commercial insurance companies” and is also a Medicare 
provider.164  However, in order for patients to be covered under Medicare for the BRCAPlus, 
BreastNext, and OvaNext tests, they must meet the Medicare testing criteria and must not have 
had BRCA1/2 testing previously. Thus, Medicare patients will not receive reimbursement if they 
order testing purely based on family history.165   
 
Ambry is also contracted with some Medicaid plans, which usually require pre-verification for 
genetic testing.  If patients are expected to pay more than $100 out of pocket for a test, Ambry 
will contact the patient for verbal approval before continuing.166  The company’s Financial 
Assistance Program (or ‘Hardship Payment Plan’) allows for non-insured and under-insured 
individuals to receive a “significant discount off [Ambry’s] Institutional Rates, often limiting the 
patient out-of-pocket expenses to only $100.”  Individuals with Medicare or Medicaid are not 
eligible for Ambry’s Financial Assistance program.  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
162 “Insurance Company Information,” Myriad Genetics. https://www.myriadpro.com/insurance-company-
information/. Accessed December 12, 2013.  
163 "Molecular Pathology," UCLA Clinical Laboratory and Pathology Services. April 24, 2014. 
http://pathology.ucla.edu/body.cfm?id=103. Accessed April 24, 2014.  
164 "Billing & Insurance Information," Ambry Genetics. January 20, 2014. http://www.ambrygen.com/billing-
insurance-information. Accessed February 10, 2014. 
165 "Billing & Insurance Information," Ambry Genetics.  
166 "BRCA1/BRCA2 Test Logistics," Ambry Genetics.  
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University of Washington 
The University of Washington offers pre-verification services for all patients, and all patients are 
re-contacted after the “pre-authorization team obtains benefit information and out of pocket 
estimates.”167  The lab can bill Medicaid in some states, so patients and care providers are 
encouraged to contact the pre-authorization team.  The BROCA risk panel is covered for 
Medicare patients, provided that patients meet Medicare's testing criteria for BRCA1/2, Lynch 
syndrome, or APC and MUTYH testing.  If patients are "covering the entire cost of testing, out 
of pocket," they "may be eligible for a discount, if they pay for services in advance."168 
 
 
Ethigen     
Ethigen does not have any information available online about their insurance coverage for 
BRCA1/2 testing.   
 
 
Fulgent Therapeutics, LLC                
Though Fulgent does not have much information on their website, they do cite “institutional, 
insurance, and patient out-of-pocket” as their three billing options.  Prepayment is required for 
patient billing and all Health Maintenance Organizations (HMO) submissions must be pre-
authorized.169  
 
 
GeneDX 
For oncology tests, such as BRCA1/2 testing, GeneDX accepts all commercial insurances.  If a 
patient is expected to pay more than $100 out-of-pocket, then GeneDX will contact the patient to 
see how he or she would like to proceed.  GeneDX also offers a financial assistance program “for 
patients who do not have commercial insurance and cannot afford to pay out of pocket.”170 
GeneDX is a Medicare provider and requires an Advance Beneficiary Notice of Noncoverage 
(ABN) prior to testing for Medicare patients.  Though GeneDX is not a participating provider 
with any state’s Medicaid plan, company representatives will still try to “negotiate a price and 
arrange [for] individual contract.”  The company warns on their website that Medicaid coverage 
for diagnostic tests varies greatly from state to state; many state plans have “refused to negotiate 
with and/or pay GeneDx for services,” including NY, Maryland, Arizona, and California.171  
 
 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
167 "UW Laboratory Medicine Clinical Test Information: Pre-Authorization for Next-Generation Sequencing 
Panels," University of Washington. March 31, 2014. 
http://web.labmed.washington.edu/tests/genetics/preauthorization. Accessed April 18, 2014.	  
168 "UW Laboratory Medicine Clinical Test Information," University of Washington. 	  
169 "Billing," Fulgent Therapeutics. http://fulgent-therapeutics.com/testing/billing/. Accessed February 22, 2014.  
170 "Oncology Genetics Billing Policy," Gene DX. http://www.genedx.com/oncology-genetics-billing-policy/. 
Accessed on February 9, 2014.  
171 “FAQs,” GeneDX. http://www.genedx.com/faqs/. Accessed February 9, 2014.  
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Quest Diagnostics  
Quest Diagnostics has “more than 2,100 patient service centers located across the United 
States.”172,173  In addition to making submitting DNA samples “geographically convenient” and 
quick, Quest’s large size (especially compared to other upcoming BRCA1/2 testing companies) is 
particularly advantageous because it means the majority of insurance companies are partnered 
with the company.  Patients can visit Quest's website, and click on their state of residence, to see 
if their insurance company is contracted with Quest.174  In addition to providing financial 
assistance to qualified patients, Quest offers a “concierge insurance preauthorization” service as 
part of their commitment to “work with health plans on [a patient’s] behalf to determine if the 
test will be covered.”  After evaluating a patient’s insurance plan, Quest will re-contact the 
patient before moving forward with testing.   
 
 
The University of Chicago 
The University of Chicago offers three main billing methods: institutional billing, self-pay, and 
insurance. The lab does not offer discounts for institutional billing and self-pay, so costs reflect 
those listed in Chapter 3.  The lab "accepts most insurance plans, with the exception of Illinois 
and out-of-state Medicaid."175  Medicare is also accepted.  Most of the commercial insurance 
plans that Chicago accepts are listed on their website, though patients are "advised to contact 
their insurance company to confirm the University of Chicago's participation prior to scheduling 
an appointment."176 
 
 
LabCorp® 
Similar to Quest Diagnostics, LabCorp is one of the largest diagnostic testing companies in the 
United States, which is advantageous for patients who hope to receive insurance coverage.  
LabCorp files with an extremely large list of insurance providers and patients are encouraged to 
visit LabCorp’s website, enter their state of residence, and see if their company is one of 
LabCorp’s most commonly billed insurance carriers.  LabCorp also has a financial assistance 
program, and offers preauthorization services for all patients.177    
 
 
 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
172 "Quest Diagnostics Introduces BRCAvantage…” Quest Diagnostics.  
173 Ray, T., "With BRCAvantage Launch, Quest Becomes Largest US Lab to Enter BRCA Testing Space," 
GenomeWeb. October 16, 2013. http://www.genomeweb.com/clinical-genomics/brcavantage-launch-quest-becomes-
largest-us-lab-enter-brca-testing-space. Accessed February 11, 2014.  
174 "Insurance Lists & Third Party Payors," Quest Diagnostics. 2014. 
https://www.questdiagnostics.com/home/patients/insurance.html. Accessed February 11, 2014.	  	  
175 "Billing," University of Chicago Genetic Services Laboratory. http://dnatesting.uchicago.edu/billing. Accessed 
April 20, 2014.  
176 "Insurance Plans," University of Chicago Genetic Services Laboratory. 
http://www.uchospitals.edu/billing/managed-care.html. Accessed April 20, 2014.  
177 "LabCorp to Offer BRCAssure Breast Cancer Mutation Tests," Laboratory Corporation of America® Holdings.  
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Invitae 
Invitae is not contracted with Medicare or Medicaid, but does bill third party insurance providers 
and pre-authorization services exist.  To bill insurance, patients must submit a letter of medical 
necessity (LOMN) from their doctor.  To help patients who are paying out of pocket, Invitae 
offers a patient payment plan.  For those with significant financial need, assistance plans exist, 
which ensure that qualified patients pay no more than $100 for testing.  However, given New 
York and Utah’s additional laboratory standards, Invitae does not accept patient samples from 
these states.178 
 
 
Center for Human Genetics       
The Center for Human Genetics does not have any information available online about their 
insurance coverage for BRCA1/2 testing.179   
 
 
Counsyl 
Counsyl is contracted with “most commercial insurance plans” and will re-contact any patients 
whose testing costs exceed $299 after insurance.   Though the company is contracted with most 
large private payers, such as Aetna, Cigna, Anthem, Highmark BCBS, and some Kaiser plans, 
they are not contracted with government plans, such as Medicaid.  Counsyl does offer payment 
plans and also has a financial aid system to assist those who meet the qualifications.180  
 
 
University of Michigan         
The University of Michigan does not have third party billing for outside facility’s sample(s) – 
they will only bill the third payer for “established University of Michigan patients.”181  For such 
patients, a list of accepted insurance plans, including a few Medicare and Medicaid plans, is 
available online.182  Though a financial assistance program exists, many qualifications must be 
met.  
 
 
 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
178 "Support," Invitae. https://www.invitae.com/en/faq/. Accessed February 11, 2014.  
179 "Human Genetics," Center for Human Genetics, Inc. http://chginc.org/. Accessed April 24, 2014.  
180 "Help Center," Counsyl. https://help.counsyl.com/home. Accessed April 24, 2014.  
181 "Billing Information," Michigan Medical Genetics Laboratories (MMGL). 
http://sitemaker.umich.edu/michigan.medical.genetics.laboratories/billing_information. Accessed April 24, 2014.  
182 "Insurance," University of Michigan Health System. http://www.uofmhealth.org/insurance. Accessed April 24, 
2014.	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Appendix 3B 
Coverage Policies 
Insurance Company Overviews 
 
 
Note to Reader:  Insurance Companies are listed alphabetically.  See Appendix 3C for specific 
policies. See research methodology described in Chapter 4.  
 
 
AETNA GROUP.  
Aetna Group considers BRCA1/2 testing medically necessary according to the guidelines set 
forth in Table 1.183,184  The company's policy for BRCA1/2 testing has not been updated since the 
June 2013 Supreme Court case.  Thus, it is not necessarily surprising that Aetna's policy 
indirectly necessitates the use of Myriad for BRCA1/2 testing.   For example, within the "BRCA 
Test Authorization Workflow" section of Aetna's medical policy, only Myriad is listed as a 
testing site.  The policy states that a "'Prior Authorization' request for BRCA Molecular Testing 
is to be sent along with the Myriad Genetics TRF form from Myriad Genetics."   
 
Aetna will not cover large rearrangement testing or re-testing.  The company’s medical policy 
states that “there is inadequate information regarding the frequency of large genomic re-
arrangements in the United States populations to indicate that use of [large rearrangement 
analysis]” is medically necessary.  Therefore, the company considers del/dup analysis, and re-
testing for specific mutations, to be “experimental and investigational.”185  Aetna’s policy states 
that it is “essential” for patients “to undergo adequate education and counseling because 
molecular susceptibility testing raises important medical, psychological, and social issues for 
patients and their families.”  Thus, genetic counseling is a “covered benefit in all Aetna 
products,” and considered “medically necessary” for familial cancer disorders.186 
 
Though Aetna’s current policies necessitate the use of Myriad and do not cover del/dup analysis, 
it is possible that these policies may change with time.  The next scheduled review date is 
February 27, 2014.187  
 
 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
183 Note: Aetna’s medical policy for BRCA1/2 testing is “based on the guidelines from the American College of 
Obstetricians and Gynecologists (2009), the American College of Medical Genetics (1999) and the U.S. Preventive 
Services Task Force (2005).” 
184 "Clinical Policy Bulletin: BRCA Testing, Prophylactic Mastectomy, and Prophylactic Oophorectomy," Aetna. 
Policy Number: 0227. March 14, 2013. Aetna. http://www.aetna.com/cpb/medical/data/200_299/0227.html. 
Accessed February 25, 2014.  
185 "Clinical Policy Bulletin: BRCA Testing…” March 14, 2013. Aetna. 
186 "Clinical Policy Bulletin: Genetic Counseling," Aetna. Policy Number: 0189. January 31, 2014. 
http://www.aetna.com/cpb/medical/data/100_199/0189.html. Accessed March 4, 2014.	  
187 "Clinical Policy Bulletin: BRCA Testing…” March 14, 2013. Aetna. 
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BLUE CROSS / BLUE SHIELD (BC/BS) 
The Blue Cross and Blue Shield Association does not have a national coverage policy for 
BRCA1/2 testing.  Thus, individuals seeking reimbursement information should contact their 
local Blue Cross Blue Shield (BCBS) company.  There are 37 different state and regional 
companies within the national group (see Table 2).188,189 
 
BCBS Anthem is an independent subsidiary of the BCBS Association and provides health 
insurance for 14 states.190  Given its large size, BCBS Anthem was chosen by the author to be 
representative of BCBS’s policies toward BRCA1/2 testing; however, readers should consult 
their local BCBS organization for particular policies.191,192  
 
BCBS Anthem covers BRCA1/2 testing in accordance with the common guidelines (see Table 3).  
All genetic testing must be accompanied by “appropriate pre- and post-test counseling” by 
“adequately trained health care professionals.”193  Anthem will cover rearrangement analysis for 
individuals who meet the testing criteria and received a negative result with an initial sequence 
analysis.  However, multi-gene panels, such as BreastNext®, BREVAGgen, DeCode 
BreastCancer®, OvaNext®, and CancerNext®, are not considered to be medically necessary 
unless “all components of the panel have been determined to be medically necessary based on 
[previously stated testing] criteria.”194   
 
 
 
 
 
 
 
 
 
 
 
 
 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
188 "About the Blue Cross and Blue Shield Association," BlueCross BlueShield Association. 
http://www.bcbs.com/about-the-association/.  Accessed March 4, 2014.  
189 "About the Blue Cross and Blue Shield Companies," BlueCross BlueShield Association. 
http://www.bcbs.com/about-the-companies/.  Accessed March 4, 2014.  
190 "Genetic Testing for Breast and/or Ovarian Cancer Syndrome," Anthem, BCBS. January 14, 2014. 
http://www.anthem.com/medicalpolicies/policies/mp_pw_c166602.htm. Accessed March 4, 2014.  
191 Note: For instance, North Carolina’s policy can be found here: 
https://www.bcbsnc.com/assets/services/public/pdfs/medicalpolicy/genetic_testing_for_breast_and_ovarian_cancer.
pdf. 
192 Note: For instance, Mississippi’s policy can be found here:  
http://www.bcbsms.com/index.php/index.php?q=provider-medical-policy-
search.html&action=viewPolicy&source=emed&path=/policy/emed/Genetic%20Testing%20for%20Hereditary%20
Breast%20and_or%20Ovarian%20Cancer.html. 
193 "Genetic Testing for Breast and/or Ovarian Cancer Syndrome," Anthem, BCBS.  
194 "Genetic Testing for Breast and/or Ovarian Cancer Syndrome," Anthem, BCBS.  
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CENTENE CORPORATION 
Centene Corporation is a national insurance company composed of local health plans for 19 
different states.195  A national policy could not be found, and individual states did not seem to 
have specific BRCA1/2 coverage policies either.  The only comment related to genetic testing 
that was available online was a press statement discussing how prior authorization forms are 
required for genetic testing.196  
 
 
 
CIGNA HEALTH GROUP.   
Cigna considers single site analysis medically necessary for individuals with a known familial 
mutation.197,198  Otherwise, if one has a personal history of breast, ovarian, or pancreatic cancer 
(and meets any of a long list of indications), then Cigna will cover full sequence analysis and 
dup/del analysis (see Table 4).  Large rearrangement testing is considered medically necessary 
when initial criteria are met, but conventional testing (i.e., just sequence analysis) returned a 
negative result.  Unlike most insurance companies, Cigna considers BRCA1/2 testing medically 
necessary if an individual has at least a 10% probability of carrying a mutation as determined by 
a validated risk assessment tool (such as BRCAPRO, University of Pennsylvania [UPenn I or 
UPENN II], BOADICEA, or Tyrer-Cusick).199   
 
In regards to multigene panels, such as BreastNext and BRCAplus by Ambry or BROCA by the 
University of Washington, Cigna argues that the use of these testing methods is “still preliminary 
and not yet recommended in guidelines from professional organizations.”  Thus, because there is 
“insufficient evidence in the published scientific literature to establish the diagnostic and clinical 
utility” of these multi-gene panels, they are considered “investigational”.200  
 
Cigna has received press coverage recently for requiring genetic counseling to accompany all 
major genetic tests.  This announcement, which took effect on September 16, 2013, established 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
195 Note: These state plans are: Arizona (Bridgeway Health Solutions), Massachusetts (CeltiCare Health Plan), 
Arkansas (NovaSys Health), Mississippi (Magnolia Health Plan), California (California Health & Wellness), 
Missouri (Home State Health Plan), Florida (Sunshine Health), New Hampshire (Granite State Health Plan), 
Georgia (Peach State Health Plan), Ohio (Buckeye Community Health Plan), Illinois (IlliniCare Health Plan), South 
Carolina (Absolute Total Care), Indiana (Managed Health Services), Texas (Superior Health Plan), Kansas 
(Sunflower Health Plan), Washington (Coordinated Care), Kentucky (Kentucky Spirit Health Plan), Wisconsin 
(Managed Health Services), Louisiana (Louisiana Healthcare Connections.  Source: "Health Plans," Centene 
Corporation. http://www.centene.com/health-plans/. Accessed March 3, 2014.  
196 "Prior Authorization Changes for Genetic Testing Codes," May 1, 2013. Peach State Health Plan, Centene 
Corporation. http://www.pshpgeorgia.com/2013/05/01/prior-authorization-changes-for-genetic-testing-codes/. 
Accessed March 3, 2014.  
197 "Medical Necessity Guidelines: Genetic Testing for Susceptibility to Breast and Ovarian Cancer," CareAllies, 
Cigna. September 15, 2013. 
http://www.cigna.com/sites/careallies/pdf/CA0001_BRCA1_BRCA2_Breast_Ovarian.pdf. Accessed March 3, 2014.  
198 "Cigna Medical Coverage Policy: Genetic Testing for Susceptibility to Breast and Ovarian Cancer," Cigna. 
February 15, 2014. 
https://cignaforhcp.cigna.com/public/content/pdf/coveragePolicies/medical/mm_0001_coveragepositioncriteria_gen
etic_testing_for_breast_and_ovarian_cancer.pdf. Accessed March 3, 2014.  
199 Cigna Medical Coverage Policy," Cigna.  
200 "Medical Necessity Guidelines," CareAllies, Cigna.  
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Cigna as the first major insurance company to require genetic counseling for BRCA1/2.201  
Cigna’s emphasis on genetic counseling and education is also apparent in their medical policy.   
In addition to meeting the following accreditations, the care provider ordering testing must have 
“evaluated the individual, completed a three generation pedigree, and intend to engage in post-
test follow-up counseling.”202 
  
1. An independent Board-Certified or Board-Eligible Medical Geneticist 
2. An American Board of Medical Genetics or American Board of Genetic Counseling-certified Genetic 
Counselor not employed by a commercial genetic testing laboratory (Genetic counselors are not 
excluded if they are employed by or contracted with a laboratory that is part of an Integrated Health 
System which routinely delivers health care services beyond just the laboratory test itself). 
3. A genetic nurse credentialed as either a Genetic Clinical Nurse (GCN) or an Advanced Practice Nurse 
in Genetics (APGN) by either the Genetic Nursing Credentialing Commission (GNCC) or the 
American Nurses Credentialing Center (ANCC) who is not employed by a commercial genetic testing 
laboratory (Genetic nurses are not excluded if they are employed by or contracted with a laboratory 
that is part of an Integrated Health System which routinely delivers health care services beyond just the 
laboratory test itself). 
 
 
COVENTRY CORPORATION GROUP 
Coventry Health Care primarily follows the “U.S. Preventive Services Task Force (USPSTF) 
evidence-based recommendations that have in effect a rating of “A” or “B” … for clinical 
preventive services.”203  Thus, their policy for breast and ovarian cancer screening is that 
“women whose family history is associated with an increased risk for deleterious mutations in 
BRCA1 or BRCA2 genes be referred for genetic counseling and evaluation for BRCA testing."  
However, Coventry notes that their “preventive health guidelines do not reflect reimbursement or 
payment practices.”  No mention of multi-gene panels or dup/del analysis was made.204   
 
 
DEAN HEALTH GROUP 
The Dean Health Group lists “BRCA counseling about genetic testing for women at higher risk” 
as a “Covered Preventive Services for Women.”  Additionally, this service is “covered in full 
without being applied to co-insurance.”  No further details are given.205 
 
 
 
 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
201 "Cigna Demands Counseling for Breast Test in Myriad Threat," Bloomberg Technology. August 19, 2013. 
http://www.bloomberg.com/news/2013-08-19/cigna-demands-counseling-for-breast-test-in-myriad-threat.html. 
Accessed March 3, 2014.	  	  
202 Cigna Medical Coverage Policy," Cigna.  
203 "Coventry Health Care Clinical Preventive Services 2013," Coventry Health Care. 2013. 
http://www.mhnet.com/web/groups/public/@cvty_regional_chcmo/documents/document/c045215.pdf. Accessed 
April 22, 2014.  
204 "Coventry Health Care Clinical Preventive Services 2013," Coventry Health Care.  
205 "Covered Preventive Services," Dean Health Group. 2012. 
http://www.deancare.com/insurance/members/preventivecarelist/. Accessed April 22, 2014.  
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EMBLEM HEALTH  
Emblem Health considers BRCA1/2 testing (specified as BRACAnalysis) to be medically 
necessary when the “results of the genetic testing will directly impact surveillance or treatment.”  
Patients must meet one of the three criteria listed in Table 5.  BART testing is covered if 
members meet the criteria for BRACAnalysis, but received a negative result.206  Emblem Health 
members are “eligible for pre- and post-test genetic counseling by a physician or a licensed, or 
certified, genetic counselor when recommended for EmblemHealth-covered tests.”207 
 
 
GEISINGER HEALTH PLAN 
The Geisinger Health Plan is a health insurance program that arose out of the Geisinger Health 
System - a healthcare system in northeastern and central Pennsylvania.  The Health Plan has 
approximately 290,000 members and offers coverage for businesses of all sizes, individuals and 
families, Medicare beneficiaries, and children enrolled in the Children's Health Insurance 
Program (CHIP).208  
 
Under the Geisinger Health Plan, BRCA1/2 testing is covered both for individuals with a 
personal history of breast, ovarian, fallopian, or peritoneal cancer and for individuals who are at 
high risk for carrying a BRCA1/2 mutation as defined by the provided criteria (Table 6).209,210 
Rearrangement testing is considered medically necessary for individuals who met the BRCA1/2 
testing criteria, but received a negative point mutation result.  Genetic counseling, by a certified 
ACGC or ABMD professional, must occur both pre-and post-genetic testing. 
 
 
GROUP HEALTH COOPERATIVE 
Group Health Cooperative is a health care system that serves more than 600,000 individuals in 
Washington and Idaho.211  A genetic testing policy was available online, but specific testing 
criteria are considered “proprietary,” and Group Health only shares specific coverage documents 
on an individual member basis.212  
 
 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
206 "BRCA 1 and 2 Genetic Testing (BRACAnalysis) and BRACAnalysis Rearrangement Testing," Emblem Health. 
August 23, 2013. http://www.emblemhealth.com/~/media/Files/PDF/_med_guidelines/MG_BRCA_Testing.pdf. 
Accessed April 22, 2014. 
207 "Genetic Counseling and Testing," Emblem Health. February 27, 2013. 
http://www.emblemhealth.com/~/media/Files/PDF/_med_guidelines/MG_Genetic_Counseling_Testing.pdf. 
Accessed April 22, 2014. 
208 "Key Facts," Geisinger Health Plan. August 21, 2012. 
http://www.thehealthplan.com/news/keyfacts.cfm#Background. Accessed March 4, 2014.  
209 "Medical Benefit Policy: Genetic Testing for BRCA1 or BRCA2 for Breast and Ovarian Cancer." Geisinger 
Health Plan. Policy: MP 97. July 2013. 
https://www.thehealthplan.com/providers_us/medpolicies/repository/4873.pdf. Accessed March 4, 2014.  
210 Note: Testing requires pre-authorization. 
211 "About Group Health," GroupHealth. https://www1.ghc.org/html/public/about. Accessed March 22, 2014.  
212 "Clinical Review Criteria," GroupHealth. March 4, 2014. http://www.ghc.org/all-
sites/clinical/criteria/pdf/genetic_screening.pdf. Accessed March 22, 2014.  
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HARVARD PILGRIM HEALTH CARE GROUP  
Harvard Pilgrim does not list a specific policy for BRCA1/2 testing, but it does list breast cancer 
screening (“Genetic Counseling and Evaluation for BRCA Testing”) as a possible service and 
provides the CPT codes.213  Additionally, Harvard lists “BRCA 1 or 2 genetic counseling, 
evaluation and testing for women with a family history associated with increased risk of 
mutation” as a preventive service that is covered with “no Member Cost Sharing.”214  
 
 
HEALTH ALLIANCE MIDWEST INC 
No coverage policies were found for BRCA1/2 testing, or for genetic testing in general.  
 
 
HEALTH NET 
For BRCA1/2 testing, Health Net follows the guidelines detailed in Table 7.215  Health Net 
considers Myriad’s BRACAnalysis Large Rearrangement Test (BART)® “medically necessary 
to detect large genomic rearrangements in individuals who are at risk for BRCA1/2 related 
cancers but have negative BRCA1/2 genetic sequence tests and meet the criteria for BRCA1/2 
testing.”216  Their coverage policy does not include BRCA1/2 rearrangement testing by other 
testing companies.  Health Net considers genetic counseling to be the responsibility of the care 
provider.  Such counseling should include “risk assessment, pre-test education and post-test 
counseling” and can be completed by the care provider or a genetic counselor.217     
 
 
HEALTH NEW ENGLAND (HNE)  
Health New England (HNE) is a Health Maintenance Organization (HMO) that serves over 
137,000 members in Massachusetts.218  HNE’s policy was last updated in June of 2013 and is 
separated into different sections for different types of insurance (see Table 8).219  Patients with 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
213 "Patient Protection and Affordable Care Act: Harvard Pilgrim Health Care—Provider Manual," Harvard Pilgrim. 
January 2014. 
https://www.harvardpilgrim.org/pls/portal/docs/PAGE/PROVIDERS/MANUALS/MEMBER%20CARE/B%20PPA
CA_011514.PDF. Accessed April 22, 2014.  214	  "Preventive Care:  Services Covered Under the Affordable Care Act," Harvard Pilgrim Health Care. April 2014. 
https://www.harvardpilgrim.org/pls/portal/docs/PAGE/MEMBERS/WELLNESS/PREVENTIVE/PREVENTIVE-
CARE-CC4297.PDF. Accessed April 22, 2014.  
215 “National Medical Policy: Genetic Testing for BRCA1 and BRCA2,” Health Net, Inc. September 2013. 
https://www.healthnet.com/static/general/unprotected/pdfs/national/policies/GeneticTestingforBRCA1andBRCA2.p
df. Accessed February 24, 2014.  
216 “National Medical Policy: Genetic Testing for BRCA1 and BRCA2,” Health Net, Inc. September 2013.  
217 “National Medical Policy: Genetic Testing for BRCA1 and BRCA2,” Health Net, Inc. September 2013.  
218 "HNE Facts at a Glance," Health New England. https://www.healthnewengland.com/HNEs_Story/facts.html. 
Accessed March 22, 2014.  
219 "Clinical Review Criteria for BRCA Genetic Testing," Health New England (HNE). May 11, 2013. 
http://www.healthnewengland.com/hne_providers/documents/BRCAforGeneticTesting-Criteria-External.pdf. 
Accessed March 22, 2014.  
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Medicare Advantage must follow the CMS criteria for BRCA1/2 testing, while those with 
commercial insurance follow USPSTF and NCCN guidelines.220  
 
 
HEALTH PARTNERS GROUP 
Health Partners requires prior authorization for BRCA1/2 testing, and the service is generally 
covered if all of the criteria listed in Table 9 are met.  Health Partners’ medical criteria are based 
off the 2013 NCCN guidelines for Genetic/Familial High-Risk Assessment, Breast and 
Ovarian.221  
 
 
HUMANA INC. 
Humana has a 'Genetic Guidance Program,' which is designed to help patients and doctors decide 
when genetic testing is best (and which specific test should be ordered).  The program also 
brings certified genetic counselors into the care process in the hope that inclusion of these 
professionals will lead to "more-informed healthcare decisions."222  In addition to the option of 
setting a patient up with a genetic counselor, the Genetic Guidance Program allows physicians to 
call Humana to speak with a board-certified genetic counselor directly about preauthorizations.  
Preauthorization of molecular diagnostic and genetic tests is required for commercial, HMO, and 
PPO members.  However, preauthorization is not required for Medicare Advantage Private Fee-
for-Service (PFFS) plans, Risk groups, Medicaid members, CarePlus members, and HumanaOne 
members.223 
 
Humana’s Genetic Guidance Program covers a long list of genetic tests and BRCA1/2 are among 
the genes included.  Full BRCA1/2 sequence analysis, known familial mutations, and del/dup 
analysis are all listed as possible testing options.224  Genetic counseling is to be performed with a 
physician or certified genetic counselor (before and after testing) for hereditary cancer 
syndromes.225  Humana considers genetic testing and genetic counseling for BRCA1/2 medically 
necessary if individuals are over 18 years old and meet the following criteria (Table 10).226   
These policies are in accordance with the NCCN's guidelines.227  Humana will cover large 
rearrangement testing if an individual has a known familial mutation only detectable by 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
220 Note: Medicare Advantage is a “type of Medicare health plan offered by a private company that contracts with 
Medicare to provide Part A and Part B benefits.”  Source: "Medicare Advantage Plans," Centers for Medicare & 
Medicaid Services. http://www.medicare.gov/sign-up-change-plans/medicare-health-plans/medicare-advantage-
plans/medicare-advantage-plans.html. Accessed March 22, 2014.  
221 "Genetic testing for breast/ovarian cancer predisposition (BRCA genetic testing)," HealthPartners. March 11, 
2014. https://www.healthpartners.com/public/coverage-criteria/brca-testing/. Accessed April 22, 2014.  
222 "Molecular Diagnostic and Genetic Testing (MD/GT)," Humana.  
https://www.humana.com/provider/medical-providers/education/referral/dna-preauth. Accessed March 4, 2014.  
223 "Molecular Diagnostic and Genetic Testing (MD/GT)," Humana.  
224 "Genetic Tests and Disease States Included in Humana’s Genetic Guidance Program," Humana.  
http://apps.humana.com/marketing/documents.asp?file=2088567. Accessed March 4, 2014.  
225 "Medical Coverage Policy: Genetic Testing and Genetic Counseling for Hereditary Cancer Syndromes," 
Humana. January 1, 2014. http://apps.humana.com/tad/tad_new/home.aspx. Accessed March 4, 2014.  
226 "Medical Coverage Policy," Humana.  
227 Shah, A., Harris, H., Brown, T., Graf, M.D., Sparks, L., Mullins, T., Bruins, C., (2011). Analysis of Insurance 
Preauthorization Requests for BRCA1 and BRCA2 Genetic Testing. Personalized Medicine 8(5): 563-569.  
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rearrangement analysis, or if an individual meets the testing criteria for BRCA1/2, but full 
sequence analysis returned a negative result.228  If full sequence analysis produced a positive 
result, then rearrangement analysis is not covered.  
 
Humana will not cover genetic testing for “hereditary multigene, next generation sequencing 
panels or pan-cancer panels (e.g., BRCAplus®, BreastNext®, CancerNext®, ColoNext®, 
FoundationOne®, OvaNext®) to determine susceptibility to hereditary cancers, to diagnose 
cancer, or determine treatment.”229   Additionally, Humana only covers testing once per lifetime 
per disease.  
 
 
KAISER FOUNDATION 
Kaiser Permanente does not have a national policy for BRCA1/2 testing.  Only one local policy 
was found (for the Mid-Atlantic Permanente Medical Group) and this policy dates back to 2009 
(see Table 11).  The policy covers BRCA1/2 testing according to NCCN guidelines and requires 
genetic counseling both pre-and post-testing.230  
 
 
MEDICA GROUP 
Medica Group’s BRCA1/2 testing policy follows the NCCN recommendations.  Medica 
considers large rearrangement testing medically necessary if an individual met the criteria for 
BRCA1/2 testing, but received a negative test result.  However, Medica specifies that BART® 
testing must be performed, implying that only Myriad can be used for this service.  Prior 
authorization is required for both BRCA1/2 testing and BART® testing.231  
 
 
MEDICAID  
See discussion in paper (Chapter 5: Policy Recommendations). There is little information 
available for what genetic tests Medicaid covers.  This issue was addressed in a recent report by 
the Centers for Medicare & Medicaid Services (CMS) titled “Payments for Laboratory Test: 
Comparing Medicare, State Medicaid, and Federal Employees Health Benefits Programs."  The 
CMS undertook this study, in which surveys were sent to State Medicaid and Federal Employee 
Health Benefit programs, to learn more about genetic laboratory test coverage and to receive 
feedback establishing payment rates.232  In regards to State Medicaid coverage, the CMS found 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
228 "Medical Coverage Policy," Humana.  
229 "Medical Coverage Policy," Humana.  
230 "BRCA Testing: Genetic Counseling and Testing for Inherited Susceptibility for Breast and/or Ovarian Cancer 
due to BRCA1/2 Defects," Kaiser Permanente, Mid-Atlantic Permanente Medical Group (MAPMG). 2009. 
https://www.mapmgonline.com/portal/documents/brca_testing.pdf. Accessed March 22, 2014. 
231 "Genetic testing for Hereditary Breast and / or Ovarian Cancer (BRCA1 and BRCA2 Genes and BRACAnalysis 
Rearrangement Test [BART])," Medica. Utilization Management Policy. Medica Policy No. III-DIA.04. February 1, 
2014.  
232 "Memorandum Report: Coverage and Payment for Genetic Laboratory Tests, OEI-07-11-000 11," Department of 
Health and Human Services. June 12, 2013. https://oig.hhs.gov/oei/reports/oei-07-11-00011.pdf. Accessed March 
22, 2014.  
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that “officials from all but one State [New Mexico] described some level of coverage for genetic 
tests.”  However, “officials from 17 States stated that their States have no specific policy 
addressing them.”  The remaining states used a variety of factors to influence coverage decisions.  
When officials from State Medicaid programs were asked to provide payment rates for genetic 
tests (including BRCA1/2 analysis), only 8 state Medicaid programs were able to provide 
payment rates.   CMS found “great variation in test prices; for example, the payment rate for a 
BRCA1 gene analysis ranged from $1,000 in Pennsylvania to nearly $4,500 in Iowa.”  See the 
table below for the prices of the remaining states.233  
 
 
Medicaid Payment Rates 
 CA DE IL IA MA PA VA 
BRCA1 
Gene 
Analysis 
$3,340 $3,120 $3,030 $4,498 $2,731 $1,000 $3,120 
BRCA2 
Gene 
Analysis 
$3,340 $3,120 $2,770 $4,947  $1,000  
 
Facing Our Risk of Cancer Empowered (FORCE), a non-profit advocacy group, has also 
testified to how widely states differ in their Medicaid coverage for BRCA1/2 testing.  According 
to FORCE, the states that most often cover testing are: Alaska, Arizona, California, Colorado, 
Connecticut, Delaware, Florida, Illinois, Indiana, Iowa, Kansas, Kentucky, Maryland, 
Massachusetts, Michigan, Minnesota, Missouri, Montana, New Jersey, New York, New Mexico, 
Ohio, Oklahoma, Oregon, Tennessee, Texas, Utah, Virginia, Vermont, Washington, West 
Virginia, and Wyoming.234  According to Emory's genetic testing website, lab members are 
working "diligently with Georgia Medicaid and other government offices to address the issue of 
non-coverage for genetic testing."235  This statement implies that Georgia's Medicaid does not 
cover genetic testing.  
 
 
MEDICAL MUTUAL OF OHIO 
Medical Mutual does not have a specific BRCA1/2 testing policy, but the test is listed as one that 
needs prior approval.236  Another page on the Medical Mutual website lists "counseling women 
at high risk of breast cancer" and "genetic screening and evaluation for the BRCA breast cancer 
gene" as covered services with no cost sharing, implying that Medical Mutual does cover the 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
233 "Memorandum Report," Department of Health and Human Services. June 	  
234 "Insurance, Financial Assistance, Cost of Services," FORCE: Facing Our Risk of Cancer Empowered. 
http://www.facingourrisk.org/info_research/finding-health-care/financial-
help/index.php?PHPSESSID=120896cb6d92db9dbab9c05549216c3b. Accessed February 10, 2014.  
235 "Billing Options," Emory Genetics Laboratory. https://genetics.emory.edu/egl/billing/index.php/1143. Accessed 
March 22, 2014.  
236 "Prior Approval and Investigational Services," Medical Mutual. April 14, 2014. 
https://provider.medmutual.com/pdf/priorapprovallist.pdf. Accessed April 22, 2014.  
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test.237  No mention was made in regards to rearrangement testing or specific laboratories that 
must be used.  
 
 
MEDICARE 
Medicare operates under a dual-system of national and local coverage determinations.  Medicare 
does not have a National Policy for BRCA1/2 testing.  In fact, Medicare only has two national 
coverage determinations for any type of genetic test: (1) testing to predict patient responsiveness 
to the drug warfarin sodium and (2) cytogenetic studies.238  Thus, individuals should refer to 
Medicare’s Local Coverage Determinations (LCDs) for Genetic Testing.239  Though Medicare 
does not have a NCD, most state’s LCDs are quite similar.  Generally, BRCA1/2 testing is 
covered for people who meet the following guidelines laid out in Table 12.240,241   Because the 
CMS defines “comprehensive genetic testing of BRCA1 and BRCA2” to include “full sequencing 
and detection of large genomic rearrangements,” Medicare covers rearrangement (dup/del) 
analysis for affected individuals.242  Medicare requires pre-test genetic counseling to be 
"provided by a qualified and appropriately trained practitioner."  Additionally, before testing, 
patients must sign an informed consent form which states that they agree to post-test 
counseling.243 Medicare does not cover testing for people who have not personally had breast or 
ovarian cancer.244  Medicare views BRCA1/2 testing for non-affected individuals as a type of 
“screening” and, therefore, ineligible for coverage.245,246   
 
In December of 2013, the Centers for Medicare and Medicaid Services (CMS) updated 
reimbursement levels for BRAC1/2 testing by decreasing the National Limit Amounts 
(NLA).247,248  Previously, CMS reimbursed up to $2,795 for BRCA1/2 testing.  However, 
effective after January 1, 2014, CMS will only cover up to $1,438 for BRCA1/2 testing (a 49% 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
237 "Women's Preventive Health Services," Medical Mutual. 2013. https://www.medmutual.com/For-
Employers/Healthcare-Reform/Affordable-Care-Act-Summary/HCR-Items/Womens-Preventive-Health-
Services.aspx. Accessed April 22, 2014.  
238 "Memorandum Report,” Department of Health and Human Services.  
239 Note: Within Medicare’s LCDs, individuals should refer to the section titled ‘Genetic Testing and Molecular 
Diagnostic Tests (MDT).’ Source: “Medical Policy: Genetic Testing for HBOC,” United HealthCare Services.   
240 Note: These Medicare coverage determinations were taken from Utah’s LCD.  Readers should consult their 
specific LCD to make sure coverage is the same.  
241 "Local Coverage Determination (LCD): Genetic Testing (L24308)," Centers for Medicare & Medicaid Services 
(CMS). Utah. October 31, 2013. http://www.cms.gov/medicare-coverage-database/details/lcd-
details.aspx?LCDId=24308&ContrId=133&ver=62&ContrVer=1&bc=AAAAAAAAQAAA&. March 4, 2014  
242 "Local Coverage Determination (LCD): Genetic Testing (L24308)," CMS.  
243 "Local Coverage Determination (LCD): Genetic Testing (L24308)," CMS.  
244 "Insurance, Financial Assistance, Cost of Services," FORCE.  
245 "Local Coverage Determination (LCD): Genetic Testing (L24308)," CMS.  
246 Note: Medicare does cover some preventative services.  For a list of such screenings that are covered, see: 
"Prevention - General Information," Centers for Medicare & Medicaid Services. April 25, 2013. 
http://www.cms.gov/Medicare/Prevention/PrevntionGenInfo/index.html?redirect=/PrevntionGenInfo/. Accessed 
March 4, 2014.  
247 "CMS Cuts Reimbursement for BRCA1/2 Testing by 49 Percent; Analyst Downgrades Myriad Shares," 
GenomeWeb. December 30, 2013. http://www.genomeweb.com/clinical-genomics/cms-cuts-reimbursement-brca12-
testing-49-percent-analyst-downgrades-myriad-share. Accessed February 10, 2014.  
248 "Reimbursement for Breast-Cancer Risk Test to Be Cut," The WSJ. December 29, 2013. 
ttp://online.wsj.com/news/articles/SB10001424052702304361604579288591617575358.  
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decrease from 2013 levels).249  According to the CMS, the Supreme Court’s decision in June of 
2013 was influential in the reimbursement decrease because this decision allowed additional 
companies to enter the market and lower BRCA1/2 testing costs.250   
 
SELECT HEALTH 
Select Health does not have a published BRCA1/2 testing policy, but does list “BRCA counseling 
about genetic testing for women at higher risk” as a preventive service offered to women with no 
cost-sharing requirements.251 
 
SPECTRUM HEALTH 
No policy found.  
 
TUFTS HEALTH PLAN 
Tufts Health Plan provides BRCA1/2 testing and counseling, with no cost-sharing 
responsibilities, as a preventive service for women, provided that they meet the pre-authorization 
guidelines.252  Tufts’ Medical Necessity Guidelines state that testing is deemed medically 
necessary for members “at high risk for breast cancer.”253  The policy then goes on to specify 
when women can be classified as “high risk,” but generally, “Tufts Health Plan defines high risk 
as a greater than ten percent risk for a positive test result based upon either the Myriad or 
BRCAPRO model.”  Table 13 lists the coverage policy in more detail.   
 
UNITED HEALTHCARE 
UnitedHealthcare covers BRCA1/2 testing in accordance with the guidelines laid out by the 
NCCN (see Table 14).254  When individuals meet the listed criteria, United Health also 
recognizes the clinical importance of large rearrangement analysis.  Genetic counseling is 
“strongly recommended prior to genetic testing for BRCA mutations.”255 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
249 Note: These new NLA amounts correspond to the CPT codes 81211 (full gene sequencing of BRCA1/2) and 
81214 (full gene sequencing of just BRCA1). For more information about CPT codes, see Appendix 6. 
250 "Gapfill Pricing Inquiries," Centers for Medicare and Medicaid Services (CMS). January 29, 2014. 
http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/Gapfill-Pricing-
Inquiries.html. Accessed February 24, 2013.  
251 "Preventive Care: At No Cost to You," Select Health. November 2010.  
http://selecthealth.org/Forms%20and%20Documents/Reform/PreventiveCare_Reform.pdf. Accessed April 22, 2014.  
252 "Preventive Services," Tufts Health Plan. April 17, 2014. 
http://www.tuftshealthplan.com/providers/pdf/payment_policies/preventive_services.pdf. Accessed April 22, 2014.  253	  "Medical Necessity Guidelines: Genetic Testing for Multi-site BRCA3, Single Site BRCA1 or BRCA2, & 
BART," Tufts Health Plan. January 8, 2014.  
http://www.tuftshealthplan.com/providers/pdf/mng/genetic_testing_brca.pdf. Accessed April 22, 2014.  
254 “Medical Policy: Genetic Testing for Hereditary Breast and/or Ovarian Cancer Syndrome (HBOC),” United 
HealthCare Services. February 1, 2014. Inc. 
https://www.unitedhealthcareonline.com/ccmcontent/ProviderII/UHC/en-
US/Assets/ProviderStaticFiles/ProviderStaticFilesPdf/Tools%20and%20Resources/Policies%20and%20Protocols/M
edical%20Policies/Medical%20Policies/Genetic_Testing_HBOC_Syndrome.pdf. Accessed February 10, 2014.  
255 “Medical Policy: Genetic Testing for HBOC,” United HealthCare Services. 	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Appendix 3C 
Coverage Policies 
Insurance Company Policies 
 
Table 1 | Aetna’s Coverage of BRCA1/2 Testing 
 
Aetna considers molecular susceptibility testing for breast and/or ovarian cancer (“BRCA testing”) 
medically necessary in any of the following categories of high-risk adults with breast or ovarian cancer 
(adapted from guidelines from the U.S. Preventive Services Task Force (for screening indications) and 
from the American College of Obstetricians and Gynecologysts and the American College of Medical 
Genetics (for testing persons with cancer)): 
 
1. Women with a history of epithelial ovarian cancer  
2. Women with personal history of breast cancer and any of the following: 
a. Breast cancer is diagnosed at age 45 years or younger, with or without family history; 
or 
b. Breast cancer is diagnosed at age 50 years or younger, with any of the following: 
i. at least 1 close blood relative with breast cancer at age 50 years or younger; or  
ii. at least 1 close blood relative with epithelial ovarian cancer; or 
iii. bilateral breast cancer, or 2 primary breast cancers with 1st primary diagnosed 
at age 50 years or younger; or 
iv. limited family structure, or no family history available because member is 
adopted. 
c. Breast cancer is diagnosed at age 60 years or younger, and is triple negative.  
d. Breast cancer is diagnosed at any age, with any of the following: 
i. at least 2 close blood relatives on the same side of the family with breast 
cancer and/or epithelial ovarian cancer at any age; or 
ii. the member has 2 breast primaries and also has at least 1 close blood relative 
with breast cancer diagnosed at age 50 years or younger; or  
iii. the member has 2 breast primaries and also has at least 1 close blood relative3 
with epithelial ovarian cancer; or 
iv. close male blood relative with breast cancer; or 
v. at least 1 1st-, 2nd-, or 3rd-degree blood relative with a known BRCA1 or 
BRCA2 mutation; or 
vi. 2 close relatives on the same side of the family with pancreatic 
adenocarcinoma at any age; or 
vii. if ethnicity is associated with higher mutation frequency (Ashkenazi 
Jewish), no additional family history is required.  
3. Women with a personal history of pancreatic adenocarcinoma at any age with 2 close relatives 
on the side same side of the family with breast cancer, epithelial ovarian cancer, and/or 
pancreatic adenocarcinoma at any age. 
4. Women without a personal history of breast cancer, epithelial ovarian cancer, or pancreatic 
adenocarcinoma, and any of the following: 
a. Women with 3 or more close blood relatives on the same side of the family with breast 
cancer, irrespective of age at diagnosis; or 
b. Women with 1 or more close blood relatives on the same side of the family with breast 
cancer and 1 or more close blood relatives on the same side of the family with ovarian 
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cancer; or 
c. Women with 2 or more close blood relatives with epithelial ovarian cancer; or 
d. Women with 1 or more male close blood relatives with breast cancer; or 
e. Women with 2 or more 1st-degree relatives with breast cancer, 1 of whom was 
diagnosed at age 50 years and younger; or 
f. Women with 1 or more 1st-degree relatives with bilateral breast cancer; or 
g. Women with 1 or more close blood relatives with both breast and epithelial ovarian 
cancer; or 
h. Women of Ashkenazi Jewish descent with 1 or more 1st-degree relatives or two or 
more 2nd-degree relatives with breast or ovarian cancer; or 
i. Women with 1 or more 1st-, 2nd-, or 3rd-degree blood relatives with a known BRCA1 
or BRCA2 mutation. 
5. Women who do not meet any of the above criteria but are determined through both 
independent formal genetic counseling and validated quantitative risk assessment tool7 to have 
at least a 10% pre-test probability of carrying a BRCA1 or BRCA2 mutation.  Note: In this 
category only, a 3-generation pedigree and quantitative risk assessment results must be 
provided to Aetna. 
6. Men with any of the following: 
a. A 1st-, 2nd-, or 3rd-degree blood relative who has a known BRCA1 or BRCA2 
mutation, where the results will influence clinical utility (i.e., reproductive decision-
making); or  
b. A personal history of breast cancer. 
 
 
Table 2 | BCBS Structure 
Publically traded companies:  
1. Anthem for-profit (Became WellPoint, Inc. in 2004) 
a. Anthem BlueCross BlueShield:  Colorado, Connecticut, Indiana, Kentucky, Maine, 
Missouri, Nevada, New Hampshire, Ohio, Parts of Virginia, Wisconsin 
b. Anthem Blue Cross:  California   
c. BlueCross BlueShield: Georgia 
d. Empire BlueCross and BlueShield: New York 
 
Multi state private companies: 
1. CareFirst 
a. District of Columbia 
b. Maryland 
c. Parts of Virginia 
2. Health Care Service Corporation (HCSC) 
a. BlueCross BlueShield of Illinois 
b. BlueCross BlueShield of New Mexico 
c. Blue Cross Blue Shield of Montana 
d. BlueCross BlueShield of Oklahoma 
e. BlueCross BlueShield of Texas 
3. Highmark 
a. Highmark BlueCross BlueShield (Western Pennsylvania) 
b. Highmark BlueShield (Northeastern, Eastern & Central Pennsylvania) 
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c. Highmark BlueCross Blue Shield Delaware (Delaware) 
d. Highmark BlueCross BlueShield West Virginia (West Virginia) 
4. Premera 
a. Premera BlueCross BlueShield of Alaska 
b. Premera BlueCross (Washington) 
5. The Regence Group (Cambia Health Solutions) 
a. Regence BlueShield of Idaho 
b. Regence BlueCross BlueShield of Oregon 
c. Regence BlueCross BlueShield of Utah 
d. Regence BlueShield (Washington) 
6. Wellmark BlueCross Blue Shield 
a. Iowa 
b. South Dakota 
 
Single state or regional companies: 
1. BlueCross BlueShield of Alabama 
2. BlueCross BlueShield of Arizona 
3. Arkansas BlueCross BlueShield 
4. Blue Shield of California 
5. BlueCross BlueShield of Florida (branded as Florida Blue) 
6. Hawaii Medical Service Association 
7. BlueCross of Idaho 
8. BlueCross BlueShield of Kansas 
9. BlueCross BlueShield of Louisiana 
10. Blue Cross Blue Shield of Massachusetts 
11. Blue Cross Blue Shield of Michigan 
12. Blue Cross Blue Shield of Minnesota 
13. Blue Cross Blue Shield of Mississippi 
14. Blue Cross and Blue Shield of Kansas City 
15. Blue Cross Blue Shield of Nebraska 
16. Horizon Blue Cross Blue Shield of New Jersey 
17. Excellus BlueCross BlueShield (Central New York, Rochester and Utica/Watertown) 
18. BlueShield of Northeastern New York (A division of HealthNow New York Inc.) 
19. BlueCross BlueShield of Western New York (A division of HealthNow New York Inc.) 
20. Blue Cross Blue Shield of North Carolina 
21. Blue Cross Blue Shield of North Dakota 
22. Blue Cross of Northeastern Pennsylvania 
23. Capital Blue Cross (Central Pennsylvania) 
24. Independence Blue Cross (Philadelphia, Southeastern Pennsylvania) 
25. Blue Cross Blue Shield of Rhode Island 
26. Blue Cross Blue Shield of South Carolina 
27. BlueCross BlueShield of Tennessee 
28. BlueCross BlueShield of Vermont 
29. BlueCross BlueShield of Wyoming 
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Table 3 | BCBS Anthem: Coverage for BRCA1/2 Testing 
 
 
For individuals from a family with a known deleterious BRCA1/BRCA2 mutation, genetic testing for 
a BRCA1 or BRCA2 mutation, associated with genetic counseling, is considered medically necessary. 
 
For individuals with a personal history of cancer, genetic testing for a BRCA1 or BRCA2 mutation, 
associated with genetic counseling, is considered medically necessary when ANY of the following 
criteria are met: 
 
• The individual was diagnosed with breast cancer prior to age 50; OR 
• The individual has a history of breast cancer diagnosed at any age and at least 1 first-, second- or third-
degree relative with breast cancer diagnosed at age 50 years or less; OR 
• The individual has multiple primary breast cancers or bilateral breast cancer; OR 
• The individual is a male with breast cancer; OR 
• The individual has triple negative breast cancer diagnosed at age 60 or less; OR 
• The individual has a history of breast cancer and a first-, second- or third-degree male relative with breast 
cancer; OR 
• The individual has a history of breast cancer and 2 or more first-, second- or third-degree relatives on the 
same side of the family with pancreatic cancer; OR 
• The individual has a history of ovarian, fallopian tube or primary peritoneal cancer; OR 
• The individual has a history of pancreatic cancer and 2 or more first-, second-, or third-degree relatives on 
the same side of the family with breast, ovarian, fallopian tube, primary peritoneal or pancreatic cancer; OR 
• The individual has a history of breast cancer and at least 2 or more first-, second- or third-degree relatives on 
the same side of the family with breast cancer; OR 
• The individual has a history of breast cancer and at least 1 first-, second- or third-degree relative with 
ovarian, fallopian tube, or primary peritoneal cancer; OR 
• The individual has a history of breast cancer and belongs to a population at risk for specific mutations due to 
ethnic background (for example, Ashkenazi Jewish, Icelandic, Swedish, Hungarian or Dutch descent). 
 
For individuals with a family history of cancer, genetic testing for a BRCA1 or BRCA2 mutation, 
associated with genetic counseling, is considered medically necessary when they have a relative who 
would meet ANY of the following criteria, but that relative is not available for testing: 
 
• The individual for whom the test is requested, has a first- or second-degree relative who had breast cancer 
diagnosed prior to age 50; OR 
• The individual for whom the test is requested, has a first- or second-degree relative with breast cancer 
diagnosed at any age and that relative has at least 1 first-, second- or third-degree relative with breast cancer 
diagnosed at age 50 years or less; OR 
• The individual for whom the test is requested, has a first- or second-degree relative who had multiple 
primary breast cancers or bilateral breast cancer; OR 
• The individual for whom the test is requested, has a first- or second-degree male relative who developed 
breast cancer; OR 
• The individual for whom the test is requested, has a first- or second-degree relative who had triple negative 
breast cancer diagnosed at age 60 or less; OR 
• The individual for whom the test is requested, has a first- or second-degree relative with breast cancer and 
that relative has a first-, second- or third-degree male relative with breast cancer; OR 
• The individual has a first- or second-degree relative with a history of breast cancer and 2 or more first-, 
second-, or third-degree relatives on the same side of the family with pancreatic cancer; OR 
• The individual has a first- or second-degree relative who has a history of ovarian cancer and 2 or more first-, 
second-, or third-degree relatives on the same side of the family with pancreatic cancer; OR 
• The individual for whom the test is requested, has a first- or second-degree relative who has a history of 
ovarian, fallopian tube, or primary peritoneal cancer; OR 
• The individual has a first- or second-degree relative with a history of pancreatic cancer, and 2 or more first-, 
second-, or third-degree relatives on the same side of the family with breast, ovarian, fallopian tube, primary 
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peritoneal or pancreatic cancer; OR 
• The individual for whom the test is requested, has a first- or second-degree relative with history of breast 
cancer, and that relative has at least 2 or more first-, second- or third-degree relatives on the same side of the 
family with breast cancer; OR 
• The individual for whom the test is requested, has a first- or second-degree relative with breast cancer, and 
that relative has at least 1 first-, second-, or third-degree relative with ovarian, fallopian tube or primary 
peritoneal cancer; OR 
• The individual for whom the test is requested, has a first- or second-degree relative who has a history of 
breast cancer and that relative belongs to a population at risk for specific mutations due to ethnic 
background (for example, Ashkenazi Jewish, Icelandic, Swedish, Hungarian or Dutch descent). 
 
For individuals with a family history of three or more first-, second- or third-degree relatives with 
ovarian, fallopian tube or primary peritoneal cancer or breast cancer, (at least one of which has breast 
cancer at or before age 50), genetic testing for a BRCA1 or BRCA2 mutation, associated with genetic 
counseling, is considered medically necessary. 
 
 
 
 
Table 4 | Cigna Health Plan: Coverage for BRCA1/2 Testing 
 
 
Known Familial Mutation 
Cigna covers BRCA1 and BRCA2 genetic testing for susceptibility to breast or ovarian cancer in adults as 
medically necessary with single site analysis for the known familial variant for a biologically-related individual 
from a family with a known BRCA1 or BRCA2 mutation.  
  
Personal History of Breast Cancer 
Cigna covers BRCA1 and BRCA2 genetic testing for susceptibility to breast or ovarian cancer in adults with full 
sequence analysis and duplication/deletion analysis of common variants as medically necessary when there is a 
personal history of breast cancer and for ANY of the following indications: 
 
• diagnosed at age 45 or younger 
• diagnosed at age 50 or younger with at least one close blood relative* with breast cancer at any age  
• diagnosed with two breast primaries (includes bilateral disease or cases where there are two or more clearly 
separate ipsilateral primary tumors) when the first breast cancer diagnosis occurred prior to age 50 
• diagnosed at age 60 or younger with a triple negative breast cancer 
• diagnosed at age 50 or younger with a limited family history (e.g., fewer than two first- or second degree 
female relatives or female relatives surviving beyond 45 years in the relevant maternal and/or paternal 
lineage) 
• diagnosed at any age and there are at least two close blood relatives* with breast cancer at any age 
• diagnosed at any age with at least one close blood relative* with breast cancer at age 50 or younger 
• diagnosed at any age and there are at least two close blood relatives* with pancreatic cancer at any age 
• diagnosed at any age with at least two close blood relatives* with aggressive prostate cancer (e.g., Gleason 
score ≥7) at any age 
• diagnosed at any age with at least one close blood relative* with epithelial ovarian cancer, fallopian tube, or 
primary peritoneal cancer 
• close male blood relative* with breast cancer 
• individual of Ashkenazi Jewish descent (testing in this situation is only covered for the three founder 
mutations [CPT code 81212] and not for full sequence analysis and duplication/deletion analysis of common 
variants) 
 
Personal History of Cancer  
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Cigna covers BRCA1 and BRCA2 genetic testing for susceptibility to breast or ovarian cancer in adults with full 
sequence analysis and duplication/deletion analysis of common as medically necessary in an adult for any of the 
following indications: 
 
• personal history of epithelial ovarian, fallopian tube, or primary peritoneal cancer  
• personal history of male breast cancer 
• personal history of pancreatic cancer or aggressive prostate cancer (Gleason score ≥7)  at any age with two 
or more close blood relatives* with breast, ovarian, pancreatic cancer, or aggressive prostate cancer (e.g., 
Gleason score ≥7) at any age 
 
Family History of Breast, Ovarian or Pancreatic Cancer  
Cigna covers BRCA1 and BRCA2 genetic testing for susceptibility to breast or ovarian cancer in adults with full 
sequence analysis and duplication/deletion analysis of common variants as medically necessary when there is no 
personal history of breast or ovarian cancer and for a family history of ANY of the following: 
 
• first- or second-degree blood relative with a history of breast cancer and any of the following: 
o diagnosed at age 45 or younger 
o diagnosed at age 50 or younger with at least one additional close blood relative* with breast 
cancer at any age 
o diagnosed with two breast primaries (includes bilateral disease or cases where there are two or 
more clearly separate ipsilateral primary tumors) when the first breast cancer diagnosis 
occurred prior to age 50 
o diagnosed at age 60 or younger with a triple negative breast cancer 
o diagnosed at age 50 or younger with a limited family history (e.g., fewer than two first- or 
second degree female relatives or female relatives surviving beyond 45 years in the relevant 
maternal and/or paternal lineage) 
o diagnosed at any age and there are at least two close blood relatives* with breast cancer at any 
age 
o diagnosed at any age with at least one close blood relative* with breast cancer at age 50 or 
younger 
o diagnosed at any age and there are at least two close blood relatives* with pancreatic cancer at 
any age 
o diagnosed at any age with at least two close blood relatives* with aggressive prostate cancer 
(e.g., Gleason score ≥7) at any age 
o diagnosed at any age with at least one close blood relative* with epithelial ovarian cancer, 
fallopian tube, or primary peritoneal cancer 
o lose male blood relative* with breast cancer 
o individual of Ashkenazi Jewish descent (testing in this situation is only covered for the three 
founder mutations (CPT code 81212) and not for full sequence analysis and 
duplication/deletion analysis of common variants) first- or second-degree blood relative with a 
history of epithelial ovarian, fallopian tube, or primary peritoneal cancer 
• first- or second-degree blood relative with a history of male breast cancer 
• first- or second-degree blood relative with a history of pancreatic cancer at any age with two or more close 
blood relatives* with breast, ovarian, or pancreatic cancer at any age 
• third-degree blood relative with breast and/or epithelial ovarian/fallopian tube/primary peritoneal cancer 
with two or more close blood relatives* with breast and/or ovarian cancer (with at least one close blood 
relative with breast cancer prior to age 50) 
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Table 5 | Emblem Health: Coverage for BRCA1/2 Testing 
 
Members are eligible for coverage of BRCA 1 and 2 Genetic Testing (BRACAnalysis when the results of the 
genetic testing will directly impact surveillance or treatment).  
 
BRCA 1 and 2 genetic testing — 1, 2 or 3 must be met: 
 
1. ≥ 3 close relatives on the same side of the family (including the member) have breast (either invasive or 
non-invasive) or ovarian cancer. 
2. < 3 close relatives on the same side of the family with breast or ovarian cancer, but any of the following 
are present:  
a. Member or close relative diagnosed with breast cancer at ≤ 45 years of age. . 
b. Close relative identified with a detectable BRCA 1 or 2 mutation. 
c. Member diagnosed with breast cancer ≤ 50 years of age and ≥ 1 close relative diagnosed with 
breast cancer at any age.  
d. Member diagnosed with breast cancer at any age and ≥ 1 close relative diagnosed with breast 
cancer ≤ 50 years of age 
e. Member or close relative diagnosed with 2 primary breast cancers (including bilateral disease or 
≥ 2 more separate primary tumors in opposite breasts) and the first cancer was diagnosed at ≤ 
50 years of age. 
f. Member or close relative diagnosed with triple negative breast cancer at ≤ 60 years of age. 
(Breast cancer that is negative for Estrogen receptor [ER], Progesterone receptor [PR] and 
HER2) 
g. Member was diagnosed with breast cancer ≤ 50 years of age and has a limited family history. 
h. The member was diagnosed with breast cancer at any age and has ≥ 2 close blood relatives with 
pancreatic cancer or aggressive prostate cancer (Gleason score>7) at any age. 
i. Member or close relative diagnosed with ovarian cancer at any age. 
j. Member or close relative with breast cancer is male. 
k. Member or close relative diagnosed with breast cancer at any age and at increased risk for 
specific mutation(s) secondary to ethnic background (e.g., Ashkenazi Jewish descent). (See 
Limitations/Exclusions)  
II. The member was diagnosed with pancreatic cancer or aggressive prostate cancer (Gleason score ≥ 7) at 
any age with ≥ 2 close relatives with breast and/or ovarian (including fallopian tube or primary 
peritoneal cancer) and/or pancreatic or aggressive prostate cancer (Gleason score ≥ 7) at any age. 
 
Members are eligible for BRACAnalysis Rearrangement Testing (BART) if they meet criteria for 
Comprehensive BRACAnalysis and the analysis is negative 
 
 
Limitations/Exclusions 
 
Authorization should initially be for the mutation(s) specific  to the ethnic group in question (e.g., Multisite 3 
BRACAnalysis or equivalent for members of Ashkenazi descent).  If multisite screening is negative, additional 
genetic testing (e.g., Comprehensive BRACAnalysis) would be warranted if the member meets the remainder of 
the criteria above.  Requests that do not meet the testing criteria will be reviewed by a medical director. 
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Table 6 | Geisinger Health Plan: Coverage for BRCA1/2 Testing 
 
 
The Plan considers molecular susceptibility testing for hereditary breast and ovarian cancer (BRCA testing) 
medically necessary in ANY of the following indications: 
 
I. Individuals with a biologically related family member with a known BRCA1/BRCA2 mutation and for 
whom the result will influence clinical decision making. 
II. Women with a personal history of breast cancer (including both invasive and ductal carcinoma in situ) and 
ANY of the following: 
a. breast cancer diagnosed at age 45 or younger; or 
b. breast cancer is diagnosed at age 50 or younger with one of the following: 
i. At least one first, second, or third-degree  relative with breast cancer at age 50 years or 
younger; or 
ii. At least one first- second-, or third degree blood relative with epithelial ovarian 
cancer/fallopian tube/primary peritoneal cancer at any age 
c. Documented evidence of two breast primaries (including bilateral disease or cases where there 
are two or more clearly separate ipsilateral primary tumors) where first breast cancer diagnosed 
prior to age 50; or 
d. Documented evidence of breast cancer at any age with two or more close first- or second-
degree blood relatives with breast cancer and/or epithelial ovarian cancer/fallopian tube/primary 
peritoneal cancer at any age; or 
e. First, second or third-degree male blood relative with documented evidence of breast cancer: or 
f. Personal history of epithelial ovarian cancer/fallopian tube/primary peritoneal cancer; or 
g. Certain ethnic descent associated with deleterious mutations (e.g. founder populations of 
Ashkenazi Jewish, Icelandic, Swedish, Hungarian, Dutch or other) or personal history of breast 
and/or ovarian cancer in first-, second- or third degree blood relative on the same side of the 
family; no additional family history required. 
h. diagnosed at age 60 or younger with a triple negative breast cancer 
III. Women with a personal history of epithelial ovarian cancer/fallopian tube/primary peritoneal cancer  
IV. Women without a personal history of breast cancer but  documented evidence of a first-, second-degree 
relative meeting any of the above criteria. 
V. Women without a personal history of breast cancer but documented evidence of a third degree relative with 
more than 2 close blood relatives with breast and/or ovarian cancer with at least one close blood relative 
with breast cancer at age 50 or younger. 
VI. Males with a personal history of breast cancer 
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Table 7 | HealthNet BRCA1/2 Testing Guidelines 
 
1. Individuals with a family member with a known BRCA1/BRCA2 mutation; or   
 
2. Non-Ashkenazi Jewish women, age 18 or older, who have not been diagnosed with either breast or 
ovarian cancer, with any of the following high-risk family history patterns: 
• Two first-degree relatives* with breast cancer, one of whom was diagnosed at age 50 or 
younger; or 
• A combination of 3 or more first- or second-degree* relatives with breast cancer, regardless of 
age of diagnosis; or 
• A combination of both breast and ovarian cancer among first- and second –degree relatives; or 
• A first-degree relative with bilateral breast cancer; or 
• A combination of 2 or more first- or second-degree relatives with ovarian cancer, regardless of 
age of diagnosis; or  
• A first- or second-degree relative with both breast and ovarian cancer, at any age; or 
• A history of breast cancer in a male relative (father, sons, brothers, uncles, grandfathers); or  
• A family member has been identified with a detectable mutation  
 
3. Women of Ashkenazi Jewish heritage, (without a personal history of either breast or ovarian cancer), 
with any of the following high-risk family history patterns: 
• First-degree relative with breast or ovarian cancer, at any age; or 
• Two second-degree relatives on the same side of the family with breast or ovarian cancer, at 
any age. 
 
4. Women with a personal history of breast cancer (including invasive and ductal carcinoma in situ 
breast cancer) and one or more of the following: 
• Diagnosed age < 45y 
• Diagnosed at any age, with > 1 close blood relative with breast cancer diagnosed < 50 y 
• Diagnosed at any age with >1 close blood relative with epithelial ovarian cancer (including 
fallopian tubes and primary peritoneal cancer) 
• Two breast primaries when first breast cancer diagnosis occurred <age 50y [Two breast 
primaries includes bilateral (contralateral) disease or two or more clearly separate ipsilateral 
primary tumors either synchronously or asynchronously] 
• Diagnosed age < 60 y with a triple negative breast cancer (i.e., ER-, PR-negative, and HER2-
negative) 
• Diagnosed age < 50y with > 1 close blood relative with breast cancer at any age OR with a 
limited family history (Individuals with a limited family history, such as fewer than 2 first, or 
second-degree female relatives or female relatives surviving beyond 45 years in either lineage, 
may have an underestimated probability of a familial mutation)  
• Diagnosed at any age, with > 2 close blood relatives with breast cancer at any age 
• Diagnosed at any age with > 2 close blood relatives with pancreatic cancer or aggressive 
prostate cancer (Gleason score >7) at any age 
• Close male blood relative with breast cancer  
• For an individual of ethnicity associated with deleterious mutations (eg, founder populations 
of Ashkenazi Jewish, Icelandic, Swedish, Hungarian or other), no additional family history 
may be required.  Note:  Testing for founder-specific mutation(s), if available, should be 
performed first.  Full sequencing may be considered if other Hereditary Breast/Ovarian Cancer 
criteria is met.   
 
5. Women with a personal history of ovarian cancer (including fallopian tubes and primary peritoneal 
cancer).  
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• For an individual of ethnicity associated with deleterious mutations  (eg, founder populations 
of Ashkenazi Jewish, Icelandic, Swedish, Hungarian or other), no additional family history 
may be required. Note:  Testing for founder-specific mutation(s), if available, should be 
performed first.  Full sequencing may be considered if other hereditary breast and ovarian 
cancer (HBOC) criteria is met.     
 
6. Males with a personal history of breast cancer 
 
7. Individuals with a personal history of pancreatic cancer or aggressive prostate cancer (Gleason score 
>7) at any age with > 2 close blood relatives with breast and/ovarian cancer and /or pancreatic or 
aggressive prostate cancer (Gleason score >7) at any age  
 
8. Family history only (Significant limitations of interpreting test results for an unaffected individual 
should be discussed) 
• First or second-degree blood relatives meeting any of the above criteria 
• Third degree blood relative with breast cancer and/or ovarian cancer with > 2 close blood 
relatives with breast cancer (at least one with breast cancer< 50y) and/or ovarian cancer 
• Clinical judgment should be used to determine if the patient has reasonable likelihood of a 
mutation, considering the unaffected patient’s current age and the age of female unaffected 
relatives who link the patient with the affected relatives. 
• Testing of unaffected individuals should only be considered when an appropriate affected 
family member is unavailable for testing.   
 
* Close blood relatives include first-, second- and third degree relatives on same side of family. First-
degree relatives include parents, siblings and children on both maternal and paternal sides.  Second-
degree relatives include grandparents, grandchildren, aunts and uncles, half-siblings, nieces and 
nephews on both maternal and paternal sides. Third-degree relatives are relatives with whom you share 
one-eighth of your genes, such as first cousins. 
 
 
Table 8 | Health New England’ Coverage of BRCA1/2 Testing 
 
Criteria for Approval: 
 
Section A. For Medicare Advantage Members  
1. Genetic tests for cancer are only a covered benefit for a beneficiary with a personal history of an 
illness, injury, or signs/symptoms thereof (i.e. clinically affected). A person with a personal history of a 
relevant cancer is a clinically affected person, even if the cancer is considered cured. Genetic testing is 
considered a non-covered screening test for patients unaffected by a relevant illness, injury, or 
signs/symptoms thereof. 
 
2. Predictive or pre-symptomatic genetic tests and services, in the absence of past or present illness in 
the beneficiary, are not covered under national Medicare rules. For example, Medicare does not cover 
genetic tests based on family history alone. 
 
3. A covered genetic test must be used to manage a patient. Medicare does not cover a genetic test for a 
clinically affected individual for purposes of family planning, disease risk assessment of other family 
members, when the treatment and surveillance of the beneficiary will not be affected, or in any other 
circumstance that does not directly affect the diagnosis or treatment of the beneficiary. 
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4. The results of the genetic test must potentially affect at least one of the management options 
considered by the referring physician in accordance with accepted standards of medical care (e.g. 
surgery, the extent of surgery, a change in surveillance, hormonal manipulation, or a change from 
standard therapeutic or adjuvant chemotherapy). 
 
5. Pre-test genetic counseling must be provided by a qualified and appropriately trained practitioner. 
 
6. An informed consent form signed by the patient prior to testing which includes a statement that 
he/she agree to post-test counseling is required. This consent form must be available on request by 
Medicare. 
 
7. Genetic analysis must be provided through a laboratory which meets the American Society of 
Clinical Oncology (ASCO) recommended requirements: 
• The lab must meet appropriate Clinical Laboratory Improvement Amendment (CLIA) 1988 
regulations; 
• Successful participation in the American College of Medical Genetics (ACMG)/College of 
American Pathologists (CAP) inspection and survey program; 
• appropriate state licensing; and 
• credentialing of laboratory directors and staff by the American Board of Medical Genetics 
(ABMG). 
 
8. In addition, criteria in section C must be met.  
 
 
Section B. For Commercial and Medicaid Members 
 
1. A covered genetic test must be used to manage a patient.  HNE does not cover a genetic test for a 
clinically affected individual for purposes of family planning, disease risk assessment of other family 
members, when the treatment and surveillance of the  
beneficiary will not be affected, or in any other circumstance that does not directly affect the diagnosis 
or treatment of the beneficiary. 
 
2. The results of the genetic test must potentially affect at least one of the management  
options considered by the referring physician in accordance with accepted standards of  
medical care (e.g., surgery, the extent of surgery, a change in surveillance, hormonal  
manipulation, or a change from standard therapeutic or adjuvant chemotherapy). 
 
3. Pre-test genetic counseling must be provided by a qualified and appropriately trained  
practitioner. 
 
4. An informed consent form signed by the patient prior to testing which includes a  
statement that he/she agrees to post-test counseling is required. This consent form must  
be available on request. 
 
5. Genetic analysis must be provided through a laboratory which meets the American  
Society of Clinical Oncology (ASCO) recommended requirements: 
a. The lab must meet appropriate Clinical Laboratory Improvement Amendment (CLIA) 1988 
regulations; 
b. Successful participation in the American College of Medical Genetics (ACMG)/College of 
American Pathologists (CAP) inspection and survey program; 
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c. Appropriate state licensing; and 
d. Credentialing of laboratory directors and staff by the American Board of Medical Genetics 
(ABMG). 
 
6. In addition, criteria in section C must be met.  
 
 
Section C. Hereditary Breast and Ovarian Cancer Syndromes Criteria 
 
1. BRCA1 and BRCA2 genetic testing is covered only for the following individuals:  For the purpose 
of this policy, only genetic relations are relevant (i.e., "blood relatives").  Nongenetic relations, such as 
through marriage or adoption, are not relevant to coverage.  A close relative means a first-degree 
(parents, full siblings, offspring) or second-degree (grandparents, grandchildren, aunts, uncles, 
nephews, nieces, half-siblings). Also, for this policy, invasive and ductal carcinoma in situ (DCIS) 
breast cancers should be included.  
 
2. Individual from a family with a known deleterious BRCA1/BRCA2 mutation 
 
3. Personal History of breast cancer plus one or more of the following: 
a. Diagnosed age < 45 years 
b. Diagnosed age < 50 years with > 1 first-, second-, or third-degree blood relative with breast 
cancer < 50 years and/or > 1 first-, second-, or third-degree blood relative with epithelial 
ovarian/fallopian tube/primary peritoneal cancer at any age 
c. Two breast primaries when first breast cancer diagnosis occurred prior to age 50 years 
d. Diagnosed < 6o years with a triple negative breast cancer 
e. Diagnosed < 50 years with a limited family history 
f. Diagnosed at any age with > first-, second-, or third-degree blood relatives with breast and/or 
epithelial ovarian/fallopian tube/primary peritoneal cancer 
g. First-, second- or third-degree male blood relative with breast cancer 
h. Personal history of epithelial ovarian/fallopian tube/primary peritoneal cancer 
i. For an individual of ethnicity associated with higher mutation frequency (e.g., Ashkenazi 
Jewish), no additional family history may be required. 
 
4. Personal history of epithelial ovarian/fallopian tube/primary peritoneal cancer 
 
5. Personal history of male breast cancer 
 
6. Personal history of breast and/or ovarian cancer at any age with >2 first-, second-, or  
third-degree blood relatives with breast and/or ovarian and/or pancreatic cancer at any  
Age 
 
7. Family history only: 
a. First- or second-degree blood relative meeting any of the above criteria 
b. First- or second-degree blood relative with breast cancer and/or ovarian/fallopian tube/primary 
peritoneal cancer with > 2 first-, second-, or third-degree blood relatives with breast cancer (at 
least one breast cancer < 50 years) and/or ovarian cancer 
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Table 9 | Health Partners’ Coverage of BRCA1/2 Testing 
 
BRCA genetic testing for breast/ovarian cancer predisposition is covered when ALL of the 
following criteria are met: 
 
I. Individual has not previously been tested for a BRCA genetic mutation 
II. Individual to be tested is at least 18 years old 
III. The member has received genetic counseling from one of the following independent, specialty-
trained professionals who is not affiliated with the genetic testing lab: 
a. board eligible or board certified genetic counselor 
b. medical geneticist 
c. other health professional with expertise and experience in cancer genetics (this list is 
not all-inclusive): oncologist, surgeon, oncology nurse, genetics clinical nurse, 
advanced practice nurse in genetics 
IV. The health professional recommends BRCA testing per National Comprehensive Cancer 
Network (NCCN) Guidelines based on the following: 
a. review of the individual and family history 
b. counseling of the individual about the potential benefits and harms of genetic testing 
c. obtaining written, informed consent from the individual to be tested 
V. Summary notes from the ordering provider must be submitted 
 
BRACAnalysis® Rearrangement Test (BART) is covered when ALL the following criteria are 
met: 
I. Individual meets all criteria in 2-5 listed above for BRCA testing; AND 
II. Previous Comprehensive BRACAnalysis® testing is negative (an exception may be made 
when surgical decisions are being based on concurrent results of BRCA1/2 and BART testing); 
AND 
III. Individual has not previously been tested using BART. 
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Table 10 | Humana’s Coverage of BRCA1/2 Testing 
 
Known Familial Mutation 
• Individual with a close blood relative* with a known deleterious or suspected deleterious BRCA1 or 
BRCA2 mutation (Note: Test for known familial mutation); 
 
Personal History of Cancer  
• Breast cancer diagnosed at 45 years or younger; OR 
• Two primary breast cancers, with the first breast cancer diagnosis occurring at or before age 50 
years; OR 
• Breast cancer diagnosed at 50 years or younger AND a limited family history, defined as fewer than 
two first or second degree female relatives or female relatives surviving beyond 45 years of age on 
either side of the family; OR 
• Breast cancer diagnosed at 50 years or younger AND at least one close blood relative* diagnosed 
with breast cancer at any age; OR 
• Triple negative breast cancer diagnosed at 60 years or younger; OR 
• Breast cancer diagnosed at any age AND at least one close blood relative* diagnosed with breast 
cancer at 50 years or younger; OR 
• Breast cancer diagnosed at any age AND at least two close blood relatives,* on the same side of the 
family, diagnosed with breast cancer at any age; OR 
• Breast cancer diagnosed at any age AND at least one close blood relative* diagnosed with epithelial 
ovarian cancer; OR 
• Breast cancer diagnosed at any age AND at least two close blood relatives,* on the same side of the 
family, diagnosed with pancreatic cancer at any age or aggressive prostate cancer(Gleason score at 
least seven) at any age; OR 
• Breast cancer diagnosed at any age AND at least two close blood relatives,* on the same side of the 
family, diagnosed with pancreatic cancer at any age or aggressive prostate cancer(Gleason score at 
least seven) at any age; OR 
• Breast cancer diagnosed at any age AND a close male blood relative* diagnosed with breast cancer 
at any age; OR 
• Breast cancer diagnosed at any age AND is of an ethnicity associated with higher mutation 
frequency (e.g., Ashkenazi Jewish**); OR 
• Epithelial ovarian, fallopian tube or primary peritoneal cancer diagnosed at any age; OR 
• Male breast cancer diagnosed at any age; OR 
• Pancreatic cancer diagnosed at any age AND at least two close blood relatives,* on the same side of 
the family, diagnosed with breast and/or ovarian cancer at any age, and/or pancreatic or aggressive 
prostate cancer (Gleason score at least seven) at any age; OR 
• Aggressive prostate cancer (Gleason score at least seven) diagnosed at any age AND at least two 
close blood relatives,* on the same side of the family, diagnosed with breast and/or ovarian cancer 
at any age, and/or pancreatic or aggressive prostate cancer (Gleason score at least seven) at any age; 
OR 
 
Family History Only  
• First or second degree blood relative diagnosed with breast cancer at 45 years or younger; OR 
• First or second degree blood relative diagnosed with two primary breast cancers, with the first 
breast cancer diagnosis occurring at or before age 50 years; OR 
• First or second degree blood relative diagnosed with breast cancer at 50 years or younger AND a 
limited family history, defined as fewer than two first or second degree female relatives or female 
relatives surviving beyond 45 years of age on either side of the family; OR 
• First or second degree blood relative diagnosed with breast cancer at 50 years or younger AND at 
least one additional close blood relative,* on the same side of the family, diagnosed with breast 
cancer at any age; OR 
• First or second degree blood relative diagnosed with triple negative breast cancer at 60 years or 
younger; OR 
• First or second degree blood relative diagnosed with breast cancer at any age AND at least one 
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close blood relative,* on the same side of the family, diagnosed with breast cancer at 50 years or 
younger; OR 
• First or second degree blood relative diagnosed with breast cancer at any age AND at least two 
additional close blood relatives,* on the same side of the family, diagnosed with breast cancer at 
any age; OR 
• First or second degree blood relative diagnosed with breast cancer at any age AND at least one 
close blood relative,* on the same side of the family, diagnosed with epithelial ovarian cancer; OR 
• First or second degree blood relative diagnosed with breast cancer at any age AND at least two 
close blood relatives,*on the same side of the family, diagnosed with pancreatic cancer at any age 
or aggressive prostate cancer (Gleason score at least seven) at any age; OR 
• First or second degree blood relative diagnosed with breast cancer at any age AND a close male 
blood relative,* on the same side of the family, diagnosed with breast cancer at any age; OR 
• First or second degree blood relative diagnosed with breast cancer at any age AND is of an 
ethnicity associated with higher mutation frequency (e.g., Ashkenazi Jewish**); OR 
• First or second degree blood relative diagnosed with epithelial ovarian, fallopian tube or primary 
peritoneal cancer at any age; OR 
• First or second degree blood relative diagnosed with male breast cancer at any age; OR 
• First or second degree blood relative diagnosed with pancreatic cancer at any age AND at least two 
close blood relatives,*on the same side of the family, diagnosed with breast and/or ovarian cancer 
at any age, and/or pancreatic or aggressive prostate cancer (Gleason score at least seven) at any 
age; OR 
• First or second degree blood relative diagnosed with aggressive prostate cancer (Gleason score at 
least seven) at any age AND at least two close blood relatives,* on the same side of the family, 
diagnosed with breast and/or ovarian cancer at any age, and/or pancreatic or aggressive prostate 
cancer (Gleason score at least seven) at any age; OR 
• Third degree relative with breast cancer and/or epithelial ovarian, fallopian tube or primary 
peritoneal cancer with at least two close blood relatives,* on the same side of the family, diagnosed 
with breast cancer (at least one with breast cancer diagnosed at 50 years or younger) and/or 
epithelial ovarian, fallopian tube or primary peritoneal cancer 
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Table 11 | Kaiser’s Coverage of BRCA1/2 Testing 
 
Clinical Indications for Referral  
 
BRCA1 and BRCA2 testing is considered medically necessary when both pre and post test genetic 
counseling is provided by a qualified and appropriately trained practitioner, and one of the following 
criteria is met:   
 
A. Persons with a family history but no personal history of breast and/or ovarian cancer in blood 
relatives from a single (same side) family linewith at least one of the following:   
1. Breast cancer in at least:   
a. two first or second degree relatives (mother, sister, daughter, grandmother, aunt, niece, 
or half sister) both diagnosed before age 50 and at least one of the relatives is first 
degree (mother, sister, or daughter) OR  
b. three first or second degree relatives regardless of age OR  
c. Two first degree relatives with breast cancer, one of whom was diagnosed at age 50 or 
younger   
2. Ovarian cancer in at least two first or second degree relatives   
3. Breast cancer in at least one first or second degree relative and ovarian cancer in at least one 
first or second degree relative   
4. Women with one or more first or second degree relatives with multiple primary  or bilateral 
breast cancer   
5. A first or second degree relative with both breast and ovarian cancer   
6. Women with increased risk for specific mutation due to ethnic background, (e.g. founder 
populations of Ashkenazi Jewish, Icelandic, Swedish, Hungarian or others), and has any first 
degree or two second degree relatives on the same side of the family with breast cancer or 
ovarian cancer at any age.  
7. History of breast cancer in male relatives  
 
B. Persons with a personal history of breast and/or epithelial ovarian cancer, fallopian tube cancer, or 
primary peritoneal cancer but no family history, with at least one of the following:   
1. Breast cancer diagnosed before age 45   
2. Breast or epithelial ovarian cancer, fallopian tube cancer, or primary  peritoneal cancer in 
women with increased risk for specific mutation due to ethnic background, (e.g. founder 
populations of Ashkenazi Jewish, Icelandic, Swedish, Hungarian or others)   
3. Personal history of breast and epithelial ovarian cancer, fallopian tube cancer, or primary 
peritoneal cancer   
4. Multiple primary or bilateral breast cancers when the first breast cancer diagnosis occurred 
before age 50.  
5. Men with breast cancer   
 
C. Persons with a personal and family history (in blood relatives from a single family line) of breast 
and/or ovarian cancer with at least one of the following:   
1. Women with breast cancer:   
2. See below 
2.1. diagnosed before age 50 and one or more first or second degree relatives with breast cancer 
diagnosed before age 50 and/or one or more first or second degree relatives with epithelial 
ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.  
2.2. diagnosed at any age and  
2.2.1. breast cancer in two or more first or second degree relatives at any age OR  
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2.2.2. epithelial ovarian, fallopian tube cancer, or primary peritoneal cancer in one or more first 
or second degree relatives   
3. Women with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer and:  
3.1. Breast cancer in one or more first or second degree relatives OR  
3.2. Epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in one or more 
first or second degree relatives   
4. Women with breast or epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal 
cancer at any age and  
4.1. Breast cancer in first or second degree male relative   
 
D. Persons with a first or second degree blood relative who has previously been tested and found to 
have a clinically significant alteration in a BRCA1/2 gene.  Note: “Clinically significant alteration” 
refers to an inherited alteration in a BRCA gene that is associated with an increased risk for the 
development of breast or ovarian cancer.  
 
E. Persons with a lifetime risk of developing breast or ovarian cancer calculated at 10% or more using 
BRCAPRO software   
 
 
 
 
Table 12 | Medicare: Coverage for BRCA1/2 Testing 
1. Personal history of breast cancer + one or more of the following: 
• Diagnosed age ≤45 y, with or without family history 
• Diagnosed age ≤50 y or two breast primaries, with ≥1 close blood relative(s) with breast cancer 
≤50 y and/or ≥1 close blood relative(s) with epithelial ovarian/fallopian tube/primary peritoneal 
cancer  
• Two breast primaries when first breast cancer diagnosis occurred prior to age 50 
• Diagnosed age <60 y with a triple negative breast cancer (ER-, PR-, HER2-) 
• Diagnosed age <50 y with a limited family history, defined as fewer than 2 first- or second 
degree female relatives or female relatives surviving beyond 45 years in either lineage 
• Diagnosed at any age, with ≥2 close blood relatives with breast and/or epithelial 
ovarian/fallopian tube/primary peritoneal cancer, at any age  
• Close male blood relative with breast cancer 
• Personal history of epithelial ovarian/fallopian tube/primary peritoneal cancer 
• If of certain ethnicity associated with higher mutation frequency, (e.g., Ashkenazi Jewish) no 
additional family history required 
• A close relative with a known BRCA1 or BRCA2 gene mutation 
 
2. Personal history of epithelial ovarian/fallopian tube/primary peritoneal cancer. 
 
3. Personal history of male breast cancer. 
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Table 13 | Tufts Health Plan: Coverage for BRCA1/2 Testing 
 
 
Tufts Health Plan may authorize coverage for BRCA1 & BRCA2, Multi-site BRCA3, or single-site BRCA1 or 
BRCA2 testing for Members at high risk for breast cancer.  Tufts Health Plan defines high risk as a greater than 
ten percent risk for a positive test result based upon either the Myriad or BRCAPRO model.   A letter of medical 
necessity from the Member’s PCP or genetic specialist must be submitted to Tufts Health Plan which includes 
how the Member’s high risk has been determined.  Tufts Health Plan may authorize coverage of this testing when 
both A and B are met.  In addition, the Member must meet one of the criteria listed under C, D, E, F or G. 
 
A. The results of the genetic test will significantly alter the medical management of the Member (documentation 
required). 
B. The recommendation for testing is based on a review of risk factors, clinical presentation and family history, 
and is supported by consultation with a licensed genetic counselor or a physician with expertise in genetic 
counseling (documentation required). 
C. Tufts Health Plan may authorize the  Multi-site BRCA3 test  for  female Members of  Ashkenazi descent with  
ONE of the following risks: 
1. Personal history of a primary breast cancer or ovarian cancer at any age. 
2. No personal history of breast or ovarian cancer and one of the following: 
a. Family history of breast or ovarian cancer, at any age, in any 1st degree relative. 
b. Family history of breast or ovarian cancer, at any age, in at least two 2nd degree relatives. 
c. A 1st degree relative with a known BRCA1or BRCA2 mutation. 
D. Tufts Health Plan may authorize the full panel BRCA 1& BRCA2 genetic tests for female Members who are 
NOT of Ashkenazi descent and a have ONE of the following risks: 
1. Personal history of primary breast cancer, diagnosed before age 50 
2. Personal history of ovarian cancer at any age 
3. Family history which includes one of the following: 
a.   Two 1st degree relatives with breast cancer, one of whom received the diagnosis at age 50 or 
younger. 
b.   A combination of three or more 1st or 2nd degree relatives with breast cancer regardless of 
age at diagnosis. 
c.  A combination of both breast and ovarian cancer among 1st or 2nd degree relatives. 
d.  A 1st degree relative with bilateral breast cancer. 
e.   A combination of two or more 1st or 2nd degree relatives with ovarian cancer regardless of 
age at diagnosis. 
f.   A 1st or 2nd degree relative with both breast and ovarian cancer at any age.   
g. A history of breast cancer in a male relative. 
 
4. A 1st degree relative with a known BRCA1or BRCA2 mutation 
 
E. Member is a male with ONE of the following: 
1. Personal history of breast cancer at any age. 
2. A 1st degree relative with a known BRCA1or BRCA2 mutation. 
 
F. The Member’s requesting provider submits the results of BRCAPRO which shows that the calculated risk of 
the Member having the mutation is ≥ (greater than or equal to) 10%. 
 
G. The Member, of any age, has triple negative breast cancer. Breast cancer is defined as triple negative breast 
cancer when the tumor that does not have receptors for any of the following;  estrogen, progesterone or human 
epidermal growth factor receptor 2 (HER2). 
 
Note:  For male Members, Multi-site BRCA3 test will be approved if Ashkenazic. If not Ashkenazic, a full panel 
BRCA1&2 will be approved. If there is a known mutation, single-site testing will be approved. 
 
Tufts Health Plan may authorize single site analysis only for Members who have a 1st degree relative with a 
known BRCA 1or 2 mutation, regardless of personal history or descent.For Members who are of a partial 
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Ashkenazic or non-Ashkenazic descent if the Member meets the Ashkenazic criteria above and the family history 
of breast and/or ovarian cancer occurred predominantly in non-Ashkenazic relatives, Tufts Health Plan may 
authorize full panel BRCA1 & BRCA2 genetic testing.For Members who are of Ashkenazic descent who meet 
the criteria for Multisite 3 testing and who have a negative multi-site 3 test, Tufts Health Plan may authorize full 
panel BRCA1 & BRCA2 genetic testing (reflex testing). All testing must be performed at a contracting laboratory 
facility when available. 
 
COVERAGE GUIDELINES FOR BART TESTING 
 
Large genomic rearrangements occur in a small percentage (<1%) of all patients tested for hereditary 
breast and ovarian cancer. In August 2002, Myriad launched an enhancement to the BRACAnalysis test 
to detect five common large rearrangements.  The BRACAnalysis Rearrangement Test, or BART, 
launched in 2006, is designed to detect large rearrangements beyond these five. 
 
Tufts Health Plan may authorize coverage of BART™ testing for Members who meet the clinical 
criteria outlined below. Please note: When using the chart below, the following conditions apply: 
· Male breast cancer qualifies at any age 
· At least one relative must be a first or second degree relative and qualifying cancers must be 
on the same side of the family 
· Breast cancer includes ductal carcinoma in situ (DCIS) and invasive cancers 
 
Member Affected With:  Additional History Required  
Breast Cancer before age 50 : 2 or more diagnoses of breast cancer before age 50 and/or ovarian cancer 
at any age 
Ovarian cancer at any age : 2 or more diagnoses of breast cancer before age 50 and/or ovarian cancer at 
any age 
Male breast cancer at any age : 2 or more diagnoses of breast cancer before age 50 and/or ovarian 
cancer at any age 
Breast cancer at or after age 50 and ovarian cancer at any age : 1 or more diagnoses of breast cancer 
before age 50 and/or ovarian cancer at any age 
Breast cancer before age 50 and ovarian cancer at any age: No additional relatives required 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  134	  
Table 14 | United Healthcare’s Coverage of BRCA1/2 Testing 
 
BRCA Testing Criteria 
 
I. BRCA1 and BRCA2 testing is proven for women with a personal history of breast cancer 
in the following situations: 
A. Breast cancer diagnosed at age 45 or younger with or without family history; OR 
B. Breast cancer diagnosed at age 50 or younger with: 
1. At least one close blood relative with breast cancer at any age; OR 
2. Limited family history (see Definitions section for further clarification) 
C. Breast cancer diagnosed at any age with: 
1. Two breast primary cancers, when first breast cancer diagnosis occurred 
prior to age 50 OR 
2. Personal history of ovarian cancer; OR 
3. At least one close blood relative with breast cancer diagnosed at age 50 or 
younger; OR 
4. At least two close blood relatives on the same side of the family with breast 
cancer at any age; OR 
5. At least one close blood relative with ovarian cancer at any age; OR 
6. At least two close blood relatives on the same side of the family with 
pancreatic or aggressive prostate (Gleason score ≥7)  cancer at any age; OR 
7. Close male blood relative with breast cancer; OR 
8. At least one close blood relative that has a BRCA1 or BRCA2 mutation; OR 
9. Ashkenazi Jewish or ethnic groups associated with founder mutations. 
Testing for Ashkenazi Jewish founder-specific mutations should be 
performed first.   
D. Triple negative breast cancer diagnosed at age 60 or younger.   
II.  BRCA1 and BRCA2 testing is proven for women with a personal history of ovarian 
cancer. 
III. BRCA1 and BRCA2 testing is proven for women and men with a personal history of 
pancreatic cancer at any age and at least two close blood relatives on the same side of the 
family with breast, ovarian, pancreatic and/or aggressive prostate (Gleason score ≥7) 
cancer at any age. 
IV. BRCA1 and BRCA2 testing is proven for men with a personal history of aggressive 
prostate (Gleason score ≥7)  cancer at any age and at least two close blood relatives on the 
same side of the family with breast, ovarian, pancreatic and/or aggressive prostate (Gleason 
score ≥7) cancer at any age. 
V. BRCA1 and BRCA2 testing is proven for men with a personal history of breast cancer. 
VI. BRCA1 and BRCA2 screening tests are proven for men and women without a personal 
history of breast or ovarian cancer with at least one of the following familial risk factors: 
A. At least one first- or second-degree blood relative meeting any of the above criteria (I-
V); OR 
B. At least one third-degree blood relative with breast cancer and/or ovarian cancer who 
has at least 2 close blood relatives with breast cancer (at least one with breast cancer at 
age 50 or younger) and/or ovarian cancer; OR 
C. C. A known BRCA1/BRCA2 mutation in the family (defined as first-, second- or third 
degree relative) 
VII. BRCA1 and/or BRCA2 testing is unproven for all other indications including: 1) screening 
of breast or ovarian cancers for individuals not listed in the proven indications above or 2) 
for risk assessment of other cancers. Further evidence is needed to establish the clinical 
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utility of testing in other populations. 
 
Large Genomic Rearrangement Testing 
Certain large genomic rearrangements are not detectable by primary sequencing assay, thereby 
necessitating supplementary testing, in some cases. In these circumstances, NCCN guidelines 
emphasize the need for comprehensive testing, which encompasses full BRCA1/2 sequencing and 
detection of large gene rearrangements. 
 
I. Detection of large genomic rearrangements (e.g., BRACAnalysis® Large Rearrangement 
Test (BART)) is proven for individuals who meet the testing criteria for BRCA1/BRCA2 
and have no known familial BRCA1/BRCA2 mutations*.  Detection of large genomic 
rearrangements (e.g., BRACAnalysis® Large Rearrangement Test (BART)) is medically 
necessary when the following criteria are met:   
A. Individual meets the testing criteria for BRCA1/BRCA2 and has no known familial 
BRCA1/BRCA2 mutations* 
B. Testing is conducted on an affected family member. If an affected family member is 
unavailable, testing is conducted on the unaffected family member with the highest 
likelihood of a BRCA1/BRCA2 mutation (NCCN, 2013) 
II. Detection of large genomic rearrangements (e.g., BRACAnalysis® Large Rearrangement 
Test (BART)) is unproven for the purpose of screening in the general population.  There is 
inadequate clinical evidence that such screening reduces mortality from breast cancer in a 
normal risk population. 
 
NOTE: National Comprehensive Cancer Network (NCCN) guidelines state that significant limitations 
of interpreting test results for an unaffected individual should be discussed.  Testing of unaffected 
individuals should only be considered when an appropriate affected family member is unavailable for 
testing.  Clinical judgment should be used to determine if the patient has reasonable likelihood of a 
mutation (NCCN, 2013).  
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Appendix 4 
Screening Tools 
 
 
Note to Reader: The following tools are those recognized by the U.S. Preventive Services Task 
Force (USPSTF) as being “clinically useful predictors of which women should be referred for 
genetic counseling due to increased risk for potentially harmful BRCA mutations.”256,257   Many 
other risk tools exist.  Each of the following tools has its “limitations” and the USPSTF has 
“found insufficient comparative evidence to recommend one tool over another.”  The tables 
presented in this Appendix were taken directly from the USPSTF’s report.258  Some tables are 
simply summaries, so readers should access the original risk tools for the most accurate 
representation.  The original journal articles are cited below.  
 
 
Contents: 
 
Table 1.   Ontario Family History Assessment Tool (FHAT)259 
Table 2.  Manchester Scoring System260  
Table 3.  Referral Screening Tool261  
Table 4.  Pedigree Assessment Tool262  
Table 5.  FHS-7263   
 
 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
256 "Final Recommendation Statement - Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-
Related Cancer in Women," U.S. Preventive Services Task Force (USPSTF). 
http://www.uspreventiveservicestaskforce.org/uspstf12/brcatest/brcatestfinalrs.htm. December 2013. Accessed 
February 2, 2013. 
257 Moyer, V.A. (2014) Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in 
Women: U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine 160, no. 4: 
271-281. 
258 Moyer, Annals of Internal Medicine. 
259 Gilpin, C. A., Carson, N., & Hunter, A. G. W. (2000). A preliminary validation of a family history assessment 
form to select women at risk for breast or ovarian cancer for referral to a genetics center. Clinical Genetics 58(4), 
299-308. 
260 Oros, K. K., Ghadirian, P., Maugard, C. M., Perret, C., Paredes, Y., Mes-­‐Masson, A. M., ... & Tonin, P. N. 
(2006). Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer 
families of French Canadian descent. Clinical Genetics 70(4), 320-329. 
261 "Breast Cancer Genetics: Referral Screening Tool (B-RST)," Georgia Breast Cancer Genomic Consortium: 
Education Surveillance and Policy. Peachtree Solutions, LLC. https://www.breastcancergenescreen.org/default.aspx. 
Accessed February 2, 2014.  
262 Hoskins, K. F., Zwaagstra, A., & Ranz, M. (2006). Validation of a tool for identifying women at high risk for 
hereditary breast cancer in population-­‐based screening. Cancer 107(8), 1769-1776. 
263 Ashton-Prolla, P., Giacomazzi, J., Schmidt, A. V., Roth, F. L., Palmero, E. I., Kalakun, L., ... & Camey, S. A. 
(2009). Development and validation of a simple questionnaire for the identification of hereditary breast cancer in 
primary care. BMC Cancer 9(1), 283.	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Appendix 5 
Genes and Conditions 
 
 
Note to Reader: The following table lists the genes referenced in Appendix 2, as well as the 
condition with which these genes are associated.  
       
Gene Condition 
APC Familial adenomatous polyposis 
ATM Moderate-risk breast cancer susceptibility 
BLM  Bloom Syndrome   
BMPR1A Juvenile Polyposis Syndrome  
BRCA1 Hereditary breast and ovarian cancer syndrome 
BRCA2 Hereditary breast and ovarian cancer syndrome 
BRIP1 Moderate-risk breast cancer susceptibility 
CDC73  Hyperparathyroidism-Jaw Tumor Syndrome  
CDH1 Hereditary diffuse gastric cancer 
CDKN2A/p16 Familial Cutaneous Malignant Melanoma; Moderate-risk breast cancer susceptibility 
CDK4    Familial Cutaneous Malignant Melanoma   
CHEK2 Breast cancer and Li-Fraumeni syndro 
EPCAM Lynch syndrome 
FLCN  Birt-Hogg-Dube Syndrome   
FH Hereditary Leiomyomatosis and Renal Cell Cancer  
MEN1     Multiple Endocrine Neoplasia, Type 1  
MET Hereditary papillary renal cell carcinoma 
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MLH1 Lynch syndrome 
MUTYH MYH-associated polyposis syndrome 
MSH2  Lynch syndrome 
MSH6 Lynch syndrome 
NBN Moderate-risk breast cancer susceptibility 
PALB2 Moderate-risk breast cancer susceptibility 
PALLD Familial pancreatic adenocarcinoma 
PMS2 Lynch syndrome 
PRKAR1A Carney Complex   
PTCH1     Gorlin Syndrome; Basal cell nevus syndrome 
PTEN  PTEN Hamartoma Tumor Syndrome 
RAD51C Moderate-risk breast cancer susceptibility 
RET  Multiple Endocrine Neoplasia, Type 2A and 2B      
SMAD4  Juvenile Polyposis Syndrome  
STK11     Peutz-Jeghers Syndrome  
TP53     Li-Fraumeni Syndrome   
VHL Von Hippel-Lindau Syndrome  
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Appendix 6 
CPT® codes264 
 
Note to Reader: The following table lists the CPT codes for the BRCA1/2 tests detailed in 
Chapter 3: A Changing Genetic Landscape, and then described again in Appendix 2.   
 
 
CPT code Code Description 
 
81211 
 
BRCA1, BRCA2 (breast cancer 1 and 2) (e.g., hereditary breast and ovarian 
cancer) gene analysis; full sequence analysis and common duplication/deletion 
variants in BRCA1 (i.e., exon 13 del 3.835kb, exon 13 dup 6kb, exon 14-20 
del 26kb, exon 22 del 510bp, exon 8-9 del 7.1kb) 
81212 BRCA1, BRCA2 (breast cancer 1 and 2) (e.g., hereditary breast and ovarian cancer) gene analysis; 185delAG, 5385insC, 6174delT variants 
81214 
BRCA1 (breast cancer 1) (e.g., hereditary breast and ovarian cancer) gene 
analysis; full sequence analysis and common duplication/deletion variants (i.e., 
exon 13 del 3.835kb, exon 13 dup 6kb, exon 14-20 del 26kb, exon 22 del 
510bp, exon 8-9 del 7.1kb) 
81215 BRCA1 (breast cancer 1) (e.g., hereditary breast and ovarian cancer) gene analysis; known familial variant 
81216 BRCA2 (breast cancer 2) (e.g., hereditary breast and ovarian cancer) gene analysis; full sequence analysis 
81217 BRCA2 (breast cancer 2) (e.g., hereditary breast and ovarian cancer) gene analysis; known familial variant Large genomic rearrangements (e.g., BART) 
81213 
BRCA1, BRCA2 (breast cancer 1 and 2) (e.g., hereditary breast and  
ovarian cancer) gene analysis; uncommon duplication/deletion  
variants 
 
 
 	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
264 "CPT Coding, Medical Billing and Insurance," American Medical Association.  
http://www.ama-assn.org/ama/pub/physician-resources/solutions-managing-your-practice/coding-billing-
insurance.page?. Accessed February 22, 2014.	  	  
